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ABSTRACT
The D-glucose disaccharide α, α’-D-trehalose is synthesized by a variety of bacteria,
fungi, plants and invertebrates to support cell survival by functioning as a fuel, a metabolic
regulator or a protectant against environmental stress. Five different trehalose biosynthetic
pathways are known to exist, one of which, the OtsA/OtsB pathway is common among
pathogenic bacteria and fungi and is also found in parasitic nematodes. Previously reported
otsA and otsB gene knockout (or knockdown) experiments have shown that both pathway
enzymes are essential for M. tuberculosis cell growth and host colonization. RNAi gene
silencing carried out in the nematode model system Caenohabditis elegans revealed that
the T6P phosphatase is essential. Based on these findings we concluded that trehalosesynthesizing pathogens are likely to be vulnerable to the action of small molecule inhibitors
of T6P phosphatase. We designed a bi-module inhibitor prototype. Accordingly, the
phosphate group of the trehalose 6-phosphate moiety was replaced by a phosphate mimetic
for targeting the active site of the catalytic domain, and the glucose unit was modified for
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targeting the cap domain for induced cap closure over the active site. Sulfate proved to be
the most effective warhead for the substrate-binding site. T6S binding was shown by using
Single Angle X-ray Scattering (SAXS) analysis to induce cap closure. Using glucose-6sulfate as the platform, a series of synthetic derivatives possessing “drug-like” functions
tethered to the glucose ring were evaluated. Of these first generation inhibitors 4-noctylphenyl-α-D-glucopyranoside 6-sulfate proved to be the tightest binding T6PP
competitive inhibitor. In parallel, we have used the glucose-6-sulfate as the scaffold in the
design of active site-directed, irreversible inhibitors. From the adducts which were
synthesized and tested for T6PP inactivation, 4-n-octylphenyl-2-(3-(flurosulfonyl)
benzoylamino)-2-deoxy-α-D-glucopyranoside-6-sulfate

was

selected

for

further

characterization, and subsequently shown to inactivate the T6PPs with stoichiometric
covalent modification and reasonable efficiency. Bioinformatic analysis and site-directed
mutagenesis methods were used to identify the modified residue, a stringently conserved
lysine residue was identified. Based on this result, the design and synthesis of the second
generation of irreversible inhibitors that are optimized this target site is planned for future
work.
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CHAPTER ONE
TREHALOSE-6-PHOSPHATE PHOSPHATASE AS A NEW
CANDIDATE DRUG TARGET IN FILARIAL NEMATODES AND
PATHOGENIC BACTERIA

Some of the most chronically debilitating diseases caused by parasitic nematodes
plague the low-income populations of Africa, Asia, and the Americas. One of these diseases
is Lymphatic filariasis, a mosquito borne disease caused by Brugia malayi, Wuchereria
bancrofti and Brugia timori. This disease affects around 120 million people worldwide in
tropical and sub-tropical countries putting 1.3 billion people at risk (WHO, 2009) [1, 2].
Filarial infections are responsible for extreme infirmity, distress, and social stigma. In fact,
lymphatic filariasis is a major cause of permanent and longterm disability in people
worldwide [3]. Because of the nature of infection and the impact on people suffering from
this disease, the Global Program for the Elimination of Lymphatic Filariasis (GPELF) was
established in 1999 with the main goal of ending the transmission of this disease by 2020.
Currently, the recommended treatment for lymphatic filariasis is the administration of
albendazole together with ivermectin or diethylcarbamazine citrate. Even though these
treatments are effective in community-wide treatment programs, they are not without
drawbacks. One problem is the fact that these drugs can only kill microfilariae, leaving the
adult worms intact. Consequently, the treatment must be continued during the entire
reproductive life span of the adult worm (about 5 years) [4]. The other issue is that the drug
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combination can prove lethal if administered to individuals with high microfilarial loads
caused by a co-infection by Loa loa [5]. Therefore, new drugs which are not subject to
these limitations are in demand.
Parasitic nematode model systems are needed to facilitate the drug-discovery
programs. The laboratory–based investigation is difficult because of the complicated life
cycle of nematodes. C. elegans has served as a model system for research on free-living
nematodes for decades [6-8]. Fortunately, B. malayi can be maintained in a jird host, which
is amenable to in vitro studies at different stages of its life-cycle [9, 10]. Presently, both C.
elegans and B. malayi serve as plausible models for research on lymphatic filarial
nematodes.Trehalose-6-phosphate phosphatase (T6PP) (UniProt: A8NS89) is one of the
highest-ranking targets in the top drug target candidates identified in B. malayi using a
ranking system [11].Trehalose-6-phosphate phosphatase participates in the OtsAB
biosynthetic pathway, which is the dominant pathway leading to the disaccharide trehalose.
The two-step pathway consists of the trehalose-6-phosphate synthase (OtsA)-catalyzed
reaction of -UDP-glucose and glucose-6-phosphate to generate ’-D-trehalose-6phosphate, which is then hydrolyzed to -D-trehalose by trehalose-6-phosphate
phosphatase (OtsB) (Scheme 1.1). Trehalose, a sugar found in many species of plants,
bacteria, fungi and invertebrate animals, but not in vertebraetes, is a non-reducing
disaccharide composed of two glucose moieties. Apart from its function as a reserve
carbohydrate, trehalose is known for its role as a stress protectant in many organisms across
all three Kingdoms wherein it protects the organism from damage via desiccation, freezing,
starvation, and osmotic stress.
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Scheme 1.1 OtsAB biosynthetic pathway.

Although trehalose performs important functions in nematodes, the reduction in
T6PP activity in C. elegans by gene knockdown is lethal not because of the absence of
trehalose but rather because of the accumulation of trehalose-6-phosphate (T6P). One
theory is that T6P acts as a toxic anti-metabolite, leading to organism death [12]. In
Saccharomyces cerevisiae, T6P acts as an important signal for metabolic regulation.
Specifically it regulates the first steps in glycolysis through the inhibition of hexokinase II,
and its accumulation is detrimental to the organism [13]. Finally, silencing of the T6PPencoding tpp gene in B. malayi caused the arrested growth of the larvae [14]. We therefore
concluded that trehalose phosphate phosphatase (T6PP) is essential to B. malayi and other
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T6P-producing organisms, and that inhibition by a small drug-like molecule could be an
effective strategy for the development of a therapeutic agent.
In Mycobacterium tuberculosis, trehalose is the major free sugar in the cytoplasm;
it is a constituent of cell wall glycolipids, and it is required for the transport of mycolic acid
during cell wall biogenesis. Mycobacterium tuberculosis causes Tuberculosis (TB), an
infectious disease. In 2010, there were an estimated 8.5–9.2 million cases of TB and 1.2–
1.5 million deaths. TB is the second leading cause of death from an infectious disease
worldwide (WHO, 2011) [15]. Resistance to anti-TB drugs, a problem recognized in the
very early days of the chemotherapeutic era, has become a global threat. New drugs which
act on new drug targets can counteract existing drug resistance. There are three potential
pathways to synthesize trehalose in mycobacteria, the previously mentioned OtsAB
pathway (which utilizes glucose and glucose-6-phosphate to generate T6P catalyzed by
trehalose synthase, then hydrolyzed to trehalose by T6PP), the TreYZ pathway (which
makes trehalose from the hydrolysis of glycogen), and the TreS enzyme (which can convert
maltose to trehalose) (Scheme 1.2) [16]. However, the OtsAB pathway is the dominant
pathway required for M. tuberculos’s growth in laboratory culture and for its virulence in
a mouse model [17]. Trehalose-6-phosphate phosphatase (TPP) is an essential enzyme for
growth of mycobacteria, which has been identified to be a potential anti-tuberculosis drug
target.
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Scheme 1.2 Three pathways for trehalose biosynthesis in M. tuberculosis

T6PP is a member of the haloalkanoate dehalogenase (HAD) superfamily of
phosphatases. HAD phosphatases catalyze the hydrolysis of organophosphate esters using
a two-step reaction sequence, which employs nucleophilic catalysis by one active site Asp
residue and acid/base catalysis by a second Asp nucleophile (Figure 1.1). The phosphoryl
group is activated for transfer by a Mg2+ cofactor and by an active site Thr/Ser and Lys
residue (Figure 1.1). Based on the known structure of the close structural homolog sucrose
6-phosphate phosphatase (S6PP) (Figure 1.2) it is evident that the T6PP is comprised of a
Rossmann-fold catalytic domain and an -fold cap domain. The catalytic domain
contains the catalytic scaffold (represented in Figure 1.1) that mediates the two phosphoryl
transfer steps, whereas the cap domain binds the organic leaving group (trehalose in the
case of T6P) that is displaced in the first step.

5

Figure 1.1. The reaction pathway (top) and active site of the HAD phosphatase
(bottom).
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Figure 1.2. The structure of S6PP in the unliganded cap-open conformation
and in substrate-bound, cap-closed conformation. The catalytic domain is
shown in gray and the cap domain in magenta. Bound substrate stabilizes the
enzyme in the cap-closed conformation.

The goal of the work reported herein was to carry out structure-function analysis to
define the T6PP substrate binding for inhibitor targeting which will provide the foundation
for future drug design. The working hypothesis is that small molecule inhibitors will block
T6PP activity in vivo and this in turn will lead to the accumulation of the T6P and result in
death of the host organism. My first objective is to identify the steric and electrostatic
features of the T6PP substrate binding site region and my second objective is to use this
information to guide the design of tight binding inhibitors. The X-ray structure
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determinations will be carried out in Karen Allen’s laboratory at Boston University. To
facilitate the structure determinations I will supply recombinant wild-type and mutant
T6PP and synthetic substrate analogs (inhibitors) for co-crystallization. I will use the
structural data obtained in combination with the Ki values measured for the inhibitors to
locate the residues that can provide the largest amount of favorable binding energy. These
results will be used to refine inhibitor design.

References:
1. Martin, J., Abubucker, S., Heizer, E., Taylor, C.M., Mitreva, M. Nematode.net
update 2011: addition of data sets and tools featuring next-generation sequencing
data. Nucleic Acids Res, 2012, 40, D720–8.
2. Ottesen, E. A., Hooper, P.J., Bradley, M., Biswas, G. The global programme to
eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis,
2008, 2, e317.
3. WHO (2009) World Health Organization Global Program to Eliminate Lymphatic
Filariasis.

Available:

http://www.who.int/lymphatic_filariasis/disease/en/.

Accessed 2 June 2014.
4. Gyapong, J.O., Kumaraswami, V., Biswas, G., Ottesen, E. A.Treatment strategies
underpinning the global programme to eliminate lymphatic filariasis. Expert Opin
Pharmacother, 2005, 6, 17–200.
5. Kamgno, J., Boussinesq, M. Encephalopathy after Ivermectin Treatment in a
Patient Infected with Loa Loa and Plasmodium spp. Am J Trop Med Hyg, 2008,

8

78, 546–551.
6. Aboobaker, A.A., Blaxter, M.L. Use of RNA interference to investigate gene
function in the human filarial nematode parasite Brugia malayi. Mol. Biochem.
Parasitol. 2003, 129, 41–51.
7. Lustigman, S., Zhang, J., Liu, J., Oksov, Y., Hashmi, S. RNA interference targeting
cathepsin L and Z-like cysteine proteases of Onchocerca volvulus confirmed their
essential function during L3 molting. Mol. Biochem. Parasitol., 2004, 138, 165–
170.
8. Pfarr, K., Heider, U., Hoerauf, A. RNAi mediated silencing of actin expression in
adult Litomosoides sigmodontis is specific, persistent and results in a phenotype.
Int. J. Parasitol., 2006, 36, 661–669.
9. Ash, L.R., Riley, J.M. Development of Subperiodic Brugia malayi in the Jird,
meriones unguiculatus, with notes on infections in other rodents. J. Parasitol., 1970,
56, 969–973.
10. Falcone, F.H., Schlaak, M., Haas, H. In vitro cultivation of Brugia malayi, a
parasitic nematode that causes human lymphatic filariasis. ALTEX, 1995, 12, 179–
187.
11. Kumar, S., Chaudhary, K., Foster, J.M., Novelli, J.F., Zhang, Y., et al. Mining
predicted essential genes of Brugia malayi for nematode drug targets. PLoS One,
2007, 2, e1189.
12. Kormish, J.D., McGhee, J.D. The C. elegans lethal gut-obstructed gob-1 gene is
trehalose- 6-phosphate phosphatase. Dev. Biol., 2005, 287, 35–47.

9

13. Blazquez, M. A., Lagunas, R., Gancedo, C., and Gancedo, J. M. Trehalose-6phosphate, a new regulator of yeast glycolysis that inhibits hexokinases. FEBS Lett.,
1993, 329,51–54.
14. Kushwaha, S., Singh, P.K., Shahab, M., Pathak, M., Bhattacharya, S.M. In vitro
silencing

of

Brugia

malayi

trehalose-6-phosphate

phosphatase

impairs

embryogenesis and in vivo development of infective larvae in jirds. PLoS Negl.
Trop. Dis., 2012, 6(8):e1770.
15. WHO, Global Tuberculosis Control. 2011.
16. De Smet, K.A.L., Weston, A., Brown, I.N., Young, D.B. and Robertson, B.D. Three
pathways for trehalose biosynthesis in mycobacteria. Microbiology, 2000, 146, 199
–208.
17. Murphy, H.N., Stewart, G.R., Mischenko, V.V., Apt, A.S., Harris, R. and McAlister,
M.S.,et al. The OtsAB pathway is essential for trehalose biosynthesis in
Mycobacterium tuberculosis. J Biol Chem, 2005, 280, 14524–14529.

10

CHAPTER TWO
CLONING, EXPRESSION, PURIFICATION AND KINETICS OF
TREHALOSE-6-PHOSPHATE PHOSPHATASE HOMOLOGUES

2.1 Introduction
The T6PPs that I have selected for study (based on availability of genomic DNA
for T6PP gene cloning) are Mycobacterium tuberculosis (bacterial causative agent of
tuberculosis), Shigella boydii (bacterial causative agent of dysentery), Salmonella
typhimurium (causative agent of Salmonellosis), Ascaris suum (pig roundworm). We
assumed that by generating recombinant T6PP from several different pathogens for
examination we might increase our chances for successful crystallization and structure
determination. Furthermore, each of the chosen T6P phosphatase orthologs can serve as a
unique subject for inhibitor development and for in vivo inhibition. The gene encoding the
T6PP from Brugia malayi (parasitic human roundworm causative agent of elephantiasis)
was cloned by our collaborators (the Carlow laboratory at New England Biolabs). They
have provided wild-type and mutant B. malayi T6PP for X-ray structure determination and
for inhibitor evaluation.
2.2 Materials and Methods
2.2.1 General Methods
All chemicals and buffers were purchased from Sigma-Aldrich. The sources of the
gene cloning materials are as follows: primers (Invitrogen); T7 Express Iq Competent E.
coli (High Efficiency) competent cells, T4 DNA ligase, restriction enzymes (New England

11

biolabs) and Pfu, Turbo polymerases (Strategene); pET23a and pET28a vector kits
(Novagen); Qiaprep Spin Miniprep Kit (Qiagen). DEAE Sepharose was from Amersham
Biosciences. Butyl and Phenyl-Sepharose resins were purchased from Sigma-Aldrich,
whereas the Ni-NTA resin was from Qiangen. Snakeskin pleated dialysis tubing was
purchased from Thermo Scientific. SDS-PAGE analysis was performed with a 12% -16%
acrylamide running gel and a 4% stacking gel (37.5:1 acrylmide:biacryamide ratio)
(BioRad, Hercules, CA). Protein solutions were concentrated using a 10K Amicon Ultra
Centrifugal filter (Millipore). The nucleotide sequence of each cloned gene or mutant gene
was determined by GENEWIZ, Inc. Electro-spray mass-spectrometry (ES-MS)
determinations were carried out by the University of the New Mexico Mass Spectrometry
Facility. Protein concentrations were determined using the Bradford assay kit from SigmaAldrich.

2.2.2

Preparation of Recombinant Wild-type T6PPs

2.2.2.1 Preparation of Recombinant Wild-type Mycobacterium tuberculosis T6PP
The gene encoding Mt-T6PP was amplified by using the polymerase chain
reaction (PCR). The reaction mixture contained M. tuberculosis genomic DNA (ATCC
25177), Deep Vent DNA Polymerase and with the forward (5'-GTGAGAGG
GTGGCATATGCGCAAGTTGGGC-3') and reverse (5'-CATGGCCGTCCTCCTC
GAGGACGGTCGGAG-3') oligonucleotide primers containing NdeI and XhoI
restriction sites, respectively. Gene amplification was carried out under the following
conditions: 50 μL reactions contained 5 μL 10×Pfu buffer, 4 μL dNTP mix (2.5mM), 1
μL Deep Vent DNA Polymerase, 2 μL forward primer (50 μM), 2 μL reverse primer

12

(50 μM), 2 μL template/genomic DNA (20ng/μL) and 34 μL DI H2O. The initial
denaturation was carried out at 94°C for 10 min followed by 25 cycles of denaturation
at 94 °C for 1 min, annealing at 51.5 °C for 2 min and extension at 72 °C for 5 min.
The final extension was carried out at 72 °C for 10 min. The PCR products were
digested with NdeI and XhoI restriction enzymes at 37 °C for 3 h, and the digested
products were harvested by agarose gel electrophoresis. At the same time, pET-15b (+)
tev (Boston University) and pET-23a (+) vectors were digested by NdeI and XhoI
restriction enzymes at 37 °C for 3h, and the digested products were harvested in the
same manner. Digested DNA was ligated to corresponding digested pET-15b (+) tev
and pET-23a (+) vectors at room temperature for 5-7 h, and the cloned products were
verified by DNA sequencing. Both of the pET-15b (+) tev-T6PP and pET-23a (+) T6PP constructs were transformed into T7 Express Iq Competent E. coli (High
Efficiency) cells from New England BioLabs. Over-expression of Mt-T6PP was
induced with 0.4 mM IPTG (isopropyl β-D-thiogalactoside) overnight at 37 °C and 175
rpm in LB cultures at logarithmic phase growth (OD600=0.4-0.6).
Cells containing Mt-T6PP were harvested at 6500 rpm for 15 min and the
collected pellet was suspended in 20 mM HEPES buffer (pH =7.5) containing 100 mM
NaCl, 5 mM MgCl2 and 2 mM DTT. The suspended cells were lysed by disruption
using a French Pressure Cell and the lysate was centrifuged at 20,000 rpm for 15 min.
For the His-tagged Mt-T6PP (from pET15b (+) tev-T6PP), the supernatant was loaded
onto a nickel nitrilotriacetic acid (Ni-NTA) agarose affinity column, which was preequilibrated with 20 mM HEPES buffer (pH =7.5) containing 100 mM NaCl, 5 mM
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MgCl2, 2 mM DTT and 40 mM imidazole. The column was subsequently washed with
the same buffer for 3-5 column volumes before the recombinant protein was eluted
with similar buffer containing 500 mM imidazole. The purity of eluted protein was
analyzed by 12% SDS-PAGE (Coomassie blue staining). Recombinant Mt-T6PP
protein was dialyzed against 20 mM HEPES buffer (pH 7.5) containing 5 mM MgCl2,
100 mM NaCl and 2 mM DTT in order to remove imidazole. The dialyzed protein was
subjected to steady-state kinetic analysis. For protein that was used for crystallization,
the concentrated, dialyzed protein was loaded onto a HiPrep Sephacryl S200 HR sizeexclusion column that had been equilibrated with 20 mM HEPES buffer (pH=7.5)
containing 5 mM MgCl2 and 2 mM DTT, and eluted with the same buffer. Protein
concentration was determined using the Bio-Rad protein assay with bovine serum
albumin as the standard
For purification of native Mt-T6PP, the protein was first precipitated from the
supernatant derived from centrifugation of the lysed cells using ammonium sulfate. The
fraction containing Mt-T6PP was then resuspended using 20 mM Hepes (pH=7.5)
buffer containing 5 mM MgCl2, 100 mM NaCl, 2 mM DTT and 17 % (NH4)2SO4, and
applied to a Butyl sepharose (BS) column with a binding buffer containing 20 mM
HEPES (pH=7.5), 5 mM MgCl2, 100 mM NaCl, 2 mM DTT and 17 % (NH4)2SO4. The
column was eluted with a linear gradient of 17%-0% (NH4)2SO4 in buffer (10 column
volumes). The fraction containing Mt-T6PP was collected and dialyzed against 20 mM
HEPES buffer (pH=7.5) containing 5 mM MgCl2 and 2 mM DTT to remove the
ammonium sulfate. The protein solution was then loaded onto a DEAE column and
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eluted with 0-1 M KCl in buffer (10 column volume). The Mt-T6PP-containing fraction
was then loaded onto a BS column, running the same gradient as before to obtain pure
protein. Lastly, the fraction containing pure Mt-T6PP was collected and dialyzed
against 20 mM HEPES buffer (pH=7.5) containing 5 mM MgCl2 and 2 mM DTT. The
protein solution was then chromatographed on a Sephacryl S-200 HR column using 20
mM HEPES buffer (pH=7.5) containing 5 mM MgCl2 and 2 mM DTT as eluant.

2.2.2.2 Preparation of Recombinant Wild-type Shigella boydii T6PP
The gene encoding the Sb-T6PP protein was amplified by PCR using DNA
synthesized by GenScript, Deep Vent DNA polymerase, along with a gene-specific
oligonucleotide forward primer (5'CCTCGCGAATGCATCTAGATCCCAT3') and
reverse primer (5'CAGGCCTCTGCAGTCGACGG3') containing NdeI and XhoI
restriction sites, respectively. The pET-28a and pET-23 vectors, digested by NdeI and
XhoI restriction enzymes, were ligated to the PCR product previously digested with the
same restriction enzymes. For pET-15b-TEV vector, it was digested by NdeI and
BamHI restriction enzymes and ligated to the PCR product previously digested with
the same restriction enzymes. The ligation product was used to transform T7 Express
Iq Competent E. coli cells (High Efficiency) that were then grown on an agar plate
containing kanamycin for the pET-28a construct and an agar plate containing ampicillin
for the pET-23a construct. A selected colony was checked for T6PP expression and the
isolated plasmid was sequenced to verify the correct gene sequence. Sb-T6PP was
further prepared using the same method described for Mt-T6PP preparation.
For the purification of His-tagged and native Sb-T6PP, the same methods as
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described previously in Mt-T6PP purification were used. For the purification of Histag removed As-T6PP, TEV protease was used to cut the tag from the His-tagged AsT6PP. Mass spectrometry was used to confirm cleavage of the tag.

2.2.2.3 Preparation of Recombinant Wild-type Ascaris suum T6PP
The DNA coding the As-T6PP protein was amplified by PCR using template
DNA synthesized by GenScript in PUC-57 with Deep Vent DNA polymerase and an
oligonucleotide forward primer (5'CGCGAATGCATCTAGATCCCATATGACT3') and
reverse primer (5'GATCGGATCCAATTTATTCAGTGGCTCGTT3') containing NdeI
and XhoI restriction sites. The pET-15b-tev and pET-23a vectors, digested by NdeI and
XhoI restriction enzymes, were ligated to the PCR product that had been purified and
digested with the same restriction enzymes. The ligation product was used to transform
T7 Express Iq Competent E. coli (High Efficiency) cells that were then grown on an
agar plate containing kanamycin for the pET-15B-tev construct and an agar plate
containing ampicillin for the pET-23a construct. A selected colony was checked for
T6PP expression, and the isolated plasmid was sequenced to verify the correct gene
sequence. Cells were cultured for protein production using the same method previously
described for Mt-T6PP.
For the purification of His-tagged As-T6PP, the same method described
previously for Mt-T6PP purification was used. For the purification of native As-T6PP,
TEV protease was used to cut the tag from the His-tagged As-T6PP. Mass spectrometry
was used to confirm cleavage of the tag.
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2.2.2.4 Preparation of Recombinant Wild-type Salmonella typhimurium T6PP
The gene encoding St-T6PP was amplified by using the polymerase chain
reaction (PCR). The reaction mixture contained Salmonella typhimurium genomic
DNA (ATCC 700720D), PfuTurbo DNA Polymerase and with the forward (5'AGACCCATATGGCAGAACCGTTA-3') and reverse (5'- CACAACCCTCGAGCCG
CTTT-3') oligonucleotide primers containing NdeI and XhoI restriction sites,
respectively. Gene amplification was carried out under the following conditions: 50 μL
reactions contained 5 μL 10×Pfu buffer, 4 μL dNTP mix(2.5mM), 1 μL Deep Vent DNA
Polymerase, 2 μL forward primer (50 μM), 2 μL reverse primer (50 μM), 2 μL
template/genomic DNA (20ng/μL) and 34 μL DI H2O. The initial denaturation was
carried out at 94°C for 2 min followed by 30 cycles of denaturation at 95 °C for 30 s,
annealing at 55.2 °C for 30 s and extension at 72 °C for 1.5 min. The final extension
was carried out at 72 °C for 10 min. The PCR products were digested with NdeI and
XhoI restriction enzymes at room temperature overnight, and the digested products
were harvested by agarose gel electrophoresis. At the same time, pET-15b (+) tev
(Boston University) was also digested by NdeI and XhoI restriction enzymes at room
temperature overnight, and the digested products were harvested in the same manner.
Digested DNA was ligated to corresponding digested pET-15b (+) tev vector at room
temperature for 5-7 h, and the cloned products were verified by DNA sequencing. The
pET-15b (+) tev-T6PP construct was transformed into T7 Express Iq Competent E. coli
(High Efficiency) cells from New England BioLabs. Over-expression of St-T6PP was
induced with 0.4 mM IPTG (isopropyl β-D-thiogalactoside) overnight at 37 °C and 175
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rpm in LB cultures at logarithmic phase growth (OD600=0.4-0.6).
Cells containing St-T6PP were harvested at 6500 rpm for 15 min and the
collected pellet was suspended in 25 mM HEPES buffer (pH =8.0) containing 25 mM
NaCl, 5 mM MgCl2. The resuspended cells were lysed by disruption using a French
Pressure Cell and the lysate was centrifugated at 20,000 rpm for 15 min. For the Histagged St-T6PP (from pET15b (+) tev-T6PP), the supernatant was loaded onto a nickel
nitrilotriacetic acid (Ni-NTA) agarose affinity column, which was pre-equilibrated with
25 mM HEPES buffer (pH =8.0) containing 25 mM NaCl, 5 mM MgCl2, and 10 mM
imidazole. The column was subsequently washed with the same buffer for 3-5 column
volumes before the recombinant protein was eluted with similar buffer containing 500
mM imidazole. The purity of eluted protein was analyzed by 16% SDS-PAGE
(Coomassie blue staining). Recombinant St-T6PP protein was dialyzed against 25 mM
HEPES buffer (pH 8.0) containing 5 mM MgCl2, 25 mM NaCl in order to remove free
phosphate. The dialyzed protein was subjected to steady-state kinetic analysis. For
protein that was used for crystallization, the concentrated, dialyzed protein was loaded
onto a HiPrep Sephacryl S200 HR size-exclusion column that had been equilibrated
with 25 mM HEPES buffer (pH=8.0) containing 5 mM MgCl2, and eluted with the
same buffer. Protein concentration was determined using the Bio-Rad protein assay
with bovine serum albumin as the standard.

2.2.3

T6PPs Molecular Weight Determination
The theoretical subunit molecular mass of each recombinant T6PP was calculated
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from the amino acid composition using the ExPASy Molecular Biology Server program
Compute pI/MW (http://web.expasy.org /compute_pi/). The approximate subunit mass of
each recombinant T6PP was determined by SDS-PAGE analysis (Figure 2.1, Figure 2.2)
using protein molecular weight standards from New England Biolabs Inc. The exact
subunit mass was determined by MS-ES mass spectrometry. The molecular mass of the
native T6PP was determined by FPLC gel filtration column chromatography against
protein standards (13.7-220 kDa from GE Healthcare). The 1.6 cm x 60 cm Sephacryl S200HR column (GE Healthcare) was eluted at 4 oC with the same type of buffer solution
that used for purification. The native molecular weight was derived from the measured
elution volume by extrapolation of the plot of the elution volume of the molecular weight
standard versus log molecular weight.

2.2.4

Steady-state kinetic constant determinations

2.2.4.1 Method for determination of Mt-T6PP steady-state kinetic constants
Phosphatase activity was measured using the EnzChek Phosphate Assay Kit.
Reactions solutions 500 μL in volume contained 25 µL 20× reaction buffer, 5 µL purine
nucleoside phosphorylase (0.5 U) and 28 nM of purified enzyme. The Absorbance at 360
nm was measured to determine the amount of free phosphate produced, which was linear
in the range of 0.05– 1 mM trehalose-6-phosphate. The steady-state kinetic parameters (Km
and kcat) were determined by fitting the initial velocity data measured at varying substrate
concentration (varied in the range Km – 10Km) to the equation:
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V0 = (Vmax[S])/([S]+Km)

Where V0 is the initial velocity, Vmax the maximum velocity, [S] the substrate
concentration, and Km the Michaelis constant for the substrate, using the SigmaPlot
Enzyme Kinetics Module. The kcat values were calculated from Vmax and [E] according
to the equation kcat = Vmax/[E], where [E] is the enzyme concentration.

2.2.4.2 Method for determination of Sb-T6PP Steady-state kinetic constants
To test for Sb-T6PP phosphatase activity, the EnzChek Phosphate Assay kit (as
described previously) was used. Reactions with a final volume of 500 μL contained 25
μL 20× reaction buffer, 5 μL purine nucleoside phosphorylase (0.5 U) and 28 nM of
purified enzyme. The absorbance at 360 nm was measured to determine the amount of
free phosphate produced, which was linear in the range of 0.5– 3 mM trehalose-6phosphate. The kinetic parameters Km, kcat and kcat/Km were determined by using the
same method previously described for Mt-T6PP.

2.2.4.3 Method for determination of As-T6PP steady-state kinetic constants
To test for Sb-T6PP phosphatase activity, the EnzChek Phosphate Assay kit (as
described previously) was used. Reactions with a final volume of 500 μL contained 25
μL 20× reaction buffer, 5 μL purine nucleoside phosphorylase (0.5 U) and 28 nM of
purified enzyme. The absorbance at 360 nm was measured to determine the amount of
free phosphate produced, which was linear in the range of 50– 500 mM trehalose-6-
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phosphate. The kinetic parameters Km, kcat and kcat/Km were determined by using the
same method previously described for Mt-T6PP.

2.2.4.4 Method for determination of St-T6PP steady-state kinetic constants
To test for St-T6PP phosphatase activity, the EnzChek Phosphate Assay kit (as
described previously) was used. Reactions with a final volume of 300 μL contained 15
μL 20× reaction buffer, 3 μL purine nucleoside phosphorylase (0.3 U) and 33 nM of
purified enzyme. The absorbance at 360 nm was measured to determine the amount of
free phosphate produced, which was linear in the range of 0.13– 1.2 mM trehalose-6phosphate [1]. The kinetic parameters Km, kcat and kcat/Km were determined by using
the same method previously described for Mt-T6PP.

2.2.4.5 Method for determination of Bm-T6PP steady-state kinetic constants
To test for Bm-T6PP phosphatase activity, the EnzChek Phosphate Assay kit
(as described previously) was used. Reactions with a final volume of 500 μL contained
25 μL 20× reaction buffer, 5 μL purine nucleoside phosphorylase (0.5 U) and 8 nM of
purified enzyme. The absorbance at 360 nm was measured to determine the amount of
free phosphate produced, which was linear in the range of 0.0625-5 mM trehalose-6phosphate. The kinetic parameters Km, kcat and kcat/Km were determined by using the
same method previously described for Mt-T6PP.

2.3 Results and Discussion
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2.3.1 Preparation of the recombinant T6P Phosphatases
His6-tagged T6P phosphatases were expressed in E. coli and purified by affinity
chromatography. The SDS-PAGE gels of the purified proteins are shown in Figure 2.3.1
and 2.3.1. Typical yields (mg protein/g cell pellet) are as follows: As-T6PP 2.7, Mt-T6PP
5.3, Sb-T6PP 3.7, St-T6PP 11.7.
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Figure 2.1. SDS -PAGE analysis of purity of the purified his-tagged

Ladder St-T6PP

Figure 2.2. SDS -PAGE analysis of purity of the purified his-tagged
St-T6PP. From left to right, Lane 1: Ladder; Lane 2: St-T6PP.
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2.3.2 ES-MS Determination of the exact mass of the purified proteins
ES-MS analysis of the purified proteins yielded the following results: His-tagged
Mt-T6PP (theoretical 44.051 kDa) 44.052 kDa; Native Mt-T6PP (theoretical 41.720 kDa)
41.720 kDa; His-tagged Sb-T6PP (theoretical 31.297 kDa) 31.297 kDa; Tev cleaved Histagged Sb-T6PP (theoretical 29.459 kDa) 29.459 kDa; His-tagged As-T6PP (theoretical
56.717 kDa) 56.718 kDa; Tev cleaved His-tagged As-T6PP (theoretical 54.581kDa) 54.582
kDa. His-tagged St-T6PP ((theoretical 31.576 kDa) 31.576 kDa. The mass spectra are
shown in the figures below.

Figure 2.3 Mass spec of His-tagged Mt-T6PP (theoretical mass: 44.051 kDa).
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Figure 2.4 Mass spec of native Mt-T6PP (theoretical mass: 41.720 kDa).

Figure 2.5 Mass spec of His-tagged Sb-T6PP (theoretical mass: 31.297 kDa).
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Figure 2.6 Mass spec of Tev cleaved His-tagged Sb-T6PP (theoretical mass: 29.459
kDa).

Figure 2.7 Mass spec of His-tagged As-T6PP (theoretical mass: 56.717 kDa).
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Figure 2.8 Mass spec of Tev cleaved His-tagged As-T6PP (theoretical mass:
54.581 kDa).

Figure 2.9 Mass spec of His-tagged St-T6PP (theoretical mass: 31.576 kDa).
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2.3.3 T6PPs Substrate Specificity Profile
The ability of purified T6PPs to catalyze the conversion of some similar
monosaccharide (glucose-6-phosphate) and disaccharide phosphates (sucrose-6-phosphate)
and p-nitrophenyl phosphate (a generic substrate for HAD phosphatases) were tested.
Under the reaction conditions employed (10 mM phosphate ester substrate, 1 mM MgCl2,
0.1 Mm sodium azide and 50 M Mt-T6PP mM in 50 mM Tris buffer at pH 7.5 and 25
o

C), No activity was observed above the detection limit of one catalytic turnover per hour.

The one exception is Mt-T6PP which displayed marginal activity towards -D-glucose-1phosphate (kcat =0.0022±0.0002 s-1 and Km = 8 ± 1 mM. Earlier, Mt-T6PP was reported
to display activity with α-D-glucose-1-phosphate, α-D-mannose-1-phosphate and
mannose-6-phosphate [2].
In general, the T6PPs show stringent substrate specificity which is unusual for
HAD phosphatases. Even the dissacharide sucrose-6-phosphate, which is highly similar
to trehalose-6-phosphate, both of them are disaccharide and have phosphate at one of the
6 positions of the monosaccharide moiety. Trehalose-6-phosphate has 1,1, α, α linkage,
but sucrose -6-phophatete has 2,1, α-linkage, besides, Trehalose-6-phosphatete was formed
by two glucose, but sucrose-6-phospahte has a glucose and a fructose [Figure 4]. However,
none of the T6PPs shows activities on it. Besides, p-nitrophenyl phosphate is a widely
used “activated” substrate for detecting phosphatase activity in HAD phosphatases, yet
remarkably none of the T6PPs showed activities with it.
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Figure 2.10. Structures of trehalose-6-phospahte and sucrose-6’-phosphate

Next, the T6PPs phosphatase activities were tested using their biological substrate
trehalose-6-phosphate [Figure 2.10]. Their kcat, Km and kcat/Km values were determined at
pH 7.5 and 25 ℃ [Table 2.1]

Table 2.1 Steady-state kinetic constants for wild-type T6PPs-catalyzed hydrolysis of
trehalose 6-phosphate at pH 7.5 and 25 ℃. See Materials and Methods for details
T6PP Source

kcat (s-1)

Km (μM)

kcat/Km (M-1s-1)

Brugia malayi 5

24±2

360±60

6.9×104

Mycobacterium tuberculosis

10±0.9

500±100

1.9×104

Shigella boydii

16±0.8

690±70

2.3×104

Ascaris suum

3.6±0.5

230±70

1.6×104

Salmonella typhimurium

6.2±0.3

310±40

1.9×104
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The kcat value is governed by the two partial reactions: the first is the phosphoryl
transfer from the bound substrate (T6P) to the Asp nucleophile, and the second step is the
hydrolysis of the aspartyl-phosphate intermediate by the attack of a water molecule [3]. A
second Asp residue (denoted Asp + 2 because it is positioned two residues from the Asp
nucleophile) functions as a general acid/base residue to protonate the leaving group in the
first partial reaction and deprotonate the water nucleophile in the second partial reaction
[Figure 2.11] [4].

Figure 2.11. Catalytic mechanism for T6PP.

The kcat/Km value, the substrate specificity constant, is determined by both the
substrate binding affinity and the efficiency that the bound substrate (aspartyl-phosphate
intermediate) is converted to the product (phosphate). The kcat/Km value is very useful for
identifying substrates that have physiologically relevant activities since the concentration
of the substrate in the cell is likely to be sub-saturating. HAD phosphatases that function
as regulators of the level and composition of organophosphate metabolite pools typically
have Km values in the milli-molar range and kcat/Km values in the 1 x 103 to 1 x 104 M-1 s-1
range, where those that target single physiological substrate typically display a kcat/Km
value in the range of 1 x 105 to 1 x 107 M-1 s-1. The kcat values typically fall in the range of
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1-20 s-1 range and the Km values from low micromolar to low millimolar. Accordingly, the
T6PPs display a moderate, but certainly a physiologically relevant level of catalytic
efficiency towards T6P. It is the high level of substrate specificity displayed each of the
T6PPs that stands-out.

2.3.4 Quaternary structure determination
The native masses were determined by using size exclusion (HiPrep Sephacryl
S200 HR) column chromatography in conjunction with protein molecular weight standards.
The results are as follows: native Mt-T6PP 39.1 kDa (monomer); native Sb-T6PP 28.8 kDa
(monomer); native As-T6PP 61.9 kDa (monomer)

2.3 Conclusion
There is an urgent need to discover novel antifilarial and antibacterial drug targets to
assail the parasite especially when the risk of development of resistance to mainstay drugs
is mounting. In trehalose biosynthesis, T6PP seems to be novel drug target as geneknockout experiments have shown that it is the pathway trehalose-6-phosphate
phosphatase (T6PP) that is essential (owing to build-up of toxic levels of T6P) to the
survival of the host organism (parasitic nematodes and bacteria). Thus, in the present study
we have cloned, expressed, purified and characterized four orthologs of trehalose-6phospahte phosphatase from different organisms, A. suum, and B. malayi T6PPs are from
nematodes, M. tubercleosis T6PP is form mycobacteria, and S. boydii, S. typhimurium
T6PPs are from bacteria, which will be used for further characterization and inhibition
studies.
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CHAPTER THREE
TREHALOSE-6-PHOSPHATE PHOSPHATASE INHIBITOR
DESIGN, SYNTHESIS AND EVALUATION

3.1 Background
Although the HADSF fold is dominant among eukaryotic and prokaryotic
phosphatases, it has yet to be fully exploited for drug discovery. This stands in contrast to
the phosphotyrosine phosphatase (PTP) family of phosphatases, for which great progress
has been made in drug-like lead-inhibitor design and focused library-screening-based drug
discovery [1-7]. To date only two reports of HADSF phosphatase inhibitor discovery have
been described. First, the human small C-terminal domain phosphatase (Scp), which
catalyzes the dephosphorylation of the C-terminal domain of eukaryotic RNA polymerase
II, was screened against a pilot library of the NIH clinical collection (400 compounds) and
the spectrum collection (2000 compounds). Among the hits, the drug Rabeprazole was
found to have the tightest binding (IC50 = 5 μM) [8]. X-ray structural analysis revealed that
this inhibitor binds to a shallow hydrophobic pocket adjacent to the catalytic site. In a
second instance, the structure of the HADSF eyes absent-2 phosphatase was subjected to
virtual screening of the InterBioScreen library and the top hits were shown by in vitro assay
to have IC50 values ranging from 4-66 μM [9]. In-silico modeling suggests Mg2+
coordination of a chelating substituent augmented by favorable electrostatic interactions
with substituents that occupy the catalytic site. Notably, both Scp and the eyes absent-2
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phosphatase belong to a subclass of HADSF phosphatases that do not possess cap domains.
Importantly, the potential for targeting a larger region of the protein contributed by the
catalytic domain and the cap domain has yet to be explored.
3.2 Research Strategy
The initial strategy used for T6PP inhibitor design is based on the expectation
catalysis by this enzyme might be prevented by binding a substance to the catalytic domain,
to the cap domain, or to both domains in either a cap-open or cap-closed conformations.
Thus, in this effort we have focused on the selection of potential inhibitors that might target
the binding sites of the cap-closed and cap-open T6PP conformers. Specifically, the initial
inhibitor approach centers substances that contain phosphate-mimetic groups, which can
bind to the active site of the catalytic domain, tethered to organic moieties, which can ligate
with the binding site of the cap domain. “Bivalent” inhibitors of this type have the potential
of being high affinity and high specificity T6PP targeting agents [10]. In this chapter, we
focus on the selection and evaluation of phosphate-mimetic groups to replace the
C(6)phosphate group of trehalose. The corresponding inert substrate analogs were
synthesized and then used as inhibitors of T6PP-catalyzed T6P hydrolysis.

3.3 Inhibitor Selection and Synthesis
As described above, in the active sites of HAD phosphates the substrate phosphoryl
substituent coordinates the Mg2+ cofactor and forms a number (>10) of hydrogen bonds
with donors located in the active site of the catalytic domain. Crystallographic snapshots
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of liganded active sites posed in the trigonal bipyramidal phosphorane transition-state

Scheme 3.1. Structures of T6PP inhibitors explored in this effort.
configuration suggest that favorable binding interactions are maximized when the ligand
conforms to the active site mold [11]. As a consequence of this analysis, we have designed
several T6P analogs that contain the trehalose skeleton, which should be appropriate for
binding to the cap domain of T6PPs. In addition these potential inhibitors contain groups
that possess charge and Mg2+ and hydrogen bonding characteristics that are analogous to
those of the phosphate moiety in T6P. Specifically, the inhibitors explored in this
investigation, including the trehalose-6-sulfate 1, -methylenephosphonate 2, and fluoromethylenephosphonate 3 [Scheme 3.1], contain groups that have been shown to
resemble phosphate moieties present in substrates for kinases and phosphatases [12-21]. In
addition, in this study we have tested the ability of trehalose-6-methyleneboronate 4 and
its in situ derived hydroxide adduct to target the T6PP catalytic sites. To our knowledge,
boronates have not been tested as phosphomimetics. However, their ability to act as
mechanism-based inhibitors of arginase and β-lactamase [22, 23] suggest that they might
participate in formation of stable complexes with HAD catalytic sites. In the case of
arginase, the trigonal boronate group plays the role of the Arg guanidinium moiety in
reaction with the metal-ion bridged hydroxide to form a stable transition-state analog
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complex. In the case of β-lactamase, the active site Ser nucleophile forms a covalent adduct
with the boronate group in a peptide-mimetic [24, 25]. We reasoned that by analogy the
T6PP Asp nucleophile might form a covalent adduct with the boronate group in 4.

3.4 Results and Discussion
3.4.1 Determination of the Source(s) of T6PP Substrate Binding Energy
The five T6P phosphatases were compared for their ability to bind substrate analog
(sucrose-6-phosphate),

substrate

fragments

(trehalose

and

glucose-6-phosphate),

tetrahedral Pi analog (tungstate) and metavanadate, a potential trigonal bipyramidalforming transition ligand). The abilities of the respective ligands to bind to the respective
T6PP active sites were determined by testing them as inhibitors of catalyzed T6P hydrolysis
by using steady-state kinetic techniques. The results are reported in Table 3.1. HAD
phosphatases differ in the ability to form the (nucleophilic) Asp carboxylate adduct with
the vanadate and/or with the vanadate complex of the alcohol complex. With the exception
of As-T6PP, the T6P phosphatase is not inhibited by vanadate. Tungstate binding is also
variable among HAD phosphatases. Based on the results reported in Table 3.1 we can
conclude that tungstate binds tightly to Bm-T6PP and Mt-T6PP, moderately to As-T6PP
and does not bind with significant affinity to Sb-T6PP and St-T6PP.
The absence of significant binding affinity observed for sucrose-6-phosphate with
all five T6P phosphatases accounts for its lack of substrate activity, as was first reported in
Chapter 2. Cleary, overall fit is important for substrate binding as well as catalysis. The
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absence of significant binding of trehalose to the T6P phosphatases suggests that the
trehalose moiety, alone, does not make a sizable contribution to the substrate binding
affinity as reflected in Ki values too large to measure using steady-state kinetic techniques.
Yet, it must be kept in mind that the trehalose moiety is required for productive binding, or
in other words, for formation of the catalytically active enzyme-substrate complex (i.e., for
turnover) (viz., glucose-6-phosphate is not turned over).
Table 3.1. Inhibition constant (Ki) of product, product analog or substrate analog
measured for T6PPs from various organisms.
Inhibitor

SbT6PP Ki

StT6PP Ki

MtT6PP Ki

BmT6PP Ki

AsT6PP Ki

Sucrose-6-P

NDa

NDa

NDa

NDa

NDa

Glucose-6-P

NDa

NDa

NDa

NDa

NDa

K2WO4

NDb

NDb

19±

4.0±0.

120±20 

Trehalose

NDa

NDa

NDa

NDa

NDa

Na3VO4

NDa

NDa

NDa

NDa

55±9 

20 mM Trehalose
+ 1.3 mM Na3VO4

-

-

-

~1.3 mM

-

a

No Inhibition detected for catalyzed hydrolysis of [T6P] =Km in the presence of 10 mM inhibitor.
No inhibition detected for catalyzed hydrolysis of 600 μM T6P in the presence of 2 mM inhibitor
c
This value was calculated, when the initial velocity is half of that without trehalose and Na 3VO4
in the presence of 200 μM T6P.
b

Likewise, the T6P fragment glucose-6-P does not bind with significant affinity to
the five T6P phosphatases. This observation suggests that binding to the individual
substrate fragments is not strong enough to overcome the loss in entropy associated with
complex formation. As will be developed further in the following section, this deduction
lead us to design inert substrate analog inhibitors having a phosphate mimetic group located
at the C(6) position of trehalose.
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3.4.2 Analysis of the T6PP Active Site
As described in Chapter 1, the phosphoryl group of the HADSF phosphatase
substrate engages in coordination bond formation with the Mg2+cofactor, in hydrogen bond
formation between the bridging oxygen and the (acid/base) Asp in its protonated state, in
ion pair formation with the conserved Lys, and hydrogen bond formation with the
conserved Thr/Ser. At the outset of my work the only known T6PP X-ray structure was that
of (Archeae) Thermoplasma acidophilum T6PP complexed with the Mg2+ cofactor, but
recently our collaborators at Boston University (Karen Allen and co-workers) solved the
structure of the (nematode) Brugia malayi T6PP complexed with Mg2+ [26] (see Figure
3.1). Despite the addition of the N-terminal MIT domain to the Bm-T6PP, the (HADSF)
phosphatase cap and core domains are quite similar in fold to those of Tm-T6PP. (Figure
3.1).
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Ta-T6PP

Bm-T6PP MIT
domain hidden

Bm-T6PP

Figure 3.1 Comparison of the structures of T6PP from Thermoplasma
acidophilum and Brugia malayi. The Bm-T6PP MIT domain
(palegreen) and helical linker (forestgreen) are hidden in the structure
to the right to highlight the similarity in structures of the respective
HADSF phosphatases.
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Likewise, the phosphate binding sites are conserved as illustrated in Figure 3.2. The
T6P phosphate group can be manually docked into position making favorable electrostatic
contacts with the Mg2+, Thr, Lys and possibly the protonated Asp (acid/base).

Figure 3.2 Cartoon representation Ta-T6PP (left panel) and Bm-T6PP (right panel)
phosphate binding site generated in Pymol. The N-terminal MIT domain of the Bm-T6PP
is not shown. Conserved elements of secondary structure are colored the same in the two
structures, as are the phosphate binding residues whose side chains are shown in stick, and
Mg2+ the cyan sphere.

How then to orient the trehalose? The trehalose moiety should fit snuggly within the
substrate binding pocket formed by the interfaced cap and catalytic domains. The trehalose
binding sites of the T6P phosphatases will be described in Chapter 4. Instead, in this chapter
I focus on the route to identification of stable functional groups that bind to the phosphate
binding site with high affinity. Ms. Christine Harvey, a graduate student in the Dr. Karen
Allen lab at BU created T6P-docked structures (manual) for Ta-T6PP and (Bm-T6PP model
looks the same) shown in Figure 3.3, highlighting the phosphate binding site.
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Figure 3.3 Two representations of the X-ray structure of Ta-T6PP manually docked
with T6P.

3.4.3 Binding Affinities of Inert T6P Analogs: Evaluation of Phosphate Mimetic
Groups.
Inert T6P analogs, 1-4 in which the C(6)phosphate is replaced with an approximate
isosteric and isoelectronic functional group (resistant to hydrolytic cleavage), were
prepared as outlined in Scheme 3.2 and described in Section 3.4.3 and tested as competitive
inhibitors (vs. T6P) of the five T6P phosphatases. The steady-state competitive inhibition
constants (Ki) determined for these substrate analog inhibitors are reported in Table 3.2.
The plots of the kinetic data sets obtained for each inhibitor-T6PP pair are provided in the
Appendix (page 187-201).
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Table 3.2. KIs (Competitive Inhibition Constant) values of trehalose with different
warheads.

Inhibitor

Bm-T6PP

Mt-T6PP

Sb-T6PP

As-T6PP

St-T6PP

1

82 ± 7 μM

130 ± 20 μM

330 ± 40 μM

49 ± 5 μM

180 ± 10 μM

2

490 ± 90 μM

500 ± 100 μM

>2 mM

520 ± 80 μM

>2 mM

3

280 ± 50 μM

470 ± 90 μM

>2 mM

490 ± 70 μM

>2 mM

4

No Inhibition

No Inhibition

No Inhibition

No Inhibition

No Inhibition

No Inhibition: No inhibition observed at the presence of 10 mM inhibitor.

The Ki values varied between inhibitors tested with the same T6PP and between T6P
phosphatases tested with the same inhibitor. The results show that the sulfate group is
superior overall in attracting favorable binding energy from the phosphate binding sites of
T6P phosphatases. The results also show that subtle differences exist between the binding
sites of the T6PP orthologs which impact inhibitor binding affinity.
The sulfate group, like the phosphate group, has tetrahedral geometry and like the
phosphate group monoanion, it carries a single negative charge. The S-O-C(6) bridging
oxygen atom of trehalose-6-sulfate (T6S) 1 can potentially serve as a hydrogen bond
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acceptor in analogy to the P-O-C(6) bridging oxygen atom of the T6P. The methylene group
of the trehalose-6-methylene phosphate 2 inhibitor of coarse cannot engage in such
interaction, thus accounting at least in part for lower binding affinity. The substitution of
the methylene hydrogen atom(s) for fluorine(s) is known to enhance the binding of the
phosphonate

inhibitor

to

tyrosine

phosphate

phosphatases.

The

trehalose-6-

monofluoromethylene phosphonate 3 did indeed show improved binding affinity, yet still
not enough and my attempts to prepare the trehalose-6- difluoromethylene phosphonate for
testing were not successful.
Also during this work I have tested the ability of trehalose-6-methyleneboronate 4
and its in situ derived hydroxide adduct to target the T6PP catalytic sites. Disappointingly,
no inhibition was found.
In summary, T6S proved to be a moderately tight binding substrate analog inhibitor
which we exploited as the “ligand of choice” in X-ray structure determinations, StructureActivity Relationship (SAR) analysis and Small Angle X-ray Scattering (SAXS) analysis.
The SAR studies are reported in Chapter 4 whereas the SAXS studies are reported in this
Chapter.

3.4.3 Synthetic Routes to the T6P Analogs 1-4.
The synthetic routes utilized for preparation of 1-4, potential inhibitors of T6PP, are
displayed in Scheme 3.2. The key intermediate employed in all of the pathways is the
selectively protected and desymmetrized trehalose derivative 5, generated by using the
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route described earlier by Berndt and his coworkers [28]. For example, 5 was transformed
to trehalose-6-sulfate (1) by treatment with the pyridine sulfur trioxide complex to produce
the benzyl-protected derivative 6, which was then subjected to hydrogenolysis to form 1.
Similar methods, involving Swern oxidation of 5 to from aldehyde 7 followed by
phosphono-olefination with methylene bis-phosphonate esters ((EtO)2OP)2CH2 and
((EtO)2OP)2CHF, hydrogenation/hydrogenolysis, and phosphonate ester cleavage, were
employed to produce the respective methylene- and fluoromethylene-phosphonate
derivatives 2 and 3. Finally, boronate derivative 4, was prepared by using a sequence that
began with Wittig olefination of aldehyde 7, iridium promoted hydroboration with of the
resulting olefin 12 with pinacolborane, and hydrogenolysis/bronate hydrolysis.
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Scheme 3.2. Synthesis of reversible inhibitors.

3.4.4 Examination of Substrate (Analog) Induced Conformational Changes in T6P
Phosphatases Using SAXS
As was described in Chapter 1, a catalytic cycle for a HADSF phosphatase involves
a sequence of conformational changes in which the cap and core domains move relative to
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one another in order to allow substrate to bind (open), catalysis to occur (closed) and
products to disassociate (open). If the T6P binds to the T6PP in the open conformation, and
additional binding energy is gained from the ligand in the closed conformation, the T6P
acts to stabilize the enzyme in its catalytically active closed conformation. This is an
example of substrate-induced fit. For the purpose of testing domain-scale conformational
changes in the T6PP, the T6S inhibitor was used in place of T6P as titrant in SAXS solutionbased experiments.
The SAXS data collection and analysis were carried out by my labmate Dr. Tyrel
Bryan. The maximum diameter was determined using the p(r) distribution and Rg values
calculated for each protein with and without inhibitor T6S (Table 3.3). These values among
the scattering and Kratky plots were used to investigate the predisposition to close the cap
due to ligand binding. Because the T6PP proteins tested are C2 HAD proteins; theoretical
scattering profiles representing the two conformers of a different C2 HAD protein were
generated to investigate differences among the scattering profiles due to cap position
relative to core domain (Figure 3.5). The two nematode T6PP proteins (A. suum, and B.
malayi) displayed no evidence of change in structure due to binding T6S. In each case the
proteins scattering curves look identical between the native protein and protein in the
presence of inhibitor (Figure 3.6, 3.7). To further support no change in domain position,
the dmax values and Rg values are the same between the two samples in both cases. This
result can be accredited to the addition of the MIT-domain in the nematode structures
compared to the smaller orthologs with a significantly smaller sequence addition to the Nterminus (M. tubercleosis T6PP) and the absence of “extra” N-terminal sequence in the
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case the two T6PP orthologs from S. boydii and S. typhimurium.
As expected with a significantly smaller insert or without the additional domain,
movement can be observed in the presence of T6S when compared to the native samples
(Figure 3.9, 3.10). Although the change in dmax in each case are small, the change in Rg
and the presence of distinct scattering patterns suggest closure of the cap.
Table 3.3 p(r) distribution and Rg values calculated for each protein with and without
the inhibitor T6S
Protein

Ligand

Guinier
Region Rg

A. suum

--T6S
--T6S
--T6S
--T6S
--T6S

30.60 ± 0.07
30.50± 0.10
27.20± 0.22
27.28 ± 0.18
23.50 ± 0.28
22.30 ± 0.13
32.51 ± 0.37
34.62 ± 0.22
23.96 ± 0.09
23.18 ± 0.16

B. Malayi
S. boydii
M. tubersleosis
S.
typhimurium
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P(r)
Distribution
Rg
31.5
31.5
26.6
27.4
23.7
22.9
32.9
35.0
24.8
23.2

dmax (Ǻ)
107
107
89
89
82
80
114
119
84
81

DNM
DNM
MOVE
MOVE
MOVE

Bm-T6PP (PDB: 4OFZ)

As-T6PP

Sb-T6PP

Mt-T6PP

St-T6PP

Figure 3.4: Structures of T6PPs were generated by using Phyre 2 except
Bm-T6PP. Blue: HAD cap domain, Magenta: HAD core domain, Green:
connector, Orange: MIT-like domain.
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Scheme 3.3. Simulation of Mt-T6PP domain movement. Blue: HAD
cap domain; Magenta: HAD core domain; Orange: N-terminal
“domain”; Cyan: T6S. Left: Mt-T6PP without inhibitor T6S, cap open
Right: Mt-T6PP with inhibitor T6S, cap closure.

In the case of Mt-T6PP, It has bigger dmax when binding with T6S inhibitor
(increased by 5 Å). We hypothesize that its extra N-terminal “domain” was pushed away
when inhibitor T6S induces the cap closure of Mt-T6PP (Scheme 3.3).
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Figure 3.5: (A) Superposition of Bt4131 (PDB: 1YMQ, blue) and T. maritima phosphatase
(PDB: 1NF2, red) to compare cap-closed and cap-open conformers. (B) CRYSOL generated
scattering curves from the two PDB structures were generated to observe curve difference
associated with cap movement (color scheme corresponds to crystal representation colors).

Figure 3.6: Kratky plot of A. suum T6PP native (black) and with T6S (red). At low q the
two scattering graphs are identical suggesting no change in the largest particle dimension.
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Figure 3.7: Kratky plot of B. malayi T6PP native (black) and with T6S (red).
The two scattering graphs are identical at low and mid q suggesting no change
in dimensions in the presences of T6S.

Figure 3.8: Kratky plot of M. tuberculeosis T6PP native (black) and with T6S
(red) showing a difference in conformations for the apo and T6S bound MtT6PP.
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Figure 3.9: Kratky plot of S. boydii T6PP native (black) and with T6S (red). Similar
to the theoretical changes due to cap-closure S.b T6PP show distinct low-q patterns
due to binding the inhibitor T6S.

Figure 3.10: Kratky plot of S. typhimurium T6PP native (black) and with T6S (red).
S.t T6PP show distinct conformations (cap-closed / cap-open) w/wo the inhibitor
T6S, respectively.
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3.5 Material and Methods
3.5.1 Inhibitor Synthesis
General information: Except specified, all commercial solvents and reagents were
purchased from Sigma-Aldrich and used without further purification. Analytical thin-layer
chromatography (TLC) was performed on Sorbent Technologies silica gel plates with
fluorescence F254 indicator and column chromatography was performed using the indicated
solvent on Merck 60 silica gel (230-400 mesh). 1H (300 and 500 MHz), 13C NMR (75 MHz
and 125 MHz), and 31P (121.5 MHz) NMR spectra were recorded on Bruker Avance 500
and Bruker Avance III 300 spectrometers. 1H, 13C and 31P NMR data are reported as follows:
for 1H NMR chemical shifts are reported in ppm relative to HDO and multiplicities are
given as s = singlet, d = doublet, t = triplet, q = quartet, m =multiplet, coupling constant
(J);

13

C NMR chemical shifts are reported in ppm using NH4HCO3 as standard; for
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P

NMR chemical shifts are reported in ppm using 50% aq H3PO4 as standard.
Synthesis of 6-O-sulfonato-α,α-D-trehalose

Scheme 1. Reagents and conditions. (a) SO3/C5H5N, C5H5N, 5 h (b) Pd(OH)2/C,
MeOH/H2O, r.t. 24 h.
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Compound 61

To a solution of SO3/C5H5N complex (432 mg, 2.7 mmol) in freshly distilled pyridine
(5mL), a solution of 5 2 (1.345g, 1.35 mmol) in freshly distilled pyridine (5 mL) was added.
The mixture was stirred for 5 h at room temperature, then the reaction mixture was
neutralized with Na2CO3(aq) (1 M, 10 mL) and concentrated under reduced pressure. The
salts were triturated with anhydrous MeOH and filtered. The filtrate was concentrated in
vacuo and the crude product was purified by silica gel column chromatography (30:1
MeOH/EtOAc) affording 6 (1.35g, 93%) as a white powder. TLC (MeoH:EtOAc, 30:1,
v/v): Rf=0.30; 1H NMR (MeOD): 3.50-3.58(3H, m), 3.62(1H, t, J=9.45 Hz), 4.00-4.07(2H,
m), 4.09-4.12(2H, m), 4.14-4.18(2H, m), 4.34-4.37(1H, m), 4.42-4.45(2H, m), 4.614.80(9H, m), 4.87-4.90(2H, m), 5.26-5.27(2H, m), 7.10-7.30(35H, m); 13C NMR (MeOD):
68.19, 70.6,71.9, 72.8, 74.8, 75.0, 75.2, 76.4, 76.6, 77.2, 796, 80.0, 81.7, 81.8, 83.3, 83.4,
94.9, 129.3, 129.4, 129.53, 129.59, 129.6, 129.7, 129.80, 129.88, 130.0, 130.1, 130.2, 130.3,
140.1, 140.2, 140.4, 140.6, 140.7, 141.0; HRMS(ES) m/z: [M-Na]－calcd. for C61H63O14S-,
1051.3939; found, 1051.4022.
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Compound 11

6 (0.96g, 0.89 mmol) was dissolved in MeOH/H2O (1:1, V/V, 40 mL) and to this was added
20% Pd(OH)2/C (1.26g) and palladium was activated by repeat purge flush cycles with
hydrogen. The mixture was stirred under 1 atm pressure at room temperature for 24 h. Then
the mixture was filtered through a Celite pad, the filtrate was concentrated in vacuo and
the crude product was purified by column chromatograph (1:4:4, water/isopropanol/ethyl
acetate) to give the desired, fully deprotected sugar, as white powder (366 mg, 93%). TLC
(water/isopropanol/ethyl acetate, 1:4:4, v/v/v): Rf=0.40; 1H NMR (D2O): 3.39-3.52(2H,
m), 3.60-3.67(2H, m), 3.72-3.86(5H, m), 3.97-4.02(1H, m), 4.23-4.26(2H, m), 5.165.18(2H, m); 13C NMR (D2O): 60.3, 66.7, 69.1, 69.5 70.0, 70.68, 70.74, 72.0, 72.19, 72.25;
HRMS(ES) m/z: [M－Na]－calcd. for C12H21O14S－,421.0652; found, 421.0648.
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Synthesis of Trehalose-6-phosphonate

Scheme 1. Reagents and conditions. (a) oxalyl chloride, DMSO, DCM, -60℃, TEA; r.t., 3
h；(b) n-BuLi, THF, -78℃, 2 h. (c) H 2, Pd/C, EtOH, rt; (d) TMSBr, MeCN/C5H5N, r.t. 4
h; H2O, overnight.
Compound 7 3

To a solution of oxalyl chloride (490 mg, 3.86 mmol) in freshly distilled DCM (10 ml) at 60℃under argon, was added dimethyl sulfoxide (603 mg, 7.72 mmol) dropwise. After
stirring for 30 min at -60℃, a solution of 5 (2.4g, 2.57 mmol) in 5ml freshly distilled DCM
was added dropwise, the resulting mixture was sirred at -60℃for 1 h, then TEA (1.04 g,
10.3 mmol) was added, and the mixture was allowed to reach to room temperature over a
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period of 30 min, then stirred at room temperature for 3 h. The solvent was concentrated
in vacuo and the crude product was purified by silica gel column chromatography (20:1
DCM/MeOH) affording 7 (2.15g, 90%). TLC (DCM): Rf=0.20; 1H NMR (CDCl3): 3.413.45(2H, m), 3.55-3.61(3H, m), 3.65(1H, dd, J1=3.5 Hz, J2=9.5 Hz), 3.75(1H, t, J= 9.65),
4.07(1H, t, J=9.3 Hz), 4.14(1H, t, J=9.7 Hz), 4.20(1H, dd, J1=3.5 Hz, J2=9.8 Hz ), 4.44(1H,
d, J=11.8 Hz), 4,52(1H, d, J=10.4 Hz), 4.59-4.63(2H, m), 4.71-4.78(4H, m), 4.86-4.97(4H,
m), 5.05-5.08(2H, m), 5.20(1H, d, J=3.4 Hz), 5.28(1H, d, J=3.0 Hz), 7.26-7.45(35H, m),
9.39(1H, s); 13C NMR (CDCl3): 61.0, 63.9, 64.0, 65.7, 66.2, 66.5, 67.6, 68.0, 68.1, 68.6,
68.8, 70.6, 71.3, 71.7, 72.3, 74.5, 74.8, 87.4, 88.1, 120.4, 120.6, 120.6, 120.7, 120.8, 120.9,
121.0, 121.1, 121.2, 121.3, 121.4, 121.4, 121.4, 121.5, 130.4, 130.8, 131.2, 131.3, 131.4,
131.7, 190.7; HRMS(ES) m/z: [M+Na]+ calcd. for C61H62O11Na+, 993.4190; found,
993.4256.
Compound 8

n-BuLi (371 μL, 2.5M in hexanes)was added to a suspension of tetraethyl
methylenediphosphonate (294 mg, 1.02 mmol) in anhydrous THF(4 ml) at -78℃. The
mixture was allowed to warm to -20℃ over a period of 1 h, then the mixture was cooled to
-78℃, and a solution of the aldehyde 7 (600 mg, 0.619 mmol) in THF(2 ml) was added
dropwise. After stirring for 30 min at -78℃, the reaction mixture was allowed to warm to
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room temperature slowly, and kept stirring at room temperature overnight. Then saturated
NH4Cl(aq) was added, the aqueous phase was extracted with Et2O, and the combined
organic extracts were dried using anhydrous Na2SO4, the solvent was removed in vacuo,
and the crude product was purified by silica gel column chromatography (20:1
DCM/MeOH) affording 8 (2.15g, 90%). TLC (DCM): Rf=0.20; 1H NMR (CDCl3):
1.32(6H, t, J=8.1Hz), 3.43(1H, dd, J1=3.4 Hz, J2=10.25 Hz), 3.55(1H, dd, J1=3.4 Hz,
J2=10.25 Hz), 3.60-3.63(2H, m), 3.72(1H, t, J=9.6 Hz), 4.03-4.21(8H, m), 4.42-5.06(14H,
m), 5.16(1H, d, J=3.35Hz), 5.29(1H, d, J=3.3Hz), 5.99-6.07(1H, m), 6.92-7.00(1H, m),
7.27-7.43(35H, m); 13C NMR (CDCl3): 9.31, 9.35, 54.6, 61.1, 63.4, 63.6, 63.7, 65.8, 65.9,
66.5, 68.1, 68.5, 68.6, 68.7, 70.7, 71.8, 72.3, 74.4, 74.8, 74.9, 86.8, 87.4, 110.1, 111.6,120.4,
120.5, 120.6, 120.9, 121.0,121.2, 121.3,121.5, 130.6, 130.7,130.9, 131.0, 131.3, 131.6,
131.8, 141.3; 31P NMR(CDCl3): 18.6; HRMS(ES) m/z: [M+Na]+ calcd. for C66H73O13PNa+,
1127.4687; found, 1127.4668.
Compound 10 4

A mixture of compound 8 (413.4 mg, 0.38 mmol), and Pd/C (10%) (161 mg, 0.16 mmol)
in ethanol (5 mL) was stirred under H2 (1 atm) for 24 h. After completion, the catalyst was
removed by filtration through Celite, and filtrate was concentrated in vacuo. The crude
product was purified by silica gel column chromatography to give 10 (180 mg, 100%).
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TLC (water/isopropanol/ethyl acetate, 1:4:20, v/v/v): Rf=0.20; 1H NMR (MeOD): 1.32(6H,
t, J=7.1Hz), 1.56-1.66(1H, m), 1.77-1.87(1H, m), 1.96-2.06(1H, m), 2.09-2.16(1H, m),
3.07(1H, t, J=9.4 Hz), 3.33(1H, t, J=9.2 Hz), 3.35(1H, dd, J1=2.5 Hz, J2=8.9 Hz ), 3.68(1H,
dd, J1=4.9 Hz, J2=11.4 Hz ), 3.75(1H, t, J=9.4 Hz), 3.78-3.84(4H, m), 4.05-4.12(4H, m),
5.05(1H, d, J=3.5 Hz), 5.08(1H, d, J=3.6 Hz); 13C NMR (MeOD): 17.5,17.6, 21.9, 26.6(d,
JC,P=18.7 Hz ), 63.4, 64.1, 72.7, 73.0, 73.2, 4.0, 74.2, 74.7 75.4, 76.5, 96.0, 96.2;
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P

NMR(D2O): 34.2; HRMS(ES) m/z: [M+Na]+ calcd. for C17H33O13PNa+, 499.1556; found,
499.1544.
Compound 2 5

To a soluton of 10 (77 mg, 0.16 mmol) in anhydrous acetonitrile (2.5 ml) was added
pyridine (25 μl) and bromotrimethylsilane(495 mg, 3.24 mmol) under N2. After stirring at
room temperature for 4 h, the solvent and bromotrimethylsilane were removed in vacuo,
then 3 ml of DI H2O was added and stirring was continued at room temperature overnight.
The aqueous phase was washed with CH2Cl2, and the aqueous phase was lyophilized, the
crude product was purified by silica gel column chromatography to give 2 (49 mg, 72%).
TLC (water/isopropanol/ethyl acetate, 1:2:4, v/v/v): Rf=0.20; 1H NMR (D2O): 1.401.62(2H, m), 1.70-1.87(2H, m), 3.04(1H, t, J=9.4 Hz), 3.22(1H, t, J=9.5 Hz), 3.38-3.45(2H,
m), 3.47-3.66(6H, m), 4.90(1H, d, J=1.4 Hz), 4.91(1H, d, J=1.4 Hz); 13C NMR (D2O): 23.6,
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24.4, 60.5, 69.6, 69.9, 70.9, 71.1, 71.3, 72.1, 72.4, 73.1, 93.0, 93.3; 31P NMR( D2O): 29.3;
HRMS(ES) m/z: [M-H+]－calcd. for C13H25O13P, 419.0955; found, 419.0941.
Synthesis of compound 3:

Scheme 3. Reagents and conditions. (a) ((EtO)2PO)2CHF, n-BuLi, THF, -78℃, 2 h；r.t.
overnight (b) H2, Pd(OH)2, 24 h. (c) TMSBr, MeCN/C5H5N, r.t. 4 h; H2O, overnight.
Compound 9 6

To a solution of ((EtO)2PO)2CHF (1.4 g, 1.4 mmol) in anhydrous THF (8 ml) at -78℃ was
added a solution of n-butyl lithium (0.4 ml, 2.5 M in THF). The mixture was allowed to
stir at -78℃for 1 h and then a solution of 7 (337 mg, 1.1 mmol) in anhydrous THF (2 ml)
was added and the reaction mixture was stirring at -78℃for 1 h, then it was allowed to
slowly warm to room temperature in a period of 1 h. The mixture was allowed to stir at
room temperature overnight and the next day the reaction was quenched with aqueous
ammonium chloride and then the aqueous layer was extracted with EtOAc, then the organic
layer was extracted with brine, the organic layer was then dried with anhydrous sodium
sulfate, filtered, and then the filtrate was concentrated in vacuo The crude product was
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purified by silica gel column chromatography to give 9 (1.3 g, 71%). TLC (hexane/ethyl
acetate, 1:1, v/v): Rf=0.3; 1H NMR (CDCl3): 1.20-1.27(6H, m), 3.37-3.71(7H, m), 3.974.20(7H, m), 4.38-5.08(14H, m), 5.15(1H, d, J=3.5 Hz), 5.24(1H, d, J=3.5 Hz), 6.006.19(1H, m), 7.28-7.40(35H, m); 13C NMR (CDCl3): 9.1, 56.2, 61.1, 63.5, 65.3, 66.4, 68.0,
68.7, 70.6, 70.8, 72.3, 74.1, 74.6, 74.8, 86.9, 87.7, 120.3, 120.5, 120.6, 120.9, 121.3, 130.7,
131.0, 131.1, 131.6, 131.9, 156.0; 31P NMR(CDCl3): 4.8 (d, JF,P=245 Hz);
Compound 11 6

To a solution of 9(1.14g, 1.02 mmol) in ethanol (15 ml)was added a catalytic amount of
20% palladium hydroxide on carbon(432mg, 0.408 mmol) and 3 drops of acetic acid; the
reaction was then subjected to a hydrogen atmosphere (1 atm) and was allowed to stir for
24 h. Then the reaction mixture was filtered through a pad of Celite to remove all palladium
using methanol as the eluent followed by removal of all solvent in vacuo. The crude product
was purified by flash chromatography to give 11 (403 mg, 80%). TLC
(water/isopropanol/ethyl acetate, 1:4:4, v/v/v): Rf=0.40; 1H NMR (D2O): 1.35-1.40(6H,
m), 1.81-2.05(1H, m), 2.40-2.56(1H, m), 3.31(1H, t, J=9.4 Hz ), 3.45(1H, t, J=9.4 Hz),
3.62(1H, dd, J1=3.8 Hz, J2=9.9 Hz), 3.69(1H, dd, J1=3.8 Hz, J2=9.9 Hz), 3.74-3.88(6H, m),
4.00(1H, t, J=9.9 Hz), 4.23-4.34(4H, m), 5.15(1H, dd, J=3.8 Hz), 5.19(1H, dd, J=3.8 Hz) ;
13

C NMR (D2O): 15.6, 15.7, 31.5, 31.7, 60.5, 64.9(d, JC,P=27.8 Hz ), 65.1(d, JC,P=26.9 Hz ),
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66.4, 66.6, 69.9, 70.9, 71.1, 72.1, 72.5, 72.6, 73.4, 93.1, 93.4;
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P NMR(D2O): 20.8 (d,

JF,P=187.5 Hz).
Compound 3

To a soluton of 11 (57 mg, 0.116 mmol) in anhydrous acetonitrile (2 ml) was added pyridine
(20 μl) and bromotrimethylsilane(353 mg, 2.3 mmol) under N2. After stirring at room
temperature for 4 h, the solvent and bromotrimethylsilane were removed in vacuo, then 3
ml of DI H2O was added and stirring was continued at room temperature overnight. The
aqueous phase was washed with CH2Cl2, and the aqueous phase was lyophilized, the crude
product was purified by flash chromatography to give 3 (40 mg, 78%). TLC
(water/isopropanol/ethyl acetate, 1:1:1, v/v/v): Rf=0.40; 1H NMR (D2O): 1.72-1.96(1H,
m), 2.26-2.41(1H, m), 3.30(1H, t, J=9.4 Hz ), 3.43(1H, t, J=9.3 Hz), 3.58-3.68(2H, m),
3.72-3.86(5H, m), 3.96(1H, t, J=9.8 Hz), 4.62-4.67(1H, m), 5.15(1H, dd, J=3.9 Hz),
5.17(1H, dd, J=4.0 Hz) ; 13C NMR (D2O): 32.69(d, J=82.4 Hz ), 60.5, 67.6(d, J=45.3 Hz),
69.7, 70.9, 71.1, 71.2, 72.1, 72.5, 73.4, 93.0, 93.4. 31P NMR (D2O): 13.2 (d, JF,P=155.2 Hz).
HRMS (ES) m/z: [M-H+]－calcd. for C13H24FO13P, 437.0860; found, 437.0861.
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Synthesis of trehalose-6-boronate

Scheme 4. Reagents and conditions. (a) Ph3PMeBr, n-BuLi, THF, -78℃; -78℃－ -20℃, 1
h; -78℃－r.t., 40 min; r.t. overnight (b) Pinacoborane, [Ir(cod)Cl]2, dppm, CH2Cl2, 24 h. (c)
H2, Pd/C, MeOH, 24 h.
Compound 12

n-BuLi (240 μL, 2.5 M in hexanes) was added to a suspension of methyltriphenylphosphonium bromide (250 mg, 0.7 mmol) in THF(2 ml) at -78℃. The reaction mixture was
slowly warm to -20℃over a period of 1 h, then it was cooled back to -78℃, and a solution
of compound 7 (194 mg, 0.2 mmol) was added dropwise. After 40 min, the reaction mixture
was allowed to warm to room temperature slowly, and kept stirring at room temperature
overnight. Then saturated NH4Cl (aq) was added, the aqueous phase was extracted with
Et2O, and the combined organic extracts were dried using anhydrous Na2SO4, the solvent
was removed in vacuo, and the crude product was purified by silica gel column
chromatography (5:1 hexane/ethyl acetate) affording 12 (124 mg, 64%). TLC
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(hexane/ethyl acetate, 7:1): Rf=0.20; 1H NMR (CDCl3): 3.35(1H, t, J=9.6 Hz), 3.45(1H,
dd, J1=2.6 Hz, J2=10.6 Hz), 3.58(1H, dd, J1=2.7 Hz, J2=10.6 Hz), 3.65-3.68(2H, m),
3.76(1H, t, J=9.5 Hz), 4.11-4.18(2H, m), 4.25-5.12(16H, m), 5.28-5.37(4H, m), 7.327.47(35H, m); 13C NMR (CDCl3): 61.2, 63.6, 64.8, 65.7, 65.8, 66.5, 68.0, 68.3, 68.6, 68.7,
70.7, 72.1, 72.5, 74.4, 74.8, 75.6, 87.0, 87.4, 110.5, 120.4, 120.5, 120.7, 120.8, 120.9, 121.1,
121.3, 121.4, 128.3, 130.8, 131.2, 131.2, 131.4, 131.8, 131.9; HRMS(ES) m/z: [M+Na]+
calcd. for C62H64O10Na+, 991.4397; found, 991.4424.
Compound 13 7

A round-bottom flask charged with [Ir(cod)Cl]2(7.3 mg, 1.5 mol%) and bis(diphenylphosphino) methane(8.4 mg, 3 mol%) was flushed with argon. CH2Cl2 (2.5 ml),
pinacolborane (112 mg, 0.874 mmol), and 12 (707 mg, 0.728 mmol) were added
successively at room temperature. The mixture was then stirred at room temperature for 24
h. The reaction was quenched with methanol and water, the product was extracted with
ether, and dried over MgSO4. The solvent was removed in vacuo, and the crude product
was purified by silica gel column chromatography (10:1 to 5:1, Hexane/Ethyl acetate)
affording 13 (531 mg, 67%). TLC (Hexane/Ethyl acetate, 6:1): Rf=0.30; 1H NMR (CDCl3):
0.68-0.91(2H, m), 1.26(6H, s), 1.27(6H, s), 1.58-1.71(1H, m), 1.89-2.00(1H, m), 3.34(1H,
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t, J=9.3 Hz), 3.44(1H, dd, J1=1.5 Hz, J2=10.4 Hz), 3.53-3.60(2H, m), 3.63-3.73(2H, m),
4.02-4.16(3H, m), 4.18-4.23(2H, m), 4.41- 5.04(14H, m), 5.22(1H, d, J=3.5 Hz), 5.33(1H,
d, J=3.5 Hz), 7.16-7.39(35H, m);

13

C NMR (CDCl3): 24.9, 24.9, 25.8, 68.4, 70.6, 71.9,

72.7, 73.0, 73.5, 75.0, 75.1, 75.6, 77.3, 79.2, 80.0, 81.6, 81.7, 81.8, 82.9, 92.9, 93.3,127.5,
127.6, 127.7, 127.9, 128.0, 128.3, 138.0, 138.3, 138.4, 138.6, 138.7, 138.9, 139.0;
HRMS(ES) m/z: [M+Na]+calcd.for C68H77BO12Na+, 1119.5406; found, 1119.5450;
[M+K]+ calcd. for C68H77BO12K+, 1135.5145; found, 1135.5183.
Compound 4

A mixture of compound 13 (300 mg, 0.27 mmol), and Pd/C (10%) (116 mg, 0.11 mmol) in
methanol (5 mL) was stirred under H2 (1 atm) for 24 h. After completion, the catalyst was
removed by filtration through Celite, and filtrate was concentrated in vacuo. The crude
product was purified by flash chromatography to give 4 (107 mg, 100%). TLC
(water/isopropanol/ethyl acetate, 1:4:4, v/v/v): Rf=0.80; 1H NMR (D2O): 0.83-1.05(2H,
m), 1.65-1.82(2H, m), 3.41-3.47(2H, m), 3.61-3.69(2H, m), 3.74- 3.78(6H, m), 5.15(1H, d,
J=4.1 Hz), 5.17(1H, d, J=4.0 Hz); 13C NMR (CDCl3): 23.5, 24.5, 60.2, 69.3, 70.6, 70.7,
70.9, 71.8, 71.9, 72.2, 75.3, 92.9, 93.0; HRMS(ES) m/z: [M+Na]+calcd.for C13H25BO12Na+,
407.1337; found, 407.1344.
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7. Yamamoto Y., Fujikawa R., Umemoto T., Miyaura N. Iridium-catalyzed
hydroboration of alkenes with pinacolborane Tetrahedron, 2004, 60, 10695–10700.
3.5.3 SAXS measurements and data analysis
Synchrotron X-ray scattering data were collected at the SSRL 4-2 BioSAXS
beamline (SLAC, Menlo Park CA). Data were collected with a MarCCD225 detector at
wavelength of 1.3 Å, at a distance of 1.7 m at 10 ºC, which corresponds to a scattering
vector range of 0.007 Å-1 < q < 0.55 Å-1, where q = 4πsinθ/λ; 2θ is the scattering angle.
Samples were placed into a cooled 96-well plate (40 µL sample volume), sample injection
was automated and data collection was done in a quartz capillary tube. For each sample 15
exposure frames of 1 sec were collected for each sample and corresponding buffer. Frames
were carefully inspected for aggregation and radiation damage induced by the X-ray source.
Scattering profiles were generated either by automated buffer subtraction using beamline
automated data processing software (SAXSpipe) or manually using beamline software
SasTool.
For each protein sample (five different orthologs) scattering profiles were collected
on at least four protein concentrations ranging between 0.5 - 10 mg/mL. To experimentally
investigate cap closure, data were collected on each protein w/wo protein inhibitor T6S.
Inhibitor concentration was dependent on calculated Ki constants for each protein, to
ensure saturation T6S concentration were 10x Ki. Scattering was tested and corrected (if
necessary) for moderate intermolecular interaction. During each collection period both
water and lysozyme (50 mM HEPES, 150 mM NaCl pH 7.0) scattering patterns were
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collected for calibration of MW. For each sample the radius of gyration (Rg) was calculated
using Guinier approximation (Guinier and Fournet, 1955) and using GNOM (Svergun,
1992), which provides the distant distribution function p(r). The p(r) function displays a
histogram or the distances within the particle, whereas dmax is represented as the maximum
dimension of the particle.

3.5.4 KI measurement
The steady-state competitive inhibition constant KI was determined for inhibitors
by fitting the initial velocity data, measured as a function of trehalose 6-phosphate (0.5 Km
to 5Km) [29] and inhibitor (0, KI, 2KI) concentration to the following using SigmaPlot
Enzyme Kinetics Module:

where vo is the initial velocity, vmax the maximum velocity, [S] the substrate concentration
and Km the Michaelis-Menten constant calculated for trehalose 6-phosphate, [I] is the
inhibitor concentration and KI is the inhibition constant.
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3.5.5 EnzChek Phosphate Assay
T6PP-catalyzed T6P hydrolysis was monitored continuously by using the
EnzChek Phosphate Assay kit. In this assay phosphate formation is coupled to the
phosphorylase reaction of MESG catalyzed by purine nucleoside phosphorylase.
(a)

(b)

Scheme 3.4. T6PP –coupled enzyme assay utilizing PNP; (a) T6PP-catalyzed hydrolysis
of trehalose 6-phosphate; (b) Enzymatic conversion of MESG to ribose 1-phosphate and
2-amino-6-mercapto-7-methylpurine by purine ribonucleoside phosphorylase(PNP).
Conversion of MESG to 2-amino-6-mercapto-7-methylpurine shifts absorbance from 330
to 360 nm, respectively. The accompanying change in the absorption maximum at 360 nm
allows quantitation of inorganic phosphate (Pi) consumed in the reaction.
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CHAPTER FOUR
SYNTHESIS AND EVALUATION OF FIRST GENERATION
TREHALOSE-6-PHOSPHATE PHOSPHATASE REVERSIBLE
BIOMODULAR INHIBITORS
4.1. Background
Carbohydrates play an important role in biological systems, including serving as
precursors for building diverse polymers, storing short-term energy, providing structural
building materials, serving as molecular "tags" to allow recognition of specific cells and
molecules. Many diseases are associated with malfunctioning biochemical processes
involving carbohydrates, and the ability to interfere in such processes by targeting the
enzyme catalyst, is of great biomedical importance.
Trehalose, a natural alpha-linked disaccharide formed by an α,α-1,1-glucoside
bond between two α-glucose units, is synthesized by a variety of bacteria, plants, fungi and
invertebrates to support cell survival by functioning as a fuel, a metabolic regulator or a
protectant against environmental stress. Five different trehalose biosynthetic pathways are
known to exist (OtsA/B or TPS/TPP pathway, TS pathway, TreY/TreZ pathway, TreP
patheay, TreT pathway) [1], one of which, the OtsA/B pathway is common among
pathogenic bacteria and fungi as well as in parasitic nematodes. The OtsA/B pathway,
which utilizes glucose and glucose-6-phosphate to generate trehalose-6-phosphate
catalyzed by trehalose synthase, then hydrolyzed to trehalose by trehalose-6-phosphate
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phosphatase (T6PP). Previously reported otsA and otsB gene knockout (or knockdown)
experiments have shown that both pathway enzymes are essential for growth of M.
tuberculosis in laboratory culture, and for its virulence in a mouse model [2]. The T6P
synthase and phosphatase are also required for trehalose production in the filamentous
fungus Fusarium graminearum, however only the T6PP proved to be indispensable for
development and virulence [3]. RNAi gene silencing carried out in the nematode model
system Caenohabditis elegans revealed that the T6PP is essential, however only when the
T6P synthase-encoding gene is functional [4].
Based on these findings we concluded that trehalose-synthesizing pathogens are
likely to be vulnerable to the action of small molecule inhibitors of their T6PPs. In Chapter
Three trehalose-6-sulfate (T6S) was identified as an inert T6P analog having moderate
binding affinity and the ability to induce cap-domain closure in the bacterial T6P
phosphatases. In the study described below, a structure-guided search for inhibitors of
T6PPs from important target pathogens was carried out. The effort was aimed at
uncovering a versatile T6PP inhibitor prototype that could be modified to target specific
T6PPs of pathogens from various taxonomic groups. For this purpose, I selected several
members of different structural families of potential T6PP inhibitors. These were designed
and synthesized, and determination of binding affinities of these substances was carried
out.
In parallel, the residues forming the substrate binding region at the T6PP cap
domain were compared and probed for contributions to substrate binding by kinetic
analysis of residue-directed mutants.
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4.3 Results and Discussion
4.3.1. Substrate Recognition: Diversity in the T6PP Cap Domain Residue Usage and
Function
Following the determination of the structure of the Bm-T6PP (with the Mg2+
cofactor bound), the residues which form the substrate-binding region of the cap domain
could be identified. This work was carried out in collaboration with Dr. Karen Allen and
co-workers at Boston University and Dr. Tilde Carlow and co-workers of New England
BioLabs. My role was to measure the steady-state kcat and Km for wild-type and mutant
Bm-T6PP-catalyzed hydrolysis of T6P and the Ki for T6S inhibition.
The conserved fold of the Ta-T6PP and Bm-T6PP structures provided more
confidence in the threading models that could be generated from the T6PP ortholog
sequences. Of the bacterial T6PP orthologs, Mt-T6PP proved to be the only one that is
sufficiently robust to withstand amino acid replacement. Therefore, the SAR analysis
carried out on Bm-T6PP was also carried out on Mt-T6PP. This work was carried out in
collaboration with my labmate Dr. Tyrel Byran, who helped generate the mutant genes and
gene products.

77

Figure 4.1 Putative substrate interacting residues in B. malayi T6PP analyzed by
mutagenesis and kinetics. The residues targeted for replacement are shown in stick.
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Figure 4.2 Putative substrate interacting residues in M. tuberculosis T6PP
analyzed by mutagenesis and kinetics. The residues targeted for replacement are
shown in stick.
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Table 4.1. Steady-state kinetic constants and dissociation constants for inhibitors for
wild-type and variant M. tuberculosis or B. malayi T6PP-catalyzed hydrolysis of
trehalose 6-phosphate.
B. malayi T6PP

M. tuberculosis T6PP
Construct

kcat
(s-1)

Km
(μM)

wild type

10±1

540±110

kcat/Km KI trehalose(M-1s-1) 6-sulfate(μM) Construct
wild type
1.9×104 130±20
59

NAa

—

—

—

E157A

R187K

0.28±0.02

25±0.6

0.11±0.01

2200±400

230±20

3800±400

1500±200

6.4×102 >4 mMb

>4 mMb

H260A

0.28±0.03

2.5×102 780±170

R291A

E292A
E295A
R297A

6.9 x 104 82 ± 7

28 ± 1

260 ± 20

1.1 x 105 -

D213A

NAa

-

-

-

D215A

~0.0004

-

-

-

Y221A

1.0 ± 0.05

330 ± 50

3.0 x 103 1,300 ± 100

Y225A

5.5 ± 0.1

150 ± 10

3.6 x 104 400 ± 40

N228A

18 ± 0.8

40 ± 8

4.5 x 105 16 ± 2

W280A

19 ± 2

150 ± 30

1.2 x 105 270 ± 50

Cap residues
0.99±0.06

14

T288A

360 ± 60

>4 mMb

29

0.098±0.002 6800±300

N263A

24 ± 2

1.1×105 71±6

K253A

R262A

KI trehalose6-sulfate(μM)

1.3×102 360±70

Cap residues
E251A

kcat/Km
(M-1s-1)

Catalytic domain residues

Catalytic domain residues
F148A

Km
(μM)

Catalytic Asp residues

Catalytic Asp residues
D147A

kcat
(s-1)

0.13±0.01

23±0.7

11±0.6

0.39±0.07

15±0.5
0.16±0.01
3±0.2

1100±300

2100±300

890±70

1400±200

2900±900

540±60
1500±200
730±90
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Q332A

0.22 ± 0.001 200 ± 40

5.5 x 102 1,000 ± 200

R337A

0.28 ± 0.03

1.5 x 103 700 ± 100

K334A

0.06 ± 0.007 500 ± 120

1.1 x 102 150 ± 20

S329A

4 ± 0.2

250 ± 50

1.5 x 104 240 ± 30

E384A

2.9 ± 0.2

100 ± 20

3.0 x 104 200 ±30

E386A

2.3 ± 0.1

82 ± 15

2.8 x 104 150 ± 20

T339A

15.3 ± 1.0

200 ± 40

7.7 x 104 35 ± 5

D336A

0.094 ± 0.004 46 ± 6

2.0 x 102 33 ± 5

D378A

10.6 ± 0.6

3.9 x 104 320 ± 30

400 ± 100

2400±500

2.6×104 320±40

3

8.2×10

1700±200

1.3×102 >4 mMb

4

380±50

2

190±20

3

460±40

2.7×10
1.1×10
4.1×10

270 ± 30

Note: The residues in Bm-T6PP and Mt-T6PP are at the same position base on sequence alignment if they
are in the same row.
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The structure of the Bm-T6PP and threading model of the Mt-T6PP are shown in
Figures 4.1 and 4.2, respectively. In each figure the residues identified for alanine
replacement by mutagenesis are highlighted. The change in steady-state kcat value observed
for the mutant reflects the impact that the alanine substitution has on the efficiency that
bound T6P is converted to product and released. Nonproductive binding (orientation of the
reaction center is not optimized for catalysis) and/or disruption of the cap closure over the
catalytic site and/or alteration of the electrostatic environment of the catalytic site can result
in reduction in the kcat value compared to that of the wild-type T6PP. The kcat/Km value
reflects substrate binding and catalysis. If the magnitude of reduction in kcat value and
kcat/Km value is the same then it follows that the T6P binding affinity has been unaltered.
On the other hand, if the kcat/Km value is decreased x-fold over the decrease observed in
the kcat value, then it follows that the substrate binding affinity is decreased x-fold. An
independent measure of the change in substrate binding affinity upon Ala mutagenesis is
the change in the inhibition constant for the inert substrate analog trehalose-6-sulfate (T6S).
The kcat and kcat/Km values for wild-type and mutant and Bm-T6PP and Mt-T6PP are listed
in Table 4.1 along with the competitive inhibition constants (Ki) measured for T6S vs T6P.
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Figure 4.3. Alignment of Mycobacterium T6PP sequences
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Figure 4.4 An alignment of nematode T6PP sequences.

As expected, replacement of the catalytic Asp147 resulted in the loss of all detectable
activity (Table 4.1). The replacements of Phe148, Arg187, Glu251, Lys253, Arg262,
Thr288, Arg291, Glu295 resulted in a dramatic change in Km for T6P suggesting a role in
substrate binding. Mutations in Phe148, Arg187, Glu251, Lys253, His260, Arg262, Arg291,
E295 resulted in large decreases in kcat (36-, 91-, 10-, 100-, 36-, 77-, 26-, 77-fold,
respectively) suggesting a role in catalysis. Each of these residues except for Phe148 are
found in the cap domain (Figure 4.2) and may interact with the sugar moiety in order to
orient the substrate for catalysis.
We also used inhibitor binding studies to test if any of the protein variants differed
in their affinity for substrate. To assess substrate affinity, the substrate analogue trehalose

83

6-sulfate was used to measure KI for all of the T6PP variants (Table 4.1). Trehalose 6sulfate was shown by steady-state inhibition kinetics to be a competitive inhibitor of wild
type T6PP with a KI of 130 μM against trehalose 6-phosphate as substrate. The variants
except E295 that have dramatic increased Km showed dramatic increases in KI for trehalose
6-sulfate: Phe148, Arg187, Glu251, Lys253, Arg262, Thr288, Arg291 (Table 4.1, Figure
4.2). From these experiments, Phe148, Arg187, Glu251, Lys253, Arg262, Thr288, Arg291
are likely to be involved in binding trehalose 6-phosphate, while E295 and His260 may
play other roles in catalysis. These roles may include desolvation, steric restraint of the
substrate for catalysis, or the positioning of other residues required for enzyme activity.
In order to design and synthesize more drug like inhibitors we need to learn from
the nature. Base on previous works,

carbohydrates binding to proteins is often

accompanied by stacking interaction with aromatic residue [8-10] Our previous work also
suggests that mutating the aromatic residues in the sugar binding sites of B. malayi T6PP
result in low binding affinity (16 fold decreased) with T6S (trehalose-6 sulfate) inhibitor
[11]. These observations suggest that inhibitors which possess variously substituted
hydrophobic aryl and/or alkyl groups attached to the 1, 2, 3 and 4 positions of the glucose6-sulfate backbone might display enhanced binding to the T6PPs. This reasoning led to the
selection of the carbohydrate analogs displayed in Scheme 1 as members of the library that
was prepared and screened in this effort.
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In the study described below, a structure-guided search for inhibitors of T6PPs from
important target pathogens was carried out. The effort was aimed at uncovering a versatile
T6PP inhibitor prototype that could be modified to target specific T6PPs of pathogens from
various taxonomic groups. For this purpose, selected several members of different
structural families of potential T6PP inhibitors were designed and synthesized. A
determination of binding affinities of these substances was carried out.
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4.3.2 Synthesis

Scheme 4.1.
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Inhibitor Preparation. Phenyl α-D-glucopyranoside (1) and phenyl -Dglucopyranoside (2a) are commercially available substances and glucose derivatives 2b
[12], 2c [13], 2d [14] and 4 [15], and glucose-6-sulfate 5a [16] were synthesized by using
the referenced procedures. The routes utilized for preparation of the other members of the
T6PP inhibitor library, displayed in Schemes 2-10 below and described completely in the
Experimental, begin with either commercially available or previously synthesized starting
materials. Each substance was shown to be >95% pure by using NMR spectroscopy and
HPLC analysis.

Scheme 4.2.

Scheme 4.3.
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Scheme 4.4.

Scheme 4.5.

Scheme 4.6.

88

Scheme 4.7.

Scheme 4.8.

Scheme 4.9.
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Scheme 4.10.

4.3.3 Catalytic hydrolysis of Compound 7 by T6PP
The catalytic activities of the T6PPs toward p-nitrophenyl phosphate (PNPP), a
common substrate of phosphatases, glucose-6-phosphate and phenyl β-D-glucose-6phosphate (7) were determined. In this series, only 7 was found to serve as a substrate for
these phosphatases with kcat values of 1.4×10-2, 0.96×10-2, 0.71×10-2, 0.71×10-2 s-1 and or
the respective Bm-T6PP, Mt-T6PP, Sb-T6PP, As-T6PP and St-T6PP. These values compare
to the kcat values observed for hydrolysis of T6P catalyzed by the T6PPs, which fall in the
range of 4-24 s-1, which shows that the phenyl glucopyranoside base compounds can bind
to T6PPs, where the binding affinity comes from the introducing phenyl group.
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Table 4.2 Steady-state kinetic constants for T6PPs-catalyzed hydrolysis of compound 7.
T6PP Source

kcat (s-1)

Brugia malayi

1.4×10-2

Mycobacterium tuberculosis

0.96×10-2

Shigella boydii

0.71×10-2

Ascaris suum

0.71×10-2

Samonella typhimurium

0.41×10-2

4.3.4 Inhibition measurement using High Throughput Screening
An initial evaluation of the inhibitory activities of a large number of the
substances shown in Scheme 1 (see Table 1) toward T6PP catalyzed hydrolysis reactions
of T6P was carried out by using a high throughput screen. For this purpose, the initial
velocities were determined for reactions of T6P promoted by Bm-T6PP, Mt-T6PP, Sb-T6PP,
As-T6PP and St-T6P in the presence of 1mM inhibitor (V’) and absence of inhibitor (Vo).
Each well of a 96-well plate contained 50 μL of a solution containing 5-25 nM freshly
purified T6PP, T6P (400 μM for Mt-T6PP, Sb-T6PP and StT6PP, 200 μM for Bm-T6PP
and As-T6PP) and 1 mM inhibitor and buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 5 mM
MgCl2, and 5% glycerol for Mt-T6PP; 50 mM HEPES pH 7.5, 25 mM NaCl, 2 mM MgCl2,
and 5% glycerol for Sb-T6PP; 50 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1mM DTT
and 5% glycerol for As-T6PP; 25 mM Tris pH 7.5, 25 mM NaCl, 2 mM MgCl2, 1 mM
DTT for Bm-T6PP; and 50 mM HEPES pH 8.0, 25 mM NaCl, 5 mM MgCl2, and 5%
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glycerol for St-T6PP. The plate was incubated at room temperature for 5 min at which time
5 μL of each solution in each well was transferred to individual wells of another 96 well
plate, each containing containing 45 μL the appropriate buffer. After adding 100 μL BioMol
Green (Enzo Life Sciences) to each well and incubating for 30 min absorbance of each well
at 625 nm were measured using a SpectraMax i3 Multi-Mode Microplate Detection
Platform. The initial velocity ratios (V’/Vo) obtained by using this procedure are given in
Table 4.3.
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Table 4.3. Inhibition measurement using HTS
Compound

Bm-T6PP

Mt-T6PP

Sb-T6PP

As-T6PP

St-T6PP

T6S

0.13

0.43

0.22

0.21

0.01

Trehalose

0.98

0.83

1.01

0.97

0.88

1

0.96

0.88

0.86

0.97

1

2a

1.12

0.81

0.9

1

0.87

2b

1

0.88

0.92

0.97

0.77

2c

0.99

1.04

0.92

0.81

1.09

2d

0.85

0.95

1

0.96

0.9

3

0.59

0.96

0.8

0.98

0.85

4

1.05

1.17

0.85

0.96

1

5a

0.93

0.97

0.75

0.94

0.84

5b

0.8

0.91

1

1.07

1.04

5c

0.42

1.17

0.76

0.71

0.64

5d

0.53

1.01

1

0.96

0.95

5e

0.67

1.16

0.84

1.04

0.99

5f

0.68

1.11

0.95

0.99

0.97

6a

0.07

0.83

0.74

0.86

0.47

6b

0.72

0.83

0.79

0.9

0.54

6c

0.85

0.85

0.85

0.91

0.8

6d

0.98

0.98

0.9

0.76

0.97

7

0.79

0.94

0.94

0.98

0.77

8a

0.52

0.94

0.76

0.92

0.81

8b

0.58

0.58

0.84

0.9

0.85

8c

0.55

1.09

1

0.94

0.96

8d

0.74

0.8

0.92

0.88

0.89

8e

0.64

1.27

0.77

0.83

0.68

8f

0.63

1

1.03

0.74

0.94

8g

0.87

0.94

0.88

0.9

0.85

8h

0.79

1.17

0.96

0.99

0.85

8i

1.05

0.67

0.81

0.78

0.95

8j

1

0.87

1.06

0.81

0.87

8k

0.89

0.89

0.85

0.9

0.73

8l

0.69

0.69

0.46

0.63

0.77

8m

0.68

0.85

0.67

0.76

0.79

8p

0.07

0.42

0.04

0.02

0.01
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4.3.5 Competitive inhibition test
We also tested the inhibition of 8p on Sb-T6PP using EnzChek Phosphate Assay,
which turns out to be competitive inhibitor. The initial velocities (v) for T6PPs catalyzed
hydrolysis of trehalose 6-phosphate (0.5 Km- 3 Km) at presence of different concentrations
of inhibitor (0, 0.5 Ki, 1.7 Ki, 2.5 ki, 3.3Ki) were measured at 25 °C using EnzCheck
Phosphate Assay Kit (Invitrogen). The assay solutions that contained 1 mM MgCl2, 0.1
mM sodium azide 1.0 unit/mL purine nucleoside phosphorylase, and 0.2 mM MESG in 50
mM Tris-HCl (pH 7.5). Absorbance changes were monitored at 360 nm (Δε = 9.8
mM−1cm−1).
Inhibitor: 8p, Enzyme: Sb-T6PP, Units: V: μM/s, S (T6P): μM

Figure 4.5. 8p’s competitive inhibition on Sb-T6PP
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4.3.6 Inhibition Constants
Analysis of the screening results given in Table 1 showed that the glucaose-6sulfate derivatives 5c, 6a, 8a, 8b and 8i, each of which contain a hydrophobic group at the
glycosidic position, display high T6PP inhibitory activities. This finding prompted a more
detailed investigation of the inhibition constants of these substances. For this purpose,
initial velocities (v) of the T6PP catalyzed hydrolysis reactions of T6P (0.5-3 Km) at 25 °C
in the presence of different concentrations (0, Ki, 2Ki) of inhibitors 5c, 6a, 8a, 8b and 8i
were determined using the EnzCheck Phosphate Assay Kit (Invitrogen). In addition to
enzyme (T6PP), substrate (T6P) and inhibitor, the assay solutions contain 1 mM MgCl2,
0.1 mM sodium azide 1.0 unit/mL purine nucleoside phosphorylase, and 0.2 mM MESG
in 50 mM Tris-HCl (pH 7.5). Absorbance changes were monitored at 360 nm (Δε = 9.8
mM−1cm−1). Initial velocity data, measured as a function of trehalose 6-phosphate (0.5 to
5Km) and inhibitor (0, KI, 2KI) concentrations, were fitted using the SigmaPlot Enzyme
Kinetics Module to the following equation:

where vo is the initial velocity, vmax the maximum velocity, [S] the substrate concentration
and Km the Michaelis Menten constant calculated for trehalose 6-phosphate, [I] is the
inhibitor concentration and KI is the inhibition constant. This treatment gave the Ki values
listed in Table 4.4.
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Because the initial screening results (Table 4.3) demonstrated that 4-octlyphenyl
-D-glucose-6-sulfate (8p) is the most active inhibitor of the five T6PPs, the closely related
4-butyl- and 4-hexylphenyl and 4-octylpheny- and -hexylphenyl and 4-octylphenyD
glucopyranoside-6-sulfate, 8n, 8o, 9a and 9b, respectively, were prepared and subjected to
kinetic studies. It is clear from viewing the results in Table 3 that the strategy of
incorporating both a negatively charged 6-sulfate and hydrophobic glycosidic group into
the glucose skeleton does lead to the design of highly active inhibitors of the T6PPs.
Moreover, a comparison of the activities of 8p and 9a shows the spacial disposition of the
glycosidic alkylphenyl group plays an important role in biding to the phosphatases.
Table 4.4. Competitive inhibition constants
Inhibitor

B. malayi

M. tuberculosis

S. boydii

A. suum

S. typhimurium

5c

320±30

6a

160±20

-

-

-

-

8a

830±100

-

-

-

-

8b

-

1600±270

-

-

-

8i

-

1700±350

-

-

-

NI

>400 h

1800±260

f

8n

NI

NI

>400

8o

>200 a

>400 b

140±20

>200 g

>400 i

8p

61±10

>300 c

13±2

180±20*

120±20

d

21±3

84±10*

56±6

78±9

350±30*

280±30

9a

5.3±0.6

>300

9b

82±10*

>400 e

*: Slow-onset inhibition observed, preincubation time: 2 minutes at room temperature;
- : Did not test;
NI: No inhibition observed when T6P = Km in the presence of 400 μM inhibitor;
a : 19% inhibition observed in the presence of 200 μM 8o;
b : 2% inhibition observed in the presence of 400 μM 8o;
c : 16% inhibition observed in the presence of 300 μM 8p;
d : 36% inhibition observed in the presence of 300 μM 9a;
e : 4% inhibition observed in the presence of 400 μM 9b;
f : 4% inhibition observed in the presence of 400 μM 8n;
g : 15% inhibition observed in the presence of 200 μM 8o;
h : 5% inhibition observed in the presence of 400 μM 8n;
i : 4% inhibition observed in the presence of 400 μM 8o;
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Interestingly, the inhibitors 8p, 9a, 9b showed slow-onset inhibition on As-T6PP,
and this phenomenon was also observed in the inhibition of Bm-T6PP by 9b. The Nterminal MIT domain of As- and Bm-T6PP lock the enzyme conformation, such that the
binding site is relatively fixed. Besides, the high flexibility of the aliphatic chain of the
inhibitors result in several conformational forms, one of which makes up only a small
proportion of all forms and interacts with the enzyme at the relatively fixed binding site.
4.3.7 SAXS studies
We also used Small Angle X-ray Scattering “SAXS” techniques to examine the
inhibitor 9a’s effect on T6PPs domain movement. Surprisingly, it makes the cap domain
more open than its apo form (Table 4.5, 4.6). We hypothesize that the inhibitor may simply
be sitting in the wedge formed in the open cap-core domain conformation.
Table 4.5. Calculated SAXS values for S. boydii T6PP w/wo ligands. Rg were calculated using
Giunier region and with Parod's, dmax was calculated using P(r) Distribution. All values were
calculated using PRIMUS.
Protein

S. boydii

Ligand

Rg (Guinier)

Rg (P(r)
distribution)

dmax (nm)

---

23.50 ± 0.28

23.7

82

T6S

22.30 ± 0.13

22.9

80

9A

24.78 ± 0.27

24.1

84
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Figure 4.6: Guinier region for S. boydii T6PP w/wo ligand. T6PP with T6S, T6PP with 9a, and
T6PP (from top to bottom, respectively).

Figure 4.7: Scattering plot overlay of S. boydii T6PP w/wo ligand. (green) T6PP with T6S,
(blue) T6PP with 9a, and (black) T6PP. Modifications within low and mid q suggest
conformation changes as an effect of ligand binding.
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Figure 4.8: Kratky plot overlay of S. boydii T6PP w/wo ligand. (green) T6PP with T6S, (blue)
T6PP with 9a, and (black) T6PP. From Kratky plots the resulting proteins are clearly folded in
solution.
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Table 4.6: Calculated SAXS values for S. typhimurium T6PP w/wo ligands. Rg were calculated
using Giunier region and with Parod's, dmax was calculated using P(r) Distribution. All values
were calculated using PRIMUS.
Protein
S. typhimurium

Ligand

Rg (Guinier)

--T6S
9A

23.96 ± 0.09
23.18 ± 0.16
25.16 ± 0.18

Rg (P(r)
distribution)
24.8
23.2
25.8

dmax (nm)
84
81
86

Figure 4.9: Guinier region for S. typhimurium T6PP w/wo ligand. T6PP with T6S, T6PP with
9A, and T6PP (from top to bottom, respectively).
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Figure 4.10: Scattering plot overlay of S. typhimurium T6PP w/wo ligand. (Green) T6PP
with T6S, (blue) T6PP with 9A, and (black) T6PP. Modifications within low and mid q
suggest conformation changes as an effect of ligand binding.
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Figure 4.11: Kratky plot overlay of S. typhimurium T6PP w/wo ligand. (Green) T6PP with
T6S, (blue) T6PP with 9A, and (black) T6PP. From Kratky plots the resulting proteins are
clearly folded in solution.

Tables (Table 4.5 and 4.6) and graphs (Graphs 4.6-4.11) represent each protein
(S.boydii and S.typhimurium) with two ligands (T6S, and 9A) and without ligand. T6S
represents the protein in the closed conformation whereas the native used as a control to
investigate the conformation change upon binding ligand. Each protein was tested with 9A
to investigate changes in conformation upon binding. Results suggest that when binding
9A observable changes in conformation are present although the change in Rg and dmax
suggest a larger increase in size compared to both native and T6S liganded. The results
conclude that substrate binds to the proteins and because changes in Rg are in the direction
of cap movement suggest that binding occurs in active site. The explanation for the increase
in size (Rg, and dmax) can be explained through interference in favorable interactions
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between substrate/protein (T6S-complex) or domain/domain (native complex). Although
the substrate binds and interferes with catalysis; the extended conformation can be
expressed by an accommodation of substrate in active site.

4.3.8 Inhibition Specificity
In order to test 9a’ inhibition specificity, we test its inhibition on several sugar
phosphatases. Yibv [17], which is from E. coli, can hydrolyze a wide scope of sugar
phosphates, substrates like glucose-6-phosphate, imido-di-phosphate, fructose-1-phophate,
ribose-5-phosphate,

acetyl-phosphate,

glycerol-1-phospahte,

glycerol-2-phospahte.

BT1713 [18], which is from Bacteroides thetaiotaomicron, is a 2-keto-3-deoxy-D-glyceroD-galacto-9-phosphonononic acid (KDN-9-P) phosphatase in the biosynthetic pathway of
the 9-carbon alpha-keto acid, 2-keto-3-deoxy-D-glycero-D-galactonononic acid (KDN). It
can also hydrolyze 2-keto-3-deoxy-8-phospho-d-manno-octulosonicacid (KDO-8-P), Nacetylneuraminate-9-phosphate (Neu5Ac-9-P), pNPP, glucose-6-phosphate, PEP, tyrosine
phosphate, and gluconate-6-phosphate. The other enzyme that we tested is GmhB (EFI
501036) [19], from Pseudomonas putida KT2440, is a D,D-heptose 1,7-bisphosphate
phosphatase, it can convert the D-glycero-beta-D-manno-heptose 1,7-bisphosphate
intermediate

into

D-glycero-beta-D-manno-heptose

1-phosphate.

D-Fructose-1,6-

bisphosphate is also its substrate. I didn’t observe any inhibition in the presence of 1/3
Km’s substrate and 200 μM of 9a (Table 4.7, Figure 4.12).
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Table 4.7 9a’s inhibition specificity test on sugar phosphate phosphatases.
Enzyme

Substrate

Km
(μM)

[S]
(μM)

V0 ([9a] = 0)
(μM/s)

V0 ([9a] = 200 μM)
(μM/s)

Yibv

Ribose-5-phosphate

2400

800

0.0589/0.0582

0.0613/0.0596

BT1713

KDN9P

100

33

0.0730/0.0827

0.0740/0.0829/0.0794

GmhB

D-glycero-beta-D-mannoheptose 1,7-bisphosphate

17.6

6

0.0944/0.1178

0.0965/0.1164

D-Fructose-1,6bisphosphate

151

53.3

0.0166/0.0169

0.0173/0.0177

(EFI 501036)

GmhB
(EFI 501036)

Yibv

[9a] = 0

BT1713

[9a] = 0

Substrate: Ribose-5-phosphate

Substrate: KDN9P

[9a] =200 μM

[9a] =200 μM

GmhB (EFI 501036)

GmhB (EFI 501036)

Substrate: D-glycero-beta-D-manno-heptose 1,7-bisphosphate

Substrate = D-Fructose-1,6-bisphosphate

[9a] = 0

[9a] = 0

[9a] =200 μM

[9a] =200 μM

Figure 4.12. Reaction curves of sugar phosphatases catalyzed hydrolysis in the presence or
absence of 9a.
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4.3.9 Molecular Modeling
To better understand the binding mode between T6PP and the newly identified
inhibitors, molecular docking studies were performed on compound 9a with Bm-T6PP by
using AutoDock Vina, 9a is the most potent (5.3 μM) within this series while displaying
significant activity against Bm-T6PP. Computations were aimed at elucidating the
structural requisites responsible for binding at Bm-T6PP active sites.
Bm-T6PP (PDB ID: 4OFZ) is in complex withe Mg2+ ions required for catalytic

Figure 4.13. Docking model generated pose of 9a bound to Bm-T6PP.
Hydrophobicity surface: dodger blue for the most hydrophilic, to white, to
orange red for the most hydrophobic.

activity. According to docking results (Figure 4.13), 9a sits in the interface of cap and
catalytic domains. Where the sulfate warhead sits in the phosphate binding site, and the 4n-Octyl phenyl hydrophobic group is sitting in the hydrophobic pocket of Bm-T6PP. This
hydrophobic region widely exist in carbohydrate processing enzymes. Although the sugar
molecules may be considered to be polar, the carbon atom at the five epimeric position of

105

the ring and at the adjacent exocyclic position form a contiguous hydrophobic region.
Where nearby this region of sugar processing enzyme form a hydrophobic surface in order
to stabilize the substrate binding [20].
As shown in Figure 4.14, the cofactor Mg2+ is coordinated by the carboxylate group
of the loop 1 Asp (213) nucleophile, the backbone amine carbonyl of the loop 1 Asp
acid/base and by the carboxylate of the Asp (424) on loop 4, and sulfate oxygen anion of
the inhibitor 9a. The Mg2+ functions to prevent charge repulsion between the sulfate

Figure 4.14. . Binding mode of compound 9a (green) within the Bm-T6PP
active site.

Warhead and the Asp 213, Asp 424. Besides coordination of the metal center, additional
key interactions are established by our reference compound within the active site. The
sulfate warhead forms electrostatic interaction with Lys398 and hydrogen binding with
Trp280 and Thr425. More importantly, the 4-n-octyl-phenyl group of 9a establishes
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hydrophobic contacts with the hydrophobic side chains of L383, V345, Y221 and is
involved in a parallel-displaced π−π interaction with Y221. The hydroxyl groups of the
inhibitor 9a are also involved in hydrogen bonding with Q332 and Y221. Overall, these
results support the theory according to which bimodular inhibitor 9a inhibit Bm-T6PP by
employing the binding affinity of warhead sufate with catalytic domain and π−π stacking
interaction and hydrophobic interaction.
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4.4 Material and Methods
4.4.1 Inhibitor Synthesis

108

General. Except when specified, all solvents and reagents were purchased and used
without further purification. Analytical thin-layer chromatography (TLC) was performed
on silica gel plates containing F254 fluorescence indicator and column chromatography was
performed using the indicated eluants on silica gel (230-400 mesh). 1H (300 and 500 MHz),
13

C NMR (75 MHz and 125 MHz), and 31P (121.5 MHz) NMR spectra were recorded on

Bruker Avance 500 and Bruker Avance III 300 spectrometers. 1H, 13C and 31P NMR data
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are reported as follows: for 1H NMR chemical shifts are reported in ppm relative to HDO,
multiplicities are given as s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet,
and coupling constant (J) are in Hz; 13C NMR chemical shifts are reported in ppm relative
to NH4HCO3 as a standard; 31P NMR chemical shifts are reported in ppm relative to 50%
aq H3PO4 as a standard. Phenyl α-D-glucopyranoside (1) and phenyl -D-glucopyranoside
(2a) were purchased from Carbosynth Limited. n-Octyl β-D-glucopyranoside was
purchased from Sigma-Aldrich. 2b,1 2c,2 2d,3 44, 5a5 were synthesized by using procedures
previously described in the corresponding references.
4-Sulfatomethylphenyl -D-Glucopyranoside (3). A solution of 3-formylphenyl
2,3,4,6-O-triacetyl-D-glucopyranoside (10)6 (0.976 g, 2.2 mmol) in 50 mL of a 1:1
mixture of THF/EtOH containing NaBH4 (42 mg, 1.1 mmol) was stirred at r.t. until
complete disappearance of starting material occurred (TLC). The mixture was poured into
ice-water, the pH was adjusted to 7.0 and extracted with chloroform. The extracts were
dried and concentrated in vacuo, giving a residue that was dissolved in anhydrous DMF (4
mL). To this solution at -20 ℃ was added a solution of SO3.pyridine (0.7 g, 4.4 mmol) in
2 mL anhydrous DMF. The resulting solution was stirred at r.t. for 12 h and concentrated
in vacuo, giving a residue that was subjected to silica gel chromatograph (10:1 to 5:1
DCM/MeOH) to give 3-sulfatomethylphenyl 2,3,4,6-O-triacetyl-D-glucopyranoside (11)
(0.857 g, 73%). 1H NMR (300 MHz, CDCl3) 7.14 (t, J = 8.1, 1H), 6.98-6.96 (m, 2H), 6.826.79 (m, 1H), 5.22-5.00 (m, 4H),4.91 (s, 2H), 4.18 (dd, J1 = 12.6, J2 = 5.4, 1H), 4.07-4.02
(m, 1H), 3.85-3.79 (m, 1H), 1.95 (s, 3H), 1.93 (s, 3H), 1.92 (s, 3H), 1.91 (s, 3H). 13C NMR
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(300 MHz, CDCl3) 170.4, 169.9, 169.3, 169.2, 156.6, 138.5, 129.3, 122.7, 116.4, 116.0,
98.6, 72.5, 71.7, 70.9, 68.9, 68.0, 61.7, 20.5, 20.5, 20.4.
Following addition sodium (38 mg, 1.64 mmol) to 70 mL of anhydrous methanol, a
solution of 11 (768 mg, 1.6 mmol) in anhydrous methanol (4.5 mL) was added dropwise.
After stirring at r.t. for 2 h, the mixture was neutralized with solid carbon dioxide, and
concentrated in vacuo, giving a residue that was subjected to silica gel chromatography to
give 0.485 g (78%) of 3. 1H NMR (300 MHz, CD3OD) 7.30 (t, J = 8.1, 1H), 7.21-7.20 (m,
1H), 7.10-7.06 (m, 2H), 5.01 (s, 2H), 4.95 (d, J = 6.9, 1H), 3.93 (dd, J1 = 12.0, J2 = 1.2,
1H), 3.74 (dd, J1 = 12.0, J2 = 4.5, 1H), 3.50-3.47 (m, 4H).

13

C NMR (75 MHz, CD3OD)

159.1, 139.4, 130.4, 122.8, 117.3, 102.3, 78.0, 77.9, 74.9, 71.3, 70.4, 62.4. HRMS (ESI)
calcd for C13H18O10S [M－H]－ m/z 365.0542, found 365.0535.
Methyl α-D-Glucopyranoside-6-sulfonate (5b). To a solution of methyl α-Dglucopyranoside (0.58 g, 3.0 mmol) in anhydrous DMF (9 mL) at -20℃，was added a
solution of SO3.pyridine (0.50 g, 3.15 mmol) in 1 mL anhydrous DMF, The resulting
solution was stirred at r.t. for 12 h and concentrated in vacuo, giving a residue that was
subjected to silica gel chromatograph to give 0.435g (50%) of 5b. 1H NMR (300 MHz,
CD3OD) 4.69 (d, J = 3.9, 1H), 4.29 (dd, J1 = 10.8, J2 =1.8, 1H), 4.16 (dd, J1 =10.8, J2 = 5.7,
1H), 3.77-3.71 (m, 1H), 3.64 (t, J = 9.2, 1H), 3.45-3.41 (m, 1H), 3.43 (s, 3H), 3.56-3.33
(m, 1H). 13C NMR (75 MHz, CD3OD) 101.2, 74.9, 73.4, 71.6, 71.53, 68.3, 55.6. HRMS
(ESI) calcd for C7H14O9S [M-H]－ m/z 273.0208, found 273.0278.
Phenyl α-D-Glucopyranoside-6-sulfonate (5c). This substance was prepared
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starting with phenyl α-D-glucopyranoside (1) using the same procedure employed for the
preparation of 5b. Yield 42%. 1H NMR (500 MHz, CD3OD) 7.30-7.27 (m, 2H), 7.16-7.15
(m, 2H), 7.01 (t, J = 7.5, 1H), 5.45 (d, J = 3.5, 1H), 4.22 (dd, J1 = 10.0, J2 = 4.0, 1H), 4.174.15 (m, 1H), 3.88 (t, J = 9.5, 1H), 3.77-3.70 (m, 1H), 3.59 (dd, J1 = 10.0, J2 = 4.0, 1H),
3.52 (t, J1 = 10.0, 1H). 13C NMR (125 MHz, CD3OD 158.6, 130.5, 123.5, 118.3, 99.4, 74.6,
73.2, 72.5, 71.1, 67.8. HRMS (ESI) calcd for C12H16O9S [M-H]－ m/z 335.0407, found
335.0438.
Methyl 2-O-Benzyl-α-D-glucopyranoside-6-sulfonate (5d). This substance was
prepared starting with 2-O-benzyl-α-D-glucopyranoside7 using the same procedure
employed for the preparation of 5b. Yield 43%. 1H NMR (300 MHz, CD3OD) 7.46-7.41
(m, 2H), 7.40-7.32 (m, 3H), 4.80 (d, J = 12.0, 1H), 4.68 (d, J = 12.0, 1H), 4.66 (d, J = 3.9,
1H), 4.29 (dd, J1 = 7.8, J2 = 2.1, 1H), 4.17 (dd, J1 = 10.8, J2 = 5.4, 1H), 3.79 (t, J = 9.3, 1H),
3.75-3.70 (m, 1H), 3.39-3.37 (m, 1H), 3.37 (s, 3H), 3.36-3.34 (m, 1H). 13C NMR (75 MHz,
CD3OD) 139.8, 129.4, 129.2, 128.8, 99.2, 80.9, 74.1, 74.0, 71.6, 71.4, 68.2, 55.5. HRMS
(ESI) calcd for C14H20O9S [M-H]－ m/z 363.0750, found 363.0738.
Methyl 3-O-Benzyl-α-D-glucopyranoside-6-sulfonate (5e). This substance was
prepared starting with 3-O-benzyl-α-D-glucopyranoside8 using the same procedure
employed for the preparation of 5b. Yield 50%. 1H NMR (300 MHz, CD3OD) 7.44-7.41
(m, 2H), 7.33-7.16 (m, 3H), 4.86 (s, 2H), 4.65 (d, J = 3.6 Hz,1H), 4.28 (dd, J1 = 10.8, J2 =
1.8, 1H), 4.16 (dd, J1 = 10.8, J2 = 5.4, 1H), 3.78-3.72 (m, 1H), 3.62-3.60 (m, 1H), 3.55-3.45
(m, 2H), 3.41 (s, 3H). 13C NMR (75 MHz, CD3OD) 140.5, 129.1, 129.0, 128.4, 101.4, 83.5,
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76.2, 73.5, 71.7, 71.4, 68.2, 55.6. HRMS (ESI) calcd for C7H14O9S [M-H]－ m/z 363.0750,
found 363.0739.
Methyl 4-O-Benzyl-α-D-glucopyranoside-6-sulfonate (5f). This substance was
prepared starting with 4-O-benzyl-α-D-glucopyranoside9 using the same procedure
employed for the preparation of 5b. Yield 51%. 1H NMR (500 MHz, CD3OD) 7.44-7.43
(m, 2H), 7.33-7.30 (m, 2H), 7.27-7.24 (m, 1H), 4.93-4.91 (m, 1H), 4.75 (m, 1H), 4.67 (d,
J = 3.5, 1H), 4.25 (s, 2H), 3.81-3.75 (m, 1H), 3.45-3.43 (m, 2H), 3.40 (s, 3H). 13C NMR
(75 MHz, CD3OD) 139.9, 129.4, 129.2, 128.6, 101.2, 79.3, 75.9, 75.5, 73.6, 70.6, 67.8,
55.7. HRMS (ESI) calcd for C14H20O9S [M-H]－ m/z 363.0750, found 363.0740.
Benzyl α-D-Glucopyranoside-6-sulfonate (6a). This substance was prepared from
benzyl α-D-glucopyranoside10 using the same procedure described for the preparation of
5b. Yield 47%. 1H NMR (300 MHz, CD3OD) 7.45-7.43 (m, 2H), 7.34-7.30 (m, 3H), 4.88
(d, J = 3.6, 1H), 4.77 (d, J = 11.7, 1H), 4.56 (d, J = 11.7, 1H), 4.26 (dd, J1 =10.8, J2 = 3.8,
1H), 4.15 (dd, J1 = 10.8, J2 = 5.4, 1H), 3.83-3.80 (m, 1H), 3.72 (t, J = 9.3, 1H), 3.46-3.37
(m, 2H). 13C NMR (75 MHz, CD3OD) 138.7, 129.3, 129.2, 128.7, 99.1, 74.7, 73.2, 71.8,
71.4, 70.3, 62.1. HRMS (ESI) calcd for C13H18O9S [M-H]－ m/z 349.0593, found 349.0585.
n-Octyl β-D-Glucopyranoside-6-sulfonate (6b). This substance was prepared
starting with n-octyl β-D-glucopyranoside using the same procedure described for the
preparation of 5b. Yield 56%. 1H NMR (300 MHz, CD3OD) 4.33-4.23 (m, 2H), 4.13 (dd,
J1 = 11.1, J2 = 5.6, 1H), 3.90-3.83 (m, 1H), 3.56-3.44 (m, 2H), 3.38-3.33 (m, 2H), 3.18 (t,
J = 7.2,1H), 1.64-1.56 (m, 2H), 1.38-1.26 (m, 10H), 0.90 (t, J = 6.6, 3H). 13C NMR (75
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MHz, CD3OD) 104.3, 77.7, 75.9, 75.0, 71.4, 71.0, 68.2, 33.0, 30.8, 30.6, 30.4, 27.1, 23.7,
14.4. HRMS (ESI) calcd for C14H28O9S [M-H]－ m/z 371.1376, found 371.1373.
1-Naphthyl β-D-Glucopyranoside-6-sulfonate (6c). This substance was prepared
starting with 1-naphthyl β-D-glucopyranoside (purchased from Carbosynth Limited) using
the same procedure described for the preparation of 5b. Yield 45%. 1H NMR (500 MHz,
CD3OD) 8.38-8.36 (m, 1H), 7.79-7.77 (m, 1H), 7.50-7.44 (m, 3H), 7.40-7.37 (m, 1H),
7.24-7.22 (m, 1H), 5.10 (d, J = 7.5, 1H), 4.39 (m, 1H), 4.21 (dd, J1 = 11.0, J2 = 5.5, 1H),
3.77-3.67 (m, 2H), 3.59-3.50 (m, 2H). 13C NMR (125 MHz, CD3OD 154.4, 135.8, 128.4,
127.3, 127.1, 127.0, 126.3, 123.2, 123.0, 110.6, 102.6, 77.7, 75.9, 75.0, 71.2, 68.1. HRMS
(ESI) calcd for C16H18O9S [M-H]－ m/z 385.0593, found 385.0589.
(4-Phenyl-1H-1,2,3-triazole)

β-D-Glucopyranoside-6-sulfonate

(6d).

This

substance was prepared starting with 2d using the same procedure described for the
preparation of 5b. Yield 55%. 1H NMR (300 MHz, D2O) 8.35 (s, 1H), 7.68-7.65 (m, 2H),
7.46-7.42 (m, 3H), 5.74 (d, J = 9.0, 1H), 4.47-4.43 (m, 1H), 4.37-4.35 (m, 1H), 4.05-4.02
(m, 2H), 3.78-3.74 (m, 2H), 13C NMR (75 MHz, D2O) 147.5, 129.0, 128.9, 125.6, 121.0,
87.4, 76.7, 75.7, 75.3, 72.2, 68.8. HRMS (ESI) calcd for C14H17N3O8S [M-H]－ m/z
386.0664, found 386.0666.
Phenyl β-D-Glucopyranoside-6-phosphate (7). To a solution of phenyl β-Dglucopyranoside (2a) (1.08 g, 4.0 mmol) in 5.08 mL of a 2.5:1:0.1 mixture of
acetonitrile/pyridine/water at 0℃ was added POCl3 (1.6 mL, 8 mmol). The resulting
solution was stirred at 0 ℃ for 2 h and poured onto 20 g of ice. After the ice melted, the pH
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of the mixture was adjusted to 7.0 by slowly adding 1 M aqueous NaOH. The resulting
solution was concentrated in vacuo, giving a residue that was subjected to silica gel
chromatograph (ethyl acetate/isopropyl alcohol/H2O/NH3•H2O = 5/5/2/0.2, v/v/v/v) to give
7 (0.38 g, 29%). 1H NMR (300 MHz, D2O) 7.42-7.37 (m, 2H), 7.16-7.12 (m, 3H), 5.13(d,
J = 7.2, 1H), 4.08-4.06 (m, 2H), 3.68-3.59 (m, 4H). 13C NMR (75 MHz, D2O) 156.5, 129.9,
123.3, 116.5, 100.2, 75.3, 75.1, 73.0, 68.7, 62.8. 31P NMR (121.5 MHz, D2O) 3.32. HRMS
(ESI) calcd for C12H17O9P [M-H]－ m/z 335.0532, found 335.0529.
Phenyl β-D-Glucopyranoside-6-sulfonate (8a). This substance was prepared using
starting with 2a using the same procedure described for the preparation of 5b. Yield 49%.
1

H NMR (300 MHz, CD3OD) 7.32-7.27 (m, 2H), 7.13-7.10 (m, 2H), 7.04-6.99 (m, 1H),

4.90 (d, J = 7.5, 1H), 4.39 (dd, J1 = 10.8, J2 = 1.4, 1H), 4.19 (dd, J1 = 10.8, J2 = 5.7, 1H),
3.69 (t, J = 7.4, 1H), 3.51-3.48 (m, 3H). 13C NMR (75 MHz, CD3OD) 159.1, 130.4, 123.4,
117.8, 102.3, 77.6, 75.9, 74.8, 71.2, 68.1. HRMS (ESI) calcd for C12H16O9S [M-H]－ m/z
335.0437, found 335.0429.
4,4’-Biphenyl β-D-Glucopyranoside-6-sulfonate (8b). This substance was
prepared starting with 4,4’-biphenyl β-D-glucopyranoside11 using the same procedure
described for the preparation of 5b. Yield 49%. 1H NMR (500 MHz, CD3OD) 7.54-7.51
(m, 4H), 7.38-7.34 (m, 2H), 7.26-7.23 (m, 1H), 7.16-7.15 (m, 2H), 4.90 (d, J = 7.0, 1H),
4.37 (m, 1H), 4.14 (dd, J1 = 11.0, J2 = 6.0, 1H), 3.68 (t, J = 7.3, 1H), 3.50-3.40 (m, 3H). 13C
NMR (125 MHz, CD3OD) 158.6, 142.0, 136.7, 129. 8, 129.0, 127.6, 118.2, 102.4, 77.7,
76.1, 74.9, 71.3, 68.2. HRMS (ESI) calcd for C18H20O9S [M-H]－ m/z 411.0705, found
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411.0746.
2,6-Dimethoxy-4-formylphenyl β-D-Glucopyranoside-6-sulfonate (8c). To a
solution of 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl bromide (0.824 g, 2 mmol) in
CH2Cl2 (8 mL), containing tetrabutylammonium bromide (0.76 g, 2 mmol) and
syringaldehyde (1.09 g, 6mmol) was added 8 mL of 1 M NaOH. The resulting mixture was
stirred vigorously at 35 ℃ for 6 h. The mixture was diluted with EtOAc and the organic
phase was separated, washed three times with a 1 M NaOH aqueous solution, water and
brine, dried and concentrated in vacuo. The resulting residue was dissolved in 20 mL of a
1:1 mixture of THF/MeOH containing anhydrous K2CO3 (0.5 g). The resulting mixture was
stirred for 20 h at r.t. and concentrated in vacuo, giving a residue that was subjected to
silica gel chromatography to give 2,6-dimethoxy-4-formylphenyl β-D-glucopyranoside
(12)14 (364 mg, 53%). 1H NMR (300 MHz, CD3OD/D2O (v/v, 1/2)) 9.91 (s, 1H), 7.39 (s,
2H), 5.24 (d, J = 7.2, 1H), 4.02 (s, 6H), 3.87-3.78 (m, 2H), 3.65-3.58 (m, 3H), 3.42-3.39
(m, 1H). 13C NMR (75 MHz, CD3OD/D2O (v/v, 1/2)) 195.0, 154.2, 140.6, 133.6, 108.4,
103.8, 77.7, 77.0, 74.9, 70.4, 61.6, 57.2.
The target 8c was prepared from 12 using the same procedure as described for the
preparation of 5b. Yield 58%. 1H NMR (300 MHz, D2O) 9.44 (s, 1H), 6.90 (s, 2H), 5.07
(d, J = 5.7, 1H), 4.30-4.18 (m, 2H), 3.82 (s, 6H), 3.64-3.60 (m, 4H). 13C NMR (75 MHz,
D2O) 194.3, 152.6, 138.8, 132.1, 107.1, 102.7, 75.4, 74.1, 73.5, 69.1, 66.8, 56.1. HRMS
－

(ESI) calcd for C15H20O12S [M-H] m/z 423.0597, found 423.0599.
3,4-Difuorophenyl β-D-Glucopyranoside-6-sulfonate (8d). 3,4-Difuorophenyl βD-glucopyranoside (13) was prepared using the same procedure as that for 2,6-dimethoxy-
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4-formylphenyl β-D-glucopyranoside (12).12 Yield 45%. 1H NMR (300 MHz, D2O) 7.147.04 (m, 1H), 7.01-6.94 (m, 1H), 6.85-6.81 (m, 1H), 4.77 (d, J = 5.1, 1H), 3.83 (dd, J1 =
12.0, J2 = 2.0, 1H), 3.63 (dd, J1 = 12.0, J2 = 5.4, 1H), 3.45-3.31 (m, 4H). 13C NMR (75 MHz,
MeOD) 155.4 (d, JC,F = 6.6), 150.90 (dd, JC,F1 = 319.1, JC,F2 = 13.7 ), 147.8 (dd, JC,F1 =
313.8, JC,F2 = 14.0), 118.2 (d, JC,F = 18.7), 113.9, 107.6 (d, JC,F =20.3), 102.8, 78.1, 77.8,
74.1, 71.2, 62.4.
The target 8d was prepared from 13 using the same procedure as that for 5b. Yield
33%. 1H NMR (300 MHz, MeOD) 7.10-7.01 (m, 1H), 6.94-6.92 (m, 1H), 6.86-6.79 (m,
1H), 4.45 (d, J = 10.8, 1H), 4.29-.20 (m, 1H), 4.03-3.82 (m, 2H), 3.65 (t, J = 9.0, 1H), 3.533.38 (m, 2H). 13C NMR (75 MHz, MeOD) 155.2 (d, JC,F = 4.7), 150.9 (dd, JC,F1 = 298.4,
JC,F2 = 4.7), 147.74 (dd, JC,F1 = 312.2, JC,F2 = 12.8), 118.3 (d, JC,F = 18.8), 113.9, 107.8 (d,
JC,F = 19.2), 102.4, 75.8, 75.5, 73.5, 70.0, 68.0. HRMS (ESI) calcd for C12H14F2O9S [M-H]
－

m/z 371.0248, found 371.0239.
4-Nitrophenyl β-D-Glucopyranoside-6-sulfonate (8e). This substance was

prepared using the same procedure as that for 5b starting with 4-nitrophenyl β-Dglucopyranoside.13 Yield 31%. 1H NMR (300 MHz, MeOD) 8.19 (d, J = 9.3, 2H), 7.24 (d,
J = 9.3, 2H), 5.08 (d, J = 7.2, 1H), 3.40 (dd, J1 = 11.1, J2 = 1.8, 1H), 4.17 (dd, J1 = 11.1, J2
= 6.0, 1H), 3.85-3.80 (m, 1H), 3.57-3.47 (m, 3H). 13C NMR (75 MHz, MeOD) 163.6, 143.7,
126.6, 117.7, 101.3, 77.3, 75.9, 74.5, 71.0, 68.0. HRMS (ESI) calcd for C12H15NO11S [MH]－ m/z 380.0288, found 380.0284.
4-Aminophenyl β-D-Glucopyranoside-6-sulfonate (8f).14 To a solution of 8e (120
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mg, 0.3 mmol) in DI water (6 mL), was added Pd(OH)2/C (32 mg, 0.06 mmol). The
resulting mixture was stirred under a H2 atmosphere for 2 h. The mixture was ﬁltered
through Celite pad and the filtrate was concentrated in vacuo, giving 8f (105 mg, 100%).
1

H NMR (500 MHz, D2O) 7.06-7.03 (m, 2H), 6.91-6.88 (m, 2H), 4.98 (d, J = 8.0, 1H),

4.38-4.35 (m, 1H), 4.29-4.26 (m, 1H), 3.82-3.80 (m, 1H), 3.63-3.55 (m, 3H).

13

C NMR

(125 MHz, D2O) 143.9, 132.4 111.3, 111.0, 94.2, 68.3, 66.6, 65.8, 62.0, 59.7. HRMS (ESI)
calcd for C12H17NO9S [M-H]－ m/z 350.0546, found 350.0536.
4-Acetamidophenyl β-D-Glucopyranoside-6-sulfonate (8g).14 A mixture of 8f (95
mg, 0.27 mmol) in 4.5 mL H2O containing K2CO3 (112 mg, 0.81 mmol) was stirred at 0 oC
before adding Ac2O (77 μL, 0.81 mmol) dropwise. Following stirring at for 3 h at 0 oC, the
mixture was concentrated in vacuo, giving a residue that was subjected to silica gel
chromatography, to give 8g (65 mg, 62%). 1H NMR (300 MHz, D2O) 7.34 (d, J = 8.7, 2H),
7.13 (d, J = 8.7, 2H), 5.08 (d, J = 7.2, 1H), 4.38-4.35 (m, 1H), 4.23 (dd, J1 = 11.4, J2 = 5.4,
1H), 3.87-3.83 (m, 1H), 3.62-3.56 (m, 3H), 2.13 (s, 3H). 13C NMR (75 MHz, D2O) 172.9,
154.1, 132.0, 123.9, 117.1, 100.5, 75.3, 73.9, 72.8, 69.1, 66.8, 22.6. HRMS (ESI) calcd for
C14H19NO10S [M-H]－ m/z 392.0651, found 392.0645.
2-Formylphenyl β-D-Glucopyranoside-6-sulfonate (8h). This substance was
prepared using the same procedure as that for 5b starting with 2-formylphenyl β-Dglucopyranoside.15 Yield 39%. 1H NMR (500 MHz, D2O) 10.03 (s, 1H), 7.72-7.64 (m, 2H),
7.27-7.17 (m, 2H), 5.20 (d, J = 7.5, 1H), 4.38-4.35 (m, 1H), 4.26-4.23 (m, 1H), 3.87-3.86
(m, 1H), 3.69-3.58 (m, 3H). 13C NMR (125 MHz, D2O) 186.1, 151.9, 130.2, 121.4, 117.6,
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116.1, 108.7, 92.8, 68.3, 66.9, 65.6, 61.9, 59.7. HRMS (ESI) calcd for C13H16O10S
[M-H]－ m/z 363.0386, found 363.0379.
3-Formylphenyl β-D-Glucopyranoside-6-sulfonate (8i). 3-Formylphenyl β-Dglucopyranoside (14) was prepared from 3-hydroxybenzaldehyde and 2,3,4,6-tetra-Oacetylglucosyl bromide using the same procedure as that for 12. Yield 29%. 1H NMR (300
MHz, CD3OD) 9.88 (s, 1H), 7.54-7.34 (m, 4H), 4.96 (d, J = 6.3, 1H), 3.88-3.84 (m, 1H),
3.67 (dd, J1 = 12.0, J2 = 5.1, 1H), 3.48-3.39 (m, 4H). 13C NMR (75 MHz, CD3OD) 193.9,
159.5, 139.2, 131.3, 125.0, 124.1, 117.7, 102.0, 78.1, 77.8, 74.7, 71.2, 62.3.
The target 8i was prepared from 14 substance was prepared using the same
procedure as that for 5b. Yield 39%. 1H NMR (300 MHz, D2O) 9.83 (s, 1H), 7.63-7.49 (m,
3H), 7.41-7.37 (m, 1H), 5.14 (d, J = 6.6, 1H), 4.33-4.29 (m, 1H), 4.15 (dd, J1 = 11.4, J2 =
5.7, 1H), 3.87-3.82 (m, 1H), 3.58-3.50 (m, 3H). 13C NMR (125 MHz, D2O) 188.6, 149.8,
130.1, 123.6, 118.0, 116.4, 109.6, 92.9, 68.2, 66.8, 65.6, 61.9, 59.7. HRMS (ESI) calcd for
C13H16O10S [M-H]－ m/z 363.0386, found 363.0384.
4-Formylphenyl β-D-Glucopyranoside-6-sulfonate (8j). 4-Formylphenyl β-Dglucopyranoside (15) using a previously described procedure.16 The target 8j was prepared
starting with 15 using the same procedure as that for 5b. Yield 59%. The precursor 4formylphenyl β-D-glucopyranoside was synthesized by using the procedure previously
described.16 1H NMR (300 MHz, D2O) 9.81 (s, 1H), 7.93 (d, J = 8.7, 2H), 7.27 (d, J = 8.7,
2H), 5.30 (d, J = 6.9, 1H), 4.46-4.43 (m, 1H), 4.31 (dd, J1 = 11.4, J2 = 5.1, 1H), 4.01-3.97
(m, 1H), 3.73-3.64 (m, 3H). 13C NMR (75 MHz, D2O) 188.5, 155.3, 126.1, 124.3, 110.0,
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92.8, 68.8, 67.5, 66.2, 62.6, 60.3. HRMS (ESI) calcd for C13H16O10S [M-H]－ m/z 363.0386,
found 363.0381.
2-Hydroxymethylphenyl β-D-Glucopyranoside-6-sulfonate (8k). To a solution of
2-formylphenyl β-D-glucopyranoside-6-sulfonate (8h) (98 mg, 0.26 mmol) in MeOH (2
mL) at 0℃, was added NaBH4 (40 mg, 1.03 mmol) The mixture was warmed to room
temperature and stirred for 1 h, The diluted with water, and concentrated in vacuo giving a
residue that was subjected to silica gel chromatography, giving 8k (61 mg, 64%). 1H NMR
(500 MHz, D2O) 7.38-7.35 (m, 2H), 7.22-7.21 (m, 1H), 7.15-7.12 (m, 1H), 5.10 (d, J =
7.5, 1H), 4.73-4.65 (m, 2H), 4.35-4.32 (m, 1H), 4.23-4.20 (m, 1H), 3.83-3.82 (m, 1H),
3.65-3.55 (m, 3H). 13C NMR (125 MHz, D2O) 122.6, 122.4, 122.2, 116.3, 108.3, 93.5, 68.3,
66.7, 65.7, 61.9, 59.7, 52.1. HRMS (ESI) calcd for C13H18O10S [M-H]－ m/z 365.0548,
found 365.0540.
3-Hydroxymethylphenyl β-D-Glucopyranoside-6-sulfonate (8l). This substance
was prepared from 3-formylphenyl β-D-glucopyranoside-6-sulfonate (8i) using the same
procedure as that for 8k. Yield 80%. 1H NMR (500 MHz, D2O) 7.37-7.36 (m, 1H), 7.107.07 (m, 3H), 5.10 (d, J = 4.5, 1H), 4.61-4.59 (m, 2H), 4.36-4.34 (m, 1H), 4.20 (dd, J1 =
11.0, J2 = 5.0, 1H), 3.86-3.85 (m, 1H), 3.61-3.56 (m, 3H). 13C NMR (125 MHz, D2O) 126.2,
123.0, 119.5, 114.9, 108.6, 108.1, 93.1, 68.2, 66.7, 65.7, 62.0, 59.7, 56.4. HRMS (ESI)
calcd for C13H18O10S [M-H]－ m/z 365.0548, found 365.0538.
4-Hydroxymethylphenyl β-D-Glucopyranoside-6-sulfonate (8m). This substance
was prepared from 4-formylphenyl β-D-glucopyranoside-6-sulfonate (8j) using the same
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procedure as that for 8k. Yield 58%. 1H NMR (500 MHz, D2O) 7.35-7.33 (m, 2H), 7.127.10 (m, 2H), 5.09 (d, J = 4.5, 1H), 4.56-4.55 (m, 2H), 4.34-4.32 (m, 1H), 4.22-4.20 (m,
1H), 3.84-3.83 (m, 1H), 3.58-3.54 (m, 3H). 13C NMR (125 MHz, D2O) 149.0, 127.8, 122.1,
109.5, 93.1, 68.2, 66.7, 65.7, 61.9, 59.7, 56.2. HRMS (ESI) calcd for C13H18O10S [M-H]－
m/z 365.0548, found 365.0538.
4-n-Butylphenyl β-D-Glucopyranoside-6-sulfonate (8n). 4-n-Butylphenyl β-Dglucopyranoside (16) was prepared from 4-n-butylphenol using the same procedure as that
for 12. Yield 30% in two steps. 1H NMR (300 MHz, CD3OD) 7.18-7.07 (m, 4H), 4.98 (d,
J = 7.2, 1H), 3.98-3.94 (m, 1H), 3.80 (dd, J1 = 11.1, J2 = 4.5, 1H), 3.61-3.53 (m, 4H), 2.59
(t, J = 7.7, 2H), 1.62-1.57 (m, 2H), 1.40-1.33 (m, 2H), 0.96 (t, J = 7.4, 3H). 13C NMR (75
MHz, CD3OD) 156.6, 138.2, 130.3, 117.6, 102.2, 77.5, 77.3, 74.5, 70.9, 62.1, 35.5, 34.8,
23.0, 14.2.
The target 8n was prepared from 16 using the same procedure as that for 5b. Yield
51%. 1H NMR (300 MHz, D2O/CD3OD (v/v, 1/1)) 7.21-7.06 (m, 4H), 4.99 (d, J = 6.9, 1H),
4.39-4.35 (m, 1H), 4.24 (dd, J1 = 11.1, J2 = 5.1, 1H), 3.78-3.77 (m, 1H), 3.59-3.56 (m, 3H),
2.59 (t, J = 7.7, 2H), 1.63-1.53 (m, 2H), 1.40-1.30 (m, 2H), 0.93 (t, J = 7.4, 3H). 13C NMR
(75 MHz, D2O/CD3OD (v/v, 1/1)) 156.1, 138.8, 130.4, 117.6, 102.1, 76.7, 75.1, 74.1, 70.4,
67.8, 35.2, 34.4, 22.7, 14.2. HRMS (ESI) calcd for C16H24O9S [M-H]－ m/z 391.1063, found
391.1075.
4-n-Hexylphenyl β-D-Glucopyranoside (17) and 4-n-Hexylphenyl α-DGlucopyranoside (18).17 To a solution of penta-O-benzoyl-D-glucose (2.8 g, 4 mmol) and
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4-n-hexylphenol (1.42 g, 8 mmol) in dichloromethane (28 ml) under argon at 0 °C was
added BF3·Et2O (1.67 mL, 13.2 mmol). The mixture was stirred at 50 °C for 48 h, diluted
with water (30 mL) and stirred for 15 min. The mixture was diluted with dichloromethane
(60 mL), washed with water, brine, and concentrated in vacuo, giving a residue that was
dissolved in THF/MeOH (100 mL/20 mL) and cooled to 0 °C. A 3N solution of aq NaOH
(9.52 mL) was added and the mixture was stirred for 9 h at room temperature, diluted with
water (40 mL), neutralized with AG 50W-X8 resin (Bio-Rad), filtered, and concentrated in
vacuo, giving a residue that was subjected to silica gel chromatography, giving 4-nhexylphenyl β-D-glucopyranoside (17) (237 mg, 17%) and 4-n-hexylphenyl α-Dglucopyranoside (18) (639 mg, 47%).
17: 1H NMR (300 MHz, CDCl3/CD3OD (v/v, 1/1)) 7.59-7.45 (m, 4H), 5.39 (d, J =
6.9, 1H), 4.39-4.26 (m, 2H), 4.06-4.04 (m, 3H), 3.93-3.92 (m, 1H), 3.04 (t, J = 7.7, 2H),
2.07-2.05 (m, 2H), 1.84-1.79 (m, 6H), 1.38 (t, J = 6.6, 3H).

13

C NMR (75 MHz,

CDCl3/CD3OD (v/v, 1/1)) 155.1, 137.0, 129.0, 116.3, 100.8, 76.1, 75.9, 73.1, 69.4, 61.0,
34.8, 31.4, 31.4, 28.6, 22.3, 13.6.
18: 1H NMR (300 MHz, CDCl3/CD3OD (v/v, 1/1)) 7.36-7.29 (m, 4H), 5.75 (d, J =
3.6, 1H), 4.19 (t, J = 9.3, 1H), 4.10-3.98 (m, 3H), 3.93-3.82 (m, 2H), 2.81 (t, J = 7.7, 2H),
1.86-1.84 (m, 2H), 1.58-1.57 (m, 6H), 1.56 (t, J = 6.6, 3H).

13

C NMR (300 MHz,

CDCl3/CD3OD (v/v, 1/1)) 154.7, 136.8, 129.0, 116.6, 97.7, 73.4, 72.2, 71.6, 69.3, 60.7,
34.8, 31.4, 31.3, 28.6, 22.3, 13.6.
4-n-Hexylphenyl β-D-Glucopyranoside-6-sulfonate (8o). This substance was
prepared from 4-n-hexylphenyl β-D-glucopyranoside (17) using the same procedure as that
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for 5b. Yield 46 %. 1H NMR (300 MHz, D2O/CD3OD (v/v, 1/1)) 7.19-7.09 (m, 4H), 4.99
(d, J = 6.6, 1H), 4.43-4.40 (m, 1H), 4.29 (dd, J1 = 11.1, J2 = 5.4, 1H), 3.80-3.76 (m, 1H),
3.65-3.57 (m, 3H), 2.60 (t, J = 7.5, 2H), 1.65-1.60 (m, 2H), 1.38-1.35 (m, 6H), 0.95 (t, J =
6.6, 3H). 13C NMR (75 MHz, CDCl3/CD3OD (v/v, 1/1)) 156.6, 138.3, 130.2, 117.7, 102.4,
77.0, 75.4, 74.4, 70.7, 67.9, 35.8, 32.6, 32.5, 29.6, 23.4, 14.4. HRMS (ESI) calcd for
C18H28O9S [M-H]－ m/z 419.1376, found 419.1388.
4-n-Hexylphenyl α-D-Glucopyranoside-6-sulfonate (9b). This substance was
prepared from 4-n-hexylphenyl α-D-glucopyranoside (18) using the same procedure as that
for 5b. Yield 55 %. 1H NMR (300 MHz, CD3OD) 7.12-7.05 (m, 4H), 5.44 (d, J = 3.6, 1H),
4.29-4.17 (m, 2H), 3.94-3.88 (m, 2H), 3.65-3.52 (m, 2H), 2.56 (t, J = 7.7, 2H ), 1.61-1.54
(m, 2H), 1.33-1.31 (m, 6H), 0.91 (t, J = 6.6, 3H). 13C NMR (75 MHz, CD3OD) 156.5, 138.0,
130.2, 118.2, 99.5, 74.5, 73.1, 72.3, 71.1, 67.8, 36.0, 32.8, 29.9, 23.2, 14.4. HRMS (ESI)
calcd for C18H28O9S [M-H]－ m/z 419.1376, found 419.1375.
4-n-Octylphenyl β-D-Glucopyranoside (19) and 4-n-Octyl phenyl α-DGlucopyranoside (20).17 These substances were prepared using the same procedure as
those for 4-n-hexylphenyl β-D-glucopyranoside (17) and 4-n-hexylphenyl α-Dglucopyranoside (18).
19: Yield 25 %. 1H NMR (300 MHz, CD3OD) 7.03-6.92 (m, 4H), 4.80 (d, J = 6.6,
1H), 3.84-3.80 (m, 1H), 3.64 (dd, J1 = 11.4, J2 = 3.6, 1H ), 3.40-3.35 (m, 4H), 2.47 (t, J =
7.5, 2H), 1.54-1.48 (m, 2H), 1.24-1.23 (m, 10H), 0.83 (t, J = 6.3, 3H). 13C NMR (75 MHz,
CD3OD) 157.2, 137.9, 130.2, 117.7, 102.5, 78.0, 77.9, 74.9, 71.3, 62.5, 36.1, 33.0, 32.9,
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30.6, 30.4, 30.2, 23.7, 14.4.
20: Yield 44 %. 1H NMR (300 MHz, CD3OD) 7.10-7.09 (m, 4H), 5.46 (d, J = 3.6,
1H), 3.90 (t, J = 9.3, 1H), 3.77-3.71 (m, 3H), 3.59 (dd, J1 = 9.6, J2 = 3.6, 1H ), 3.47 (t, J =
9.2, 1H ), 2.57 (t, J = 7.7, 2H), 1.62-1.58 (m, 2H), 1.33-1.32 (m, 10H), 0.92 (t, J = 6.8, 3H).
13

C NMR (75 MHz, CD3OD) 156.7, 138.0, 130.2, 118.2, 99.6, 74.9, 74.2, 73.3, 71.5, 62.3,

36.1, 33.0, 32.9, 30.6, 30.4, 30.3, 23.7, 14.4.
4-n-Octylphenyl β-D-Glucopyranoside-6-sulfonate (8p). This substance was
prepared from 4-n-octylphenyl β-D-glucopyranoside (19) using the same procedure as that
for 5b. Yield 42 %. 1H NMR (300 MHz, D2O) 6.97-6.90 (m, 4H), 4.72 (d, J = 6.3, 1H),
4.30-4.27 (m,1H), 4.17-4.13 (m, 1H ), 3.61-3.43 (m, 4H), 2.37 (t, J = 7.1, 2H), 1.44-1.43
(m, 2H), 1.24-1.23 (m, 10H), 0.88 (t, J = 6.2, 3H). 13C NMR (75 MHz, D2O) 155.2, 137.3,
129.3, 117.3, 101.7, 75.2, 73.8, 72.8, 68.7, 66.3, 35.0, 31.9, 31.5, 29.5, 29.4, 22.6, 13.9.
HRMS (ESI) calcd for C20H32O9S [M-H]－ m/z 447.1689, found 447.1693.
4-n-Octylphenyl α-D-Glucopyranoside-6-sulfonate (9a). This substance was
prepared from 4-n-octylphenyl α-D-glucopyranoside (20) using the same procedure as that
for 5b. Yield 68 %. 1H NMR (300 MHz, D2O) 6.96-6.83 (m, 4H), 5.38 (d, J = 3.6, 1H),
4.28-4.19 (m, 1H), 3.96-3.90 (m, 2H), 3.76-3.59 (m, 3H), 2.3 (t, J = 7.7, 2H), 1.43-1.42 (m,
2H), 1.24-1.23 (m, 10H), 0.87 (t, J = 6.6, 3H).

13

C NMR (75 MHz, D2O) 154.8, 136.7,

129.1, 117.0, 97.8, 72.8, 71.2, 70.5, 68.7, 66.2, 35.0, 31.9, 31.6, 29.6, 29.5, 22.7, 13.9.
HRMS (ESI) calcd for C20H32O9S [M-H]－ m/z 447.1689, found 447.1695.
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4.4.2 References for Inhibitor Synthesis
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2. Somsak, L.; Felföldi, N.; Kónya,B.; Hüse, C.; Telepo, K.; Bokor, É.; Czifrák K.
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rabbits.Bioorg. Med. Chem. Lett. 2004, 14, 225–229.
5. Guiseley, K. B.; Ruoff, P. M. Monosaccharide Sulfates. I. Glucose 6-Sulfate.
Preparations, Characterization of the Crystalline Potassium Salt, and Kinetic Studies.
J. Org. Chem. 1961, 26 (4), 1248–1254.
6. Miura M.; Wu H.Glycosylated carboranylporphyrins for use in boron neutron capture
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7. Zhou, Y.; Lia, J.; Zhan, Y.; Pei, Z.; Dong, H. Halide promoted organotin-mediated
carbohydrate benzylation: mechanism and application. Tetrahedron 2013, 69(13),
2693-2700.
8. Liau, B. B.; Milgram, B. C.; Shair, M. D. Total Syntheses of HMP-Y1, Hibarimicinone,
and HMP-P1. J. Am. Chem. Soc. 2012, 134 (40), 16765–16772.
9. Tani, S.; Sawadi, S.; Kojima, M.; Akai, S.; Sato, K.-i. A novel method for regioselective
ring-opening reduction of 4,6-O-benzylidene hexopyranoside derivatives using CoCl2
and BH3·THF.Tetrahedron Letters, 2007, 48(17), 3103-3104.
10. Pearce, O. M. T.; Varki, A. Chemo-enzymatic synthesis of the carbohydrate antigen Nglycolylneuraminic acid from glucose. Carbohydrate Research, 2010, 345(9), 1225–
1229.
11. Dai X.; Wu S.; Yang W. Chemical synthesis process for preparing gastrodin and its
analogous henolic glycoside formula (I). Zhuanli Shenqing Gongkai Shuomingshu,
2003, 1428345.
12. Kröger, L.; Thiem, J. Synthesis and evaluation of glycosyl donors with novel leaving
groups for transglycosylations employing b-galactosidase from bovine testes.
Carbohydrate Research, 2007, 342(3-4), 467–481.
13. Green, D. E.; Ferreira, C. L.;Stick,

; Patrick, B. O.; Adam, M. J.; Orvig, C.

Carbohydrate-Bearing 3-Hydroxy-4-pyridinonato Complexes of Gallium(III) and
Indium(III). Bioconjugate Chemistry, 2005, 16(6), 1597-1609.
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and Kobayashi, K. Design of N-acetyl-6-sulfo-β-D-glucosaminide-based inhibitors of
inﬂuenza virus sialidase. Bioorganic & Medicinal Chemistry, 2004, 12(6), 1367–1375.
15. Loganathan, D.; Trivedi, G. K. Phase-transfer-catalyzed d-glucosylation: Synthesis of
benzoylated aryl β-d-glucopyranosides and β-d-glucopyranosyl-substituted cinnamates.
Carbohydrate Research, 1987, 162(1), 117–125.
16. Wen, H.; Lin, C.; Que, L.; Ge, H.; Ma, L.; Cao, R.; Wan, Y.; Peng, W.; Wang, Z.; Song,
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acetylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 2007,
43(1):166-73
17. France, R. R.; Compton, R. G.; Davis, B. G.; Fairbanks, A. J.; Rees, N. V.; Wadhawan,
J. D. Selective electrochemical glycosylation by reactivity tuning. Org. Biomol. Chem.,
2004, 2, 2195-2202.

4.5 Site-Directed Mutagenesis
Site directed mutagenesis was carried out using a PCR-based strategy with the WTMt-T6PP/pET-15-TEV plasmid and commercial primers. Reaction solutions also
contained dNTP (Invitrogen) and Deep Vent DNA polymerase. The PCR was carried out
using the Techgene thermal cycler manufactured by TECHNE. The PCR products were
treated with DpnI for 1 h at 37°C to remove the wild type plasmid before transformation
of T7 Express Iq Competent E. coli (High Efficiency) cells. The sequence of the mutated
gene was confirmed by DNA sequencing carried out by GENEWIZ, Inc. The plasmid was
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prepared using a QIAprep Spin Minniprep kit (Qiagen). The expression levels of the genes
encoding T6PP mutants were examined by SDS-PAGE analysis of the cellular protein.
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CHAPTER FIVE
IRREVERSIBLE INHIBITION OF HAD FAMILY MEMBER
TREHALOSE-6-PHOSPHATE PHOSPHATASE WITH ACTIVE SITE
DIRECTED BIOMODULAR INHIBITORS

5.1 Abstract
Molecules that bind selectively to a given drug target and then undergo a rapid
chemoselective reaction to form a covalent conjugate have utility in drug development.
The design of these molecules to generate irreversible inhibitors for biological research and
drug discovery is an important challenge in carbohydrate chemistry. Herein a library of
known Trehalsoe-6-phosphate phosphatase (T6PP) inhibitors with nucleophilic warheads
was conceived of by structure-based design principles and was chemically synthesized.
When bound in T6PP active site, the aryl sulfonyl fluorides of 26 react rapidly and
chemoselectively with highly conserved Lys residues which located in cap domain. Our
results suggest that development of broad-range anthelmintic and antibacterial therapeutics
employing targeting this highly conserved Lys may be possible.

5.2. Introduction
Trehalose, a natural alpha-linked disaccharide formed by an α,α-1,1-glucoside bond
between two α-glucose units, is synthesized and stored in a wide variety of organisms such
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as bacteria, plants, fungi and invertebrates to support cell survival by functioning as a fuel,
a metabolic regulator or a protectant against environmental stress [1-3]. Unlike these other
organisms, humans are unable to produce trehalose but can utilize trehalose through a
trehalase enzyme [4-6]. Five different trehalose biosynthetic pathways are known to exist
[7], one of which, the OtsA/B pathway is common among pathogenic bacteria and fungi
as well as in parasitic nematodes. The OtsA/B pathway, which utilizes glucose and glucose6-phosphate to generate trehalose-6-phosphate catalyzed by trehalose synthase, then
hydrolyzed to trehalose by trehalose-6- phosphate phosphatase (T6PP). Previously
reported otsA and otsB gene knockout (or knockdown) experiments have shown that both
pathway enzymes are essential for Mycobacterium tuberculos’s growth in laboratory
culture and for its virulence in a mouse model [8]. The T6P synthase and phosphatase are
also required for trehalose production in the filamentous fungus Fusarium graminearum,
however only the T6PP proved to be indispensable for development and virulence [9]. It is
also required for cell wall integrity and fungal virulence in the human fungal pathogen
Aspergillus fumigatus [10] Disruption of the TPS2Gene which encode Trehalose-6Phosphate Phosphatase Decreases Candida albicans’s Infectivity [11]. Silencing of tpp
gene in Caenorhabditis elegans and Brugia malayi caused the arrested growth of larvae
revealed that the T6PP is essential, however only when the T6P synthase-encoding gene is
functional [12, 13].
Based on these findings we concluded that trehalose synthesizing pathogens are
likely to be vulnerable to the action of small molecule inhibitors of their T6PPs. Moreover,
the ranking of potential drug targets for the parasitic nematode Brugia malayi placed T6PP
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among the most attractive candidates [14]. T6PP belongs to HADSF, its active site is
formed by substrate-induced association of a mobile cap domain with the catalytic site of
the Rossmann-fold catalytic domain. For phosphatase-specific targeting, one end of the
inhibitor is to be optimized for complementation of the catalytic site common to each
phosphatase, and the other end optimized to complement the interfaced region of the cap
domain, unique to each phosphatase. Phosphate-like functional groups were screened for
binding affinity to the catalytic site by using trehalose as the carrier; the sulfate group
proved to be most effective (Chapter 3). The ability of trehalose-6-sulfate to induce cap
closure was examined by SAXS, and shown to occur in the bacterial T6PP, but not in the
nematode T6PP.The X-ray structure determined for the nematode T6PP is consistent with
restricted cap movement. Organic groups, attached to glucose-6-sulfate, were then
screened for binding affinity towards the cap domain, with promising results for future lead
inhibitor development (Chapter 4). In general, to design inhibitors for carbohydrate
processing proteins is challenging, since carbohydrates themselves do not bind to proteins
with great affinity, for which the monomeric KD values are typically in the micromolar to
millimolar range [15-17]. This low affinity is likely due to the extensive hydrophilic
character of these polyhydroxylated compounds. In order to overcome this limitation, we
turn onto use irreversible inhibitor design strategy. Compared to reversible inhibitors,
irreversible inhibitors has important and potentially advantageous consequences for drug
pharmaco-dynamics in which the level and frequency of doing relates to the extent and
duration of the resulting pharmacological effect. In particular, when covalent modification
of a drug target is irreversible, the restoration of pharmacological activity requires re-
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synthesis of the protein target. Some highly nucleophilic warheads, which are widely used
in irreversible inhibitor design, were attached to one of highest ranking reversible inhibitors
we have synthesized (Scheme 5.2), they were screened for their inactivation activities. An
irreversible inhibitor which has fluorosulfonylbenzoate group can inactivate all the T6PPs
we tested. It is possible that the fluorosulfonylbenzoate can selectively react with active
residues in the interface between cap and core domains of the T6PPs. To directly
demonstrate that inhibitor 26 inactivates the T6PPs by covalent modification, we analyzed
T6PPs treated with or without 26 using mass spectrometry. It shows that this compound
lead to covalent labelling of the enzyme within the enzyme substrate binding site residues.
This results are promising for the discovery of broad-range anthelmintic and antibacterial
drugs.
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Scheme 5.2. Structure-based covalent inhibitor design using trehalose-6-sulfate, 4n-Octyl phenyl- glucopyranoside 6-sulfate and phenyl a-D glucopyranoside 6-sulfate
as the platform.
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5.3. Results
5.3.1 Synthesis of T6PP irreversible inhibitors
The routes utilized for preparation of the members of the T6PP irreversible inhibitor
library, displayed in Schemes 5.3-5.5 below and described completely in the Experimental,
begin with either commercially available or previously synthesized starting materials. Each
substance was shown to be >95% pure by using NMR spectroscopy.

Scheme 5.3. Synthesis of T6S analogs irreversible inhibitors 4, 5, 6, 9.
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Scheme 5.4. Synthesis of phenyl -D glucopyranoside 6-sulfate analogs
irreversible inhibitors 13, 14, 15, 16, 17.
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Scheme 5.5. Synthesis of 4-n-Octyl phenylD glucopyranoside 6-sulfate
analogs irreversible inhibitors 26, 28, 30, 31.

5.3.2 Biological activity of irreversible inhibitors
5.3.2.1 Screening the irreversible inhibitors’ inactivation and inhibition activities on
T6PPs
In order to get their inhibitory information, I set up a HTS assay to screen the
inhibitors on the T6PPs. In general, In an incubation reaction mixture containing: T6PP,
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with inhibitor or without inhibitor (control), it was incubated at room temperature for half
hour, then took 5 μL of this reaction mixture to a 96 well plate, each well contains 45 μL
reaction mixture: buffer, [T6P] = Km. The reaction mixture was sit at room temperature
for 5 min, then 100 μL biomol green dye (Enzo Life science). And the resulting mixture
was incubated at room temperature for 30 min to allow development of the green color,
and measured OD620nm on a microtiter-plate reader. The percentage inactivation was
calculated using the ratio of OD620nm’ / OD620nm, where OD620nm’ is the absorption of the
reaction mixture with inhibitor, and the OD620nm is the absorption without inhibitor. The
inhibition constants were measured using Enzchek phosphate assay kit (Life Technologies).
For the quick inhibition constants measurements, when the initial reaction rate with Ki
inhibitor is half of that rate without inhibitor when the substrate concentration is Km. The
following is their inhibitory results:

Table 5.1. HTS for inhibitors’ inactivation activities on T6PPS and reversible
inhibition constants (Kis).
Inhibition Constant (KI) and Relative Activity after Incubation

Enzyme

5

4

9

6

14

15

13

17

16

31

30

28

26

a

> 1 mM

1 mM

1 mM

1 mM

> 1 mM

0.04 mM

None

0.5 mM

1 mM

0.02 mM

0.1 mM

0.1 mM

0.02 mM

As-T6PP

b

> 1 mM

> 1 mM

1 mM

> 1 mM

> 1 mM

0.2 mM

1 mM

1 mM

> 1 mM

0.2 mM

0.2 mM

> 0.2 mM

0.2 mM

Mt-T6PP

c

> 1 mM

> 1 mM

> 1 mM

None

None

None

> 1 mM

> 1 mM

None

0.4 mM

0.4 mM

0.2 mM

0.05 mM

Sb-T6PP

a

None

None

None

None

0.5 mM

0.017 mM

1 mM

0.33 mM

1 mM

St-T6PP

d

None

None

None

None

1 mM

0.08 mM

> 2 mM

0.4 mM

> 1 mM

Bm-T6PP

a

0.017 mM 0.008 mM 0.033 mM 0.013 mM
0.1 mM

: Incubation reaction conditions: T6PP (1 eq), inhibitors (200 eq), incubated at r.t. for 30 min.
Incubation reaction conditions: As-T6PP (1 eq), inhibitors (25 eq), incubated at r.t. for 30 min.
: Incubation reaction conditions: Mt-T6PP (1 eq), inhibitors (300 eq), incubated at r.t. for 30 min.
d
: Incubation reaction conditions: St-T6PP (1 eq), inhibitors (40 eq), incubated at r.t. for 30 min.
Background colors: percentage of inactivation.
No background: no inactivation observed.
Yellow background: less than 20 % activity lost after 1 hour incubation.
Orange background: more than 20 % and less than 80% activity lost after 1 hour incubation.
Red: more than 80% activity lost after 1 hour incubation.
b:
c
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0. 1mM

0.2 mM

0.01 mM

As we can see in table 5.1, some inhibitors are neither reversible inhibitors nor
irreversible inhibitors, such as: 5, 6, 9. Inhibitor 4 can selectively inactivate Mt-T6PP,
however, it shows low binding affinity to this enzyme. Inhibitors 13, 14, 16, 17, 28, 30, 31
show moderate inactivation activities on some of the T6PPs, they may selectivity react with
some poorly conserved residues in T6PPs. Both 15 and 26 can inactivate T6PPs we have
tested, however, inhibitor 15 shows poor binding affinity on Mt-T6PP. Then inhibitor 26
was selected for further characterization of its inactivation mechanism.

5.3.2.2 Kinetic analysis of T6PPs inactivation by 26.
In general, the action of a target-specific covalent inhibitor can be described by the
mechanism shown below:

Scheme 5.6. General inactivation mechanism.

It occurs at two steps in the inhibition: the first step is the compound (I) binds to the
target protein (E) non-covalently, and places its moderately reactive electrophile close to a
specific nucleophile on the protein; the second step is that the resulting complex (E·I) then
undergoes specific bond formation, which gives rise to the inhibited complex (E-I).
Incubation of 26 with T6PPs, results in a time- and concentration-dependent loss of
phosphatase activity (Figs 5.1-5, a). The simplest kinetic scheme consistent with the data
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is reversible binding of the inactivator to the enzyme active sit to give a Michaelis complex
(E·I). The stability of this complex is governed by a dissociation constant (Ki) and a
chemical inactivation step (Kinact) (scheme 7). Extensive dialysis and buffer exchange of
the reaction mixture failed to restore enzyme activities, which also suggests the inactivation
of the T6PPs by 26 is irreversible. We also found that the rate of inactivation decreased in
the presence of the competitive inhibitor trehalose-6-sulfate (Figs 5.1-5, b), indicating the
inactivation is driven by action occurring at the enzymatic active site, these results also
suggest that 26 inactivation action involves at least two steps: binding to the T6PPs active
site, followed by covalent modification of active site residue(s). Analysis of pseudo-firstorder rate constant (Appendix A5.10) as a function of inhibitor concentration reveals a
hyperbolic curve, yielding values for the binding constant Ki and inactivation rate constant
kinact (Table 5.2).

Table 5.2. Kinetic analyses T6PPs’ inactivation by 26 at 25 ℃ and pH 7.5.
T6PP Source

kinact (min-1)

KI (μM)

kinact/KI (M-1min-1)

Ascaris suum

0.12±0.02

332±87

3.6×102

Brugia malayi

0.11±0.01

85±18

1.3×103

Mycobacterium tuberculosis

0.33±0.07

310±80

1.1×103

Shigella boydii

0.42±0.09

252±62

1.7×103

Salmonella typhimurium

0.053±0.009

242±48

2.2×102
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Figure 5.1. Kinetic analysis of As-T6PP inactivation by 26 at 25℃. (a) Time and concentration dependence of inhibitor 26
mediate As-T6PP (1 μM) inactivation. (b) Protection of 26 mediated As-T6PP inactivation by T6S. As-T6PP (1 μM) was
incubated with 120 μM 26 in the presence or absence of 100 μM T6S, respectively (c) Concentration dependence of the pseudofirst-order rate constants kobs for 26 mediated As-T6PP inactivation. The points are experimental and the line connecting them
is the line fitted to the equation kobs = (kinact [I])/(KI +[I]), yielding values for the binding constant KI and the inactivation rate
constant kinact of 332 μM and 0.12 min-1, respectively.
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Figure 5.2. Kinetic analysis of Bm-T6PP inactivation by 26 at 25℃. (a) Time and concentration dependence of inhibitor 26
mediate Bm-T6PP (1 μM) inactivation. (b) Protection of 26 mediated Bm-T6PP inactivation by T6S. Bm -T6PP (1 μM) was
incubated with 50 μM 26 in the presence or absence of 200 μM T6S, respectively (c) Concentration dependence of the pseudofirst-order rate constants kobs for 26 mediated Bm-T6PP inactivation. The points are experimental and the line connecting them
is the line fitted to the equation kobs = (kinact [I])/(KI +[I]), yielding values for the binding constant KI and the inactivation rate
constant kinact of 86 μM and 0.11 min-1, respectively.

a

b

c
0 .0 6
1 .0

I = 10 μM

I = 40 μM

0 .6

I = 50 μM

0 .4
I = 60 μM

0 .2

T6S = 180 μM

0 .6

0 .4

0

10

20

30

40

50

60

0 .0 4
0 .0 3
0 .0 2
0 .0 1

0 .2

0 .0 0

0 .0

0 .0

0 .0 5
-1

0 .8

K o b s ( m in

I = 30 μM

R e la tiv e A c tiv ity

R e la tiv e A c tiv ity

I = 20 μM

0 .8

T6S = 0

)

1 .0

0

20

40

T im e (m in )

T im e ( m in )

60

0

20

40

60

80

I (μ M )

Figure 5.3. Kinetic analysis of Mt-T6PP inactivation by 26 at 25℃. (a) Time and concentration dependence of inhibitor 26
mediate Mt-T6PP (1 μM) inactivation. (b) Protection of 26 mediated Mt -T6PP inactivation by T6S. Mt-T6PP (1 μM) was
incubated with 50 μM 26 in the presence or absence of 180 μM T6S, respectively (c) Concentration dependence of the pseudofirst-order rate constants kobs for 26 mediated Mt-T6PP inactivation. The points are experimental and the line connecting them is
the line fitted to the equation kobs = (kinact [I])/(KI +[I]), yielding values for the binding constant KI and the inactivation rate constant
kinact of 310 μM and 0.33 min-1, respectively.
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Figure 5.4. Kinetic analysis of Sb-T6PP inactivation by 26 at 25℃. (a) Time and concentration dependence of inhibitor 26
mediate Sb-T6PP (1 μM) inactivation. (b) Protection of 26 mediated Sb-T6PP inactivation by T6S. Sb-T6PP (1 μM) was
incubated with 30 μM 26 in the presence or absence of 660 μM T6S, respectively. (c) Concentration dependence of the pseudofirst-order rate constants kobs for 26 mediated Sb-T6PP inactivation. The points are experimental and the line connecting them is
the line fitted to the equation kobs = (kinact [I])/(KI +[I]), yielding values for the binding constant KI and the inactivation rate
constant kinact of 252 μM and 0.42 min-1, respectively.
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Figure 5.5. Kinetic analysis of St-T6PP inactivation by 26 at 25℃. (a) Time and concentration dependence of inhibitor
26 mediate St-T6PP (5.7 μM) inactivation. (b) Protection of 26 mediated St-T6PP inactivation by T6S. St-T6PP (5.7 μM)
was incubated with 80 μM 26 in the presence or absence of 400 μM T6S, respectively. (c) Concentration dependence of
the pseudo-first-order rate constants kobs for 26 mediated St-T6PP inactivation. The points are experimental and the line
connecting them is the line fitted to the equation kobs = (kinact [I])/(KI +[I]), yielding values for the binding constant KI and
the inactivation rate constant kinact of 242 μM and 0.053 min-1, respectively.

5.3.2.3 Mass spectrometry analysis of T6PPs inactivation by 26.
In order to directly demonstrate that inhibitor 26 inactivates the T6PPs by covalent
modification, I analyzed T6PPs treated with or without 26 using mass spectrometry. In the
case of Mt-T6PP, the mass of unmodified Mt-T6PP measured by ESI mass spectrometer
was 44052 Da (Figue 5.6, left), which is consistent with the theoretical value (44051 Da).
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Mt-T6PP treated with 26 showed an altered mass of 44666 Da (Figue 5.6, right). This
corresponds to a mass difference of 614 Da (Table 5.2), consistent with the formation of a
sulfide covalent adduct between Mt-T6PP and 26 (The theoretical mass shift is 614 Da).

Figure 5.6. Mass spectrometry analysis of Mt-T6PP inactivation by 26. ESI mass
spectra of Mt-T6PP treated with (right) or without (left) 26.

Figure 5.7. Mass spectrometry analysis of Sb-T6PP inactivation by 26. ESI mass
spectra of Sb-T6PP treated with (right) or without (left) 26.
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Figure 5.8. Mass spectrometry analysis of Bm-T6PP inactivation by 26. ESI mass
spectra of Bm-T6PP treated with 26.

Figure 5.9. Mass spectrometry analysis of St-T6PP inactivation by 26. ESI mass
spectra of St-T6PP treated with 26.
Table 5.3. Mass of covalent modification of T6PPs by 26
T6PP Source (Theoretical Mass
(Da))

Unmodified
(Da)

Modified
(Da)

Mass Difference
(Da)

Brugia malayi (57450)

57448

58060

612

Mycobacterium tuberculosis
(44052)

44052

44666

614

31297, 31475a

31912,
32089a

615, 616a

31576, 31754a

32191,
32209a

615, 615a

Shigella boydii (31298)
Salmonella typhimurium (31577)

a

: The protein has been modified by alpha-N-6-phosphogluconoylation of a "his tag" with an extra mass of 178

Da in the fusion protein.
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5.3.3. Identification of modified residues by compound 26.
In order to explore the mechanism of T6PPs inactivation mediated by compound 26,
we need to determine which residue reacted with the sulfonyl fluoride of compound 26.
Base on the binding model of Bm-T6PP with T6P substrate in Figure 5.10 [18], there are
several residues which may interact with the substrate D336, R337, K334, Q332, and Y221.
However, the residue Y221 is far away from the trehalose unit, it is difficult for it to contact
with sulfonyl fluoride group of compound 26. As previously reported, sulfonyl fluoride can
modify reactive serines, context-specific threonine, lysine, tyrosine, cysteine and histidine
residues [19]. Thus residue K334 is highly possible to be modified by compound 26. In

Figure 5.10 Substrate interacting residues in B. malayi analyzed by mutagenesis and kinetic.

Order to confirm this hypothesis, we analyzed Bm-T6PP-K334A mutant [18] treated with
or without 26 using mass spectrometry. The results shown in Figure 5.11 indicate that
compound 26 is unable to modify Bm-T6PP-K334A mutant, consistent with the formation
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of a covalent adduct between Bm-T6PP and 26 involving the Lys334 residue.

Figure 5.11 Mass spectrometry analysis of the Bm-T6PP Lys334 to Ala mutant (1 μM) in
the presence and absence of 20 μM 26 under the same incubation conditions used for the
wild type enzyme. The ESI mass spectra of Bm-T6PP-K334A treated with (bottom) or
without (top) 26.

Figure 5.12 Sequence alignments of nematode and bactera T6PP enzymes. Sb (Shigella boydii);
St (Salmonella typhimurium); Mt (Mycobacterium tuberculosis); Bm (Brugia malayi);
As (Ascaris suum). The Lys highlighted in red is highly conserved.

Interestingly, Lys334 in Bm-T6PP is highly conserved in nematode and bateria
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T6PPs base on the sequennce alignments(Figure 5.12). In order to further confirm that
compound 26 selectively react with highly conserved Lys in T6PPs, we analyzed MtT6PP-K253A mutant (chapter 3) treated with or without 26 using mass spectrometry
(Figure 5.13). We got the same results as for Bm-T6PP-K253A, the mutant Mt-T6PPK253A could be modified by compound 26 under the same incubation conditions used
for the wild type enzyme.

Figure 5.13 Mass spectrometry analysis of the Mt-T6PP Lys253 to Ala mutant (1 μM) in the
presence and absence of 20 μM 26 under the same incubation conditions used for the wild
type enzyme. The ESI mass spectra of Mt-T6PP-K253A treated with (bottom) or without
(top) 26.

5.3.4. Molecular Modeling
In order to better to understand how the compound 26 inactivate, molecular docking
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studies were performed on this compound with Bm-T6PP by using AutoDock Vina.
Bm-T6PP (PDB ID: 4OFZ) is in complex withe Mg2+ ions required for catalytic activity.
According to docking results (Figure 5.14), 26 sits in the interface of cap and catalytic
domains. The phosphate mimic sulfate group sits in the phosphate binding site, and the 4-

Figure 5.14. Docking model generated pose of 26 bound to Bm-T6PP.
Hydrophobicity surface: dodger blue for the most hydrophilic, to white, to
orange red for the most hydrophobic.

n-Octyl phenyl hydrophobic group is sitting in the hydrophobic pocket of Bm-T6PP.
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Figure 5.15. Binding mode of compound 26 (light blue) within the Bm-T6PP
substrate binding site.

From Figure 5.15, we can see the cofactor Mg2+ is coordinated by the carboxylate
group of the loop 1 Asp213 nucleophile and Asp424 on loop 4, and sulfate oxygen anion
of the inhibitor 26. The Mg2+ functions to prevent charge repulsion between the sulfate and
the Asp213, Asp424. Besides coordination of the metal center, additional key interactions
are established by compound 26 within the active site. The sulfate warhead forms
hydrogen binding with Lys398 and Tyr221 and Thr425. And the 4 position hydroxyl group
can interact with Ser427 via hydrogen bond. More importantly, the 4-n-octyl-phenyl group
of 26 establishes hydrophobic contacts with the hydrophobic side chains of Leu383, Val
345, Tyr 221 and Tyr225 in order to increase the binding affinity. In the cap domain, there
are several hydrogen bond formed with the sulfonyl fluoride warhead group (Figure 5.14,
right). In the inactivation reaction, Lys334 was deprotonated by Glu383, and then
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nucleophilic attack sulfonyl fluoride which was activated by Gln332 via hydrogen bonding
(Figure 5.16) to form covalent adduct.

Figure 5.16. Proposed mechanism of 26 mediated Bm-T6PP inactivation.

5.3.4 Inactivation specificity of 26.
In order to test the inactivation specificity by 26, I tested its inactivation activities
on several sugar phosphatases. Yibv [19], which is from E. coli, can hydrolyze a wide scope
of sugar phosphates, substrates like glucose-6-phosphate, imido-di-phosphate, fructose-1phophate, ribose-5-phosphate, acetyl-phosphate, glycerol-1-phospahte, glycerol-2phospahte. BT1713 [20], which is from Bacteroides thetaiotaomicron, is a 2-keto-3-deoxyD-glycero-D-galacto-9-phosphonononic acid (KDN-9-P) phosphatase in the biosynthetic
pathway of the 9-carbon alpha-keto acid, 2-keto-3-deoxy-D-glycero-D-galactonononic
acid (KDN). It can also hydrolyze 2-keto-3-deoxy-8-phospho-d-manno-octulosonicacid
(KDO-8-P), N-acetylneuraminate-9-phosphate (Neu5Ac-9-P), pNPP, glucose-6-phosphate,
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PEP, tyrosine phosphate, and gluconate-6-phosphate. The other enzyme that we tested is
GmhB (EFI 501036) [21], from Pseudomonas putida KT2440, is a D,D-heptose 1,7bisphosphate phosphatase, it can convert the D-glycero-beta-D-manno-heptose 1,7bisphosphate intermediate into D-glycero-beta-D-manno-heptose 1-phosphate. DFructose-1,6-bisphosphate is also its substrate. I didn’t observe significant inactivation in
the presence of 30 eq of 26 (Figue 5.17).
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Figure 5.17. Inactivation specificity of 26. Incubation conditions: In 1 mL reaction mixture, containing 1 eq enzyme
(BT1713, or GmhB, or Yibv), 30 eq inhibitor 26 in a buffer of 50 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1 mM DTT,
5% glycerol. Their catalytic hydrolysis of sugar phosphate activity were measured by using EnzChek Phosphate Assay. The
substrates that were used: KDN-9-P for BT1713, D-Fructose-1,6-bisphosphate for GmhB, and ribose-5-phosphate for Yibv.

5.5 Conclusion
Trehalose -6-phosphate phosphatase involved in the biosynthesis of trehalose, one
of the important molecule that exist in a wide variety of organisms to support cell survival
by functioning as a fuel, a metabolic regulator or a protectant against environmental stress.
T6PP is a potential drug target in pathogenic bacteria and fungi as well as in parasitic
nematodes. Here, we describe the discovery of a novel class of covalent inhibitors that
broadly inhibit T6PP through the generation of a reactive sulfonyl fluoride group within
their T6P substrate binding site. Until the discovery of this compound, there were no
generally applicable irreversible inhibitors for T6PP. The reactive sulfonyl fluoride

153

primarily remain localized within the interface between the core and cap domains
(substrate binding site), since its inactivation activity decreased in the presence of
reversible competitive T6PP inhibitor T6S. No significant inactivation on other sugar
phosphatases were observed show that this inhibitor has its selective inhibition on T6PPs.
This inhibitor will serve as powerful research tools for further exploration of T6PP drug
target. In addition, these inhibitors will serve as starting points for the generation of T6PPselective inhibitors through systematic modification of their aryl substituents to take
advantage of the unique active site topologies of T6PPs. These observation highlight the
potential for developing broad-range anthelmintic and antibacterial therapeutics employing
targeting this highly conserved Lys may be possible.

5.5 Material and Methods
5.5.1 Inhibitor Synthesis
General. Except when specified, all solvents and reagents were purchased and used
without further purification. Analytical thin-layer chromatography (TLC) was performed
on silica gel plates containing F254 fluorescence indicator and column chromatography was
performed using the indicated eluants on silica gel (230-400 mesh). 1H (300 MHz),

13

C

NMR (75 MHz), and 31P (121.5 MHz) NMR spectra were recorded on Bruker Avance III
300 spectrometers. 1H,

13

C and

31

P NMR data are reported as follows: for 1H NMR

chemical shifts are reported in ppm relative to HDO, multiplicities are given as s = singlet,
d = doublet, t = triplet, q = quartet, td = triplet of doublets, br = broad signal, m = multiplet,
and coupling constant (J) are in Hz; 13C NMR chemical shifts are reported in ppm relative
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to NH4HCO3 as a standard; 31P NMR chemical shifts are reported in ppm relative to 50%
aq H3PO4 as a standard.

6-O-vinyl sulfonate-2,3,4,2’,3’,4’-hexakis-O-(trimethylsilyl)-α,α-trehalose (2) and
6,6’ Di-O-vinyl sulfonate-2,3,4,2’,3’,4’-hexakis-O-(trimethylsilyl)-α,α-trehalose (3).
To a solution of 11 (1.2 g, 1.55 mmol) in anhydrous dichloromethane (9 mL) at 0 ℃ was
added DIPEA (1.2 g, 9.3 mmol). 2-chloroethane-sulfonyl chloride (0.33 g, 1.86 mmol) was
added over half hour. The resulting solution was stirred at 0 ℃ for 4 h and concentrated in
vacuo, giving a residue that was subjected to silica gel chromatograph to give 0.52 g (34%)
of 2 and 0.41 g (27%) of 3.
2: 1H NMR (300 MHz, CDCl3) 6.55 (dd, J1 = 9.6 Hz, J2 = 16.8 Hz, 1H), 6.40 (d, J
= 16.8 Hz, 1H), 6.11 (dd, J1 = 9.6 Hz, J2 = 4.4 Hz, 1H), 4.89 (d, J = 3.0 Hz, 2H), 4.20-4.19
(m, 2H), 4.03-4.0 (m, 1H), 3.91-3.89 (m, 3H), 3.72-3.68 (m, 2H), 3.50-3.40 (m, 4H), 1.73
(br, 1H), 0.17-0.12 (m, 54H). 13C NMR (75 MHz, CDCl3) 132.7, 130.1, 94.9, 94.7, 73.5,
73.2, 72.9, 72.6, 71.6, 71.5, 70.8, 69.6, 61.7, 1.13, 1.07, 0.98, 0.28, 0.21.
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3: 1H NMR (300 MHz, CDCl3) 6.54 (dd, J1 = 9.6 Hz, J2 = 16.5 Hz, 2H), 6.40 (d, J
= 16.5 Hz, 2H), 6.13 (d, J = 9.6 Hz, 2H), 4.88 (d, J = 3.0 Hz, 2H), 4.20-4.19 (m, 4H), 4.033.98 (m, 2H), 3.86 (t, J = 9.0 Hz, 2H), 3.45-3.40 (m, 4H), 0.16-0.12 (m, 54H). 13C NMR
(75 MHz, CDCl3) 132.6, 130.2, 94.8, 73.4, 72.6, 71.6, 70.9, 69.5, 1.15, 1.07, 0.29.
6-O-vinyl sulfonate-α,α-trehalose (4). 2 (200 mg, 0.21 mmol) was dissolved in a
mixture of TFA/THF/H2O (8/17/3, V/V/V, 2.5 mL), The resulting solution was stirred at
r.t. for 1 h and concentrated in vacuo, giving a residue that was subjected to silica gel
chromatograph to give 108 mg (98%) of 4. 1H NMR (300 MHz, D2O) 6.80 (dd, J1 = 10.2
Hz, J2 = 16.5 Hz, 1H), 6.50 (d, J = 16.5 Hz, 1H), 6.37 (d, J = 10.2 Hz, 1H), 5.19 (d, J = 3.9
Hz, 1H), 5.16 (d, J = 3.9 Hz, 1H), 4.44-4.43 (m, 2H), 4.07-4.0 (m, 1H), 3.87-3.73 (m, 5H),
3.67-3.60 (m, 2H), 3.51-3.43 (m, 2H). 13C NMR (75 MHz, D2O) 133.1, 130.5, 93.6, 93.4,
72.5, 72.3, 72.2, 70.9, 70.8, 69.7, 69.6, 69.1, 60.5. HRMS (ESI+) calcd for C14H24O13S
[M+Na]+ m/z 455.0830, found 455.0836.
6,6’ Di-O-vinyl sulfonate-α,α-trehalose (5). This substance was prepared from 3
using the same procedure as that for 4. Yield 99 %. 1H NMR (300 MHz, D2O) 6.79 (dd, J1
= 9.9 Hz, J2 = 16.8 Hz, 2H), 6.50 (d, J = 16.8 Hz, 2H), 6.36 (d, J = 9.9 Hz, 2H), 5.16 (d, J
= 3.6 Hz, 2H), 4.44-4.43 (m, 4H), 4.14-4.02 (m, 2H), 3.83 (t, J = 9.6 Hz, 2H), 3.64 (dd, J1
= 3.6 Hz, J2 = 10.2 Hz, 2H), 3.48 (t, J = 9.6 Hz, 2H).

13

C NMR (75 MHz, D2O) 133.1,

130.5, 93.8, 72.4, 70.7, 69.8, 69.6, 69.1. HRMS (ESI+) calcd for C16H25O15S2 [M+Na]+ m/z
545.0611, found 545.0613.
6-O-vinyl sulfonate-6’-sulfate-α,α-trehalose (6). To a solution of compound 3
(640 mg, 0.74 mmol) in anhydrous pyridine (20 mL) at 0 ℃，was added a solution of
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SO3.pyridine (141 mg, 0.89 mmol) in 1 mL anhydrous pyridine, The resulting solution was
warmed to room temperature and stirred for 12 h, then concentrated in vacuo, the resulting
residue was dissolved in a mixture of TFA/THF/H2O (8/17/3, V/V/V, 1 mL), The resulting
solution was stirred at r.t. for 1 h and concentrated in vacuo giving a residue that was
subjected to silica gel chromatograph to give 82 mg (22%) of 6. 1H NMR (300 MHz, D2O)
6.80 (dd, J1 = 9.9 Hz, J2 = 16.5 Hz, 1H), 6.52 (d, J = 16.5 Hz, 1H), 6.38 (d, J = 9.9 Hz, 1H),
5.20 (d, J = 3.6 Hz, 1H), 5.16 (d, J = 3.6 Hz, 1H), 4.47-4.44 (m, 2H), 4.28-4.25 (m, 2H),
4.08-4.00 (m, 2H), 3.85 (t, J = 9.6 Hz, 2H), 3.67 (dd, J1 = 3.6 Hz, J2 = 9.9 Hz, 2H), 3.553.46 (m, 2H). 13C NMR (75 MHz, D2O) 133.1, 130.5, 93.8, 93.7, 72.4, 72.3, 70.7, 70.3,
69.8, 69.6, 69.3, 69.2, 66.9. HRMS (ESI-) calcd for C14H23O16S2 [M]- m/z 511.0428, found
511.0411.

6-O-(Ethylphosphorylfluoro)-2,3,4,2',3',4,6’-hepta-O-benzyl-α,α-D-trehalose
(8).3 To a solution of compound 72 (0.47 g, 0.48 mmol) in anhydrous pyridine (10 mL),
was added ethylphosphonic dichloride (0.71 g, 4.8 mmol). The resulting solution was
stirred at r.t. overnight. The reaction mixture was concentrated under reduced pressure and
the resulting residue was dissolved in a mixture of dichloromethane and H2O (5 mL/10
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mL), and stirred at r.t. for 1 hour, then acidified with 1 N HCl, and extracted with
dichloromethane, dried over Na2SO4 and concentrated in vacuo, giving a residue, which
was dissolved in anhydrous DMF under argon atmosphere, and fluoro-N,N,N',N'-bis
(tetramethylene) formamidinium hexafluorophosphate (466 mg, 1.48 mmol) was added.
Then DIPEA (190 mg, 1.48 mmol) was added, the resulting mixture was stirred overnight
at room temperature and concentrated in vacuo, giving a residue that was subjected to silica
gel chromatograph to give 387 mg (77%) of 8. 1H NMR (300 MHz, CDCl3) 7.38-7.16 (m,
35H), 5.26 (d, J = 3.3 Hz, 1H), 5.24 (d, J = 3.9 Hz, 1H), 5.06 (d, J = 8.4 Hz, 1H), 5.02 (d,
J = 8.4 Hz, 1H), 4.96-4.84 (m, 4H), 4.80-4.41 (m, 8H), 4.23-4.04 (m, 6H), 3.76-3.69 (m,
1H), 3.65 (dd, J1 = 9.6 Hz, J2 = 3.6 Hz, 1H), 3.60-3.52 (m, 3H), 3.45-3.40 (m, 1H), 1.961.81 (m, 2H), 1.30-1.15 (m, 3H). 13C NMR (75 MHz, CDCl3) 138.9, 138.6, 138.4, 138.1,
138.0, 137.9,128.5, 128.2, 128.2, 128.1, 127.9, 127.8, 127.6, 127.5, 94.7, 94.5, 94.2, 94.0,
81.9, 81.9, 81.6, 81.5, 79.5, 77.8, 77.4, 77.0, 75.8, 75.7, 75.3, 75.2, 73.6, 73.2, 73.1, 72.8,
70.9, 69.6 (d, JC,P = 4.4 Hz ), 68.2, 65.2 (d, JC,P = 17.3 Hz ), 65.1 (d, JC,P = 17.5 Hz ), 17.8
(dd, JC,P = 146.0 Hz, JC,F = 25.4 Hz), 17.7 (dd, JC,P = 144.5 Hz, JC,F = 25.4 Hz), 6.3, 6.2.
31

P NMR (121.5 MHz, D2O) 33.9 (d, JP,F = 1071.5 Hz), 33.3 (d, JP,F = 1077.9 Hz).
6-O-(Ethylphosphorylfluoro-α,α-D-trehalose (9). Compound 8 (367 mg, 0.34

mmol) was dissolved in ethanol (35 mL). Pd/C (10% w/w, 700 mg) was added and the
resulting suspension was stirred under an atmosphere of hydrogen (30 psi) at room
temperature for 24 h. The catalyst Pd/C was removed by filtration and the reaction was
concentrated in vacuo, giving a residue that was subjected to silica gel chromatograph to
give 107 mg (71%) of 9. 1H NMR (300 MHz, D2O) 5.20 (d, J = 3.6 Hz, 1H), 5.16 (d, J =
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3.6 Hz, 1H), 4.45-4.39 (m, 2H), 4.01-3.96 (m, 1H), 3.88-3.71 (m, 5H), 3.66-3.60 (m, 2H),
3.51 (dd, J1 = 9.6 Hz, J2 = 2.7 Hz, 1H), 3.43 (t, J = 9.6 Hz, 1H), 2.18-2.05 (m, 2H), 1.341.04 (m, 3H). 13C NMR (75 MHz, D2O) 93.6, 93.5, 93.4, 72.6, 72.4, 72.3, 72.2, 71.0, 70.9,
70.5, 70.4, 69.7, 69.2, 69.1, 69.0, 66.1, 66.0, 60.5, 16.6 (dd, JC,P = 138.6 Hz, JC,F = 18.4
Hz), 16.5 (dd, JC,P = 140.2 Hz, JC,F = 18.0 Hz), 5.0, 4.9. 31P NMR (121.5 MHz, D2O) 38.9
(d, JP,F = 1075.6 Hz), 38.7 (d, JP,F = 1078.2 Hz). HRMS (ESI+) calcd for C14H26FO12P
[M+Na]+ m/z 459.1044, found 459.1028.

4-Nitrophenyl α-D-glucopyranoside-6-sulfate (11). To a solution of 4-Nitrophenyl α-Dglucopyranoside (4.0 g, 13.3 mmol) in anhydrous DMF (40 mL) at -20 ℃，was added a
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solution of SO3·pyridine (2.2 g, 14 mmol) in 4 mL anhydrous DMF, The resulting solution
was stirred at r.t. for 12 h and concentrated in vacuo, giving a residue that was subjected to
silica gel chromatograph to give 2.92 g (58%) of 11. 1H NMR (300 MHz, CD3OD) 8.23 (d,
J = 9.3 Hz, 2H), 7.34 (d, J = 9.3 Hz, 2H), 5.64 (d, J = 3.6 Hz, 1H), 4.18-4.16 (m, 2H), 3.86
(t, J = 9.3 Hz, 1H), 3.76 (td, J1 = 9.9 Hz, J2 = 3.6 Hz, 1H), 3.65 (dd, J1 = 9.9 Hz, J2 = 3.6
Hz, 1H), 3.50 (t, J = 9.9 Hz, 1H). 13C NMR (75 MHz, CD3OD) 163.6, 144.1, 126.7, 118.1,
99.3, 74.5, 73.2, 72.9, 71.1, 67.8.
4-Aminophenyl α-D-glucopyranoside-6-sulfate (12). Compound 11 (2.4 g, 6.31
mmol) was dissolved in methanol/H2O mixture (50 mL/25 mL). Pd/C (10% w/w, 300 mg)
was added and the resulting suspension was stirred under an atmosphere of hydrogen (30
psi) at room temperature for 3 h. The catalyst Pd/C was removed by filtration and the
reaction was concentrated in vacuo, giving a residue that was subjected to silica gel
chromatograph to give 2.2 g (99%) of 12. 1H NMR (300 MHz, D2O) 7.07 (d, J = 8.7 Hz,
2H), 6.88 (d, J = 8.7 Hz, 1H), 5.45 (d, J = 3.6 Hz, 1H), 4.27-4.25 (m, 2H), 4.10-4.06 (m,
1H), 3.92 (t, J = 9.6 Hz, 1H), 3.74 (dd, J1 = 9.9 Hz, J2 = 3.6 Hz, 1H), 3.59 (dd, J1 = 9.9 Hz,
J2 = 9.0 Hz, 1H). 13C NMR (75 MHz, D2O) 150.3, 140.5, 119.1, 118.1, 98.5, 72.9, 71.0,
70.5, 69.1, 66.8.
4-Acrylaminophenyl α-D-glucopyranoside-6-sulfate (13). Compound 12 (105.3
mg, 0.3 mmol) was dissolved in a THF/H2O mixture (1 mL/2 mL) and cooled to 0 ℃.
Acryloyl chloride (54.3 mg, 0.6 mmol) and K2CO3 (165.6 mg, 1.2 mmol) were added, the
resulting solution was warmed to room temperature and stirred overnight. The reaction was
concentrated in vacuo, giving a residue that was subjected to silica gel chromatograph to
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give 73 mg (60%) of 13. 1H NMR (300 MHz, D2O) 7.48 (d, J = 9.0 Hz, 2H), 7.22 (d, J =
9.0 Hz, 2H), 6.45 (dd, J1 = 17.1 Hz, J2 = 9.9 Hz, 1H), 6.33 (dd, J1 = 17.1 Hz, J2 = 1.8 Hz,
1H), 5.88 (dd, J1 = 9.9 Hz, J2 = 1.8 Hz, 1H), 5.62 (d, J = 3.6 Hz, 1H), 4.25-4.24 (m, 2H),
4.05-4.00 (m, 1H), 3.92 (t, J = 9.6 Hz, 1H), 3.77 (dd, J1 = 9.9 Hz, J2 = 3.6 Hz, 1H), 3.59
(dd, J1 = 9.9 Hz, J2 = 9.2 Hz, 1H). 13C NMR (75 MHz, D2O) 166.7, 153.5, 131.8, 130.2,
128.2, 123.4, 117.8, 97.5, 72.7, 70.8, 70.4, 68.9, 66.7. HRMS (ESI-) calcd for C15H18NO10S
[M]- m/z 404.0651, found 404.0651.
4-(3-(Flurosulfonyl)benzoylamino)phenyl α-D-Glucopyranoside-6-sulfate (14).
Freshly prepared 14a4 (66.6 mg, 0.3 mmol) in THF (366 μL) was added dropwise to the
stirred solution of compound 12 (116 mg, 0.33 mmol) and trimethylamine (104 μL, 0.75
mmol) in anhydrous THF (8 mL) at 0 ℃ under argon atmosphere. The resulting solution
was stirred at 40 ℃ for 12 h and concentrated in vacuo, giving a residue that was subjected
to silica gel chromatograph to give 97 mg (60%) of 14. 1H NMR (300 MHz, CD3OD) 8.62
(d, J = 1.5 Hz, 1H), 8.44 (d, J = 7.8 Hz, 1H), 8.27 (d, J = 7.8 Hz, 1H), 7.90 (t, J = 7.8 Hz,
1H), 7.66 (dd, J1 = 6.9 Hz, J2 = 2.1 Hz, 2H), 7.22 (dd, J1 = 6.9 Hz, J2 = 2.1 Hz, 2H), 5.46
(d, J = 3.6 Hz, 1H), 4.22-4.21 (m, 2H), 3.91-3.85 (m, 2H), 3.61 (dd, J1 = 9.6 Hz, J2 = 3.6
Hz, 1H), 3.52 (dd, J1 = 9.9 Hz, J2 = 9.0 Hz,, 1H). 13C NMR (75 MHz, CD3OD) 165.7, 155.8,
138.3, 135.9, 135.0, 134.1, 132.0, 131.6, 128.6, 123.8, 118.7, 99.8, 74.7, 73.2, 72.6, 71.3,
67.9. HRMS (ESI-) calcd for C19H19FNO12S2 [M]- m/z 536.0333, found 536.0333.
tert-Butyl 3-((octyloxy)sulfonyl)benzoate.5 To a solution of 1-octanol (916 mg,
7.05 mmol) in anhydrous dichloromethane (2 mL), DIPEA (546 mg, 4.23 mmol) and
DMAP (17.2 mg, 0.1 mmol) was added at 0 ℃ under argon atmosphere. tert-Butyl 3-
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(chlorosulfonyl) benzoate5 (390 mg, 1.41 mmol) in anhydrous dichloromethane (1 mL) was
added dropwise and stirred for 30 min at 0 ℃. The reaction mixture was warmed to room
temperature and stirred for 24 h and concentrated in vacuo, giving a residue that was
subjected

to

silica

gel

chromatograph

to

give

370

mg

of

tert-butyl

3-

((octyloxy)sulfonyl)benzoate (71 %). 1H NMR (300 MHz, CDCl3) 8.48 (s, 1H), 8.26 (d, J
= 7.8 Hz, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.62 (t, J = 7.8 Hz, 1H), 4.08 (t, J = 6.6 Hz, 2H),
1.70-1.58 (m, 2H), 1.61 (s, 9H), 1.32-1.20 (m, 10 H), 0.86 (t, J = 6.8 Hz, 3H). 13C NMR
(75 MHz, CDCl3) 163.9, 137.0, 134.5, 133.6, 131.4, 129.4, 128.8, 82.6, 71.4, 31.8, 29.2,
29.0, 28.3, 25.5, 22.7, 14.2.
3-((Octyloxy)sulfonyl)benzoic acid.5 To a solution of tert-Butyl 3-((octyloxy)
sulfonyl)benzoate (300 mg, 0.81 mmol) in anhydrous dichloromethane (11 mL), TFA (3.7
mL) was added. After stirring for 1 h at room temperature, the mixture was c concentrated
in vacuo to give 245 mg of 3-((octyloxy)sulfonyl)benzoic acid (98%). 1H NMR (300 MHz,
CDCl3) 8.65 (s, 1H), 8.40 (d, J = 7.5 Hz, 1H), 8.16 (d, J = 7.5 Hz, 1H), 7.71 (t, J = 7.5 Hz,
1H), 4.11 (t, J = 6.8 Hz, 2H), 1.70-1.65 (m, 2H), 1.26-1.20 (m, 10 H), 0.86 (t, J = 6.8 Hz,
3H).

13

C NMR (75 MHz, CDCl3) 169.6, 136.8, 135.2, 132.4, 131.0, 129.8, 129.5, 71.8,

31.7, 29.0, 28.9, 25.3, 22.6, 14.0.
Octyl 3-(chlorocarbonyl)benzenesulfonate (15a). 3-((octyloxy)sulfonyl) benzoic
acid (254 mg, 0.81 mmol) was dissolved in thionyl chloride ( 6 mL).The reaction mixture
was heated under reflux for 4 h. The solvent was evaporated and then co-evaporated with
anhydrous toluene to give unstable 15a, which was dissolved in anhydrous THF (1 mL) to
make 0.81 M solution.
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4-(3-((octyloxy)sulfonyl)benzoylamino)phenyl α-D-Glucopyranoside-6sulfate (15). Freshly prepared 15a (370 μL, 0.81M, 0.3 mmol) was added dropwise to the
stirred solution of compound 12 (116 mg, 0.33 mmol) and trimethylamine (104 μL, 0.75
mmol) in anhydrous THF (6 mL) at 0 ℃ under argon atmosphere. The resulting solution
was stirred at 40 ℃ for 12 h and concentrated in vacuo, giving a residue that was subjected
to silica gel chromatograph to give 86.5 mg (45%) of 15. 1H NMR (300 MHz, D2O) 8.30
(s, 1H), 8.11 (d, J = 7.8 Hz, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.59 (t, J = 7.8 Hz, 1H), 7.32 (d,
J = 8.4 Hz, 2H), 6.98 (d, J = 8.4 Hz, 2H), 5.41 (d, J = 3.0 Hz, 1H), 4.26-4.23 (m, 1H), 4.104.07 (m, 1H), 4.00 (t, J = 6.6 Hz, 2H), 3.93-3.87 (m, 2H), 3.66-3.55 (m, 2H), 1.55-1.45 (m,
2H), 1.09-1.05 (m, 10 H), 0.72 (t, J = 6.6 Hz, 3H) . 13C NMR (75 MHz, D2O) 164.9, 153.8,
135.8, 135.3, 132.0, 130.3, 130.0, 126.8, 123.5, 117.6, 98.0, 72.8, 71.8, 71.2, 70.6, 68.8,
66.5, 31.7, 29.0, 28.9, 28.7, 25.2, 22.5, 13.8. HRMS (ESI-) calcd for C27H36NO13S2 [M]m/z 646.1628, found 646.1660.
4-(6-Bromohexanoylamino) phenyl α-D-Glucopyranoside-6-sulfate (16). A
solution of compound 12 (105.3 mg, 0.3 mmol), 6-bromohexanoyl chloride (64.1 mg, 0.3
mmol), triethylamine (209 μL, 1.5 mmol) in anhydrous THF (15 mL) was heated under
reflux for 4 h under argon atmosphere. The reaction mixture was cooled to room
temperature and concentrated in vacuo, giving a residue that was subjected to silica gel
chromatograph to give 52 mg (33%) of 16. 1H NMR (300 MHz, D2O) 7.39 (d, J = 9.0 Hz,
2H), 7.18 (d, J = 9.0 Hz, 2H), 5.57 (d, J = 3.6 Hz, 1H), 4.27-4.19 (m, 2H), 4.03-3.90 (m,
2H), 3.75 (dd, J1 = 9.9 Hz, J2 = 3.6 Hz 1H), 3.66-3.56 (m, 2H), 3.50 (t, J = 6.6 Hz, 1H),
2.40 (t, J = 7.2 Hz, 2H), 1.90-1.77 (m, 2H), 1.75-1.64 (m, 2 H), 1.55-1.44 (m, 2 H). 13C
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NMR (75 MHz, D2O) 175.4, 153.4, 131.8, 123.7, 117.7, 97.5, 72.7, 70.8, 70.4, 68.8, 66.5,
45.3, 34.7, 31.5, 26.6, 24.3. HRMS (ESI-) calcd for C18H25BrNO10S [M]- m/z 526.0383,
found 526.0378.
4-(2-Bromoacetylamino) phenyl α-D-Glucopyranoside-6-sulfate (17). To a
solution of compound 12 (70.2 mg, 0.2 mmol) and triethylamine (27.8 μL, 0.2 mmol) in
anhydrous dichloromethane (2.5 mL), was added 2-bromoacetic anhydride (114.3 mg, 0.44
mmol) in one portion. The resulting solution was stirred at room temperature for 40 min
and concentrated in vacuo, giving a residue that was subjected to silica gel chromatograph
to give 62 mg (66%) of 17. 1H NMR (300 MHz, CD3OD) 7.54 (d, J = 9.0 Hz, 2H), 7.18 (d,
J = 9.0 Hz, 2H), 5.45 (d, J = 3.6 Hz, 1H), 4.24-4.23 (m, 2H), 4.01 (s, 2H), 3.92-3.86 (m,
2H), 3.62 (dd, J1 = 9.6 Hz, J2 = 3.6 Hz, 1H), 3.54 (dd, J1 = 9.6 Hz, J2 = 9.0 Hz, 1H). 13C
NMR (75 MHz, CD3OD) 167.4, 155.5, 134.1, 122.7, 118.7, 99.7, 74.6, 73.2, 72.5, 71.2,
67.8, 29.7. HRMS (ESI-) calcd for C14H18BrNO10S [M]- m/z 469.9757, found 469.9748.
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4-n-Octylphenyl-3,4,6-tri-O-acetyl-2-azido-2-deoxy α-D-glucopyranoside (19)
and 4-n-Octylphenyl-3,4,6-tri-O-acetyl-2-azido-2-deoxy β-D-glucopyranoside (20). To
a solution of 1,3,4,6-tetraacetate-2-azido-2-deoxy-D-glucopyranose 186 (3.56 g, 9.54
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mmol) and 4-n-octylphenol (2.36 g, 11.45 mmol) in anhydrous dichloromethane (50 ml)
under argon at 0 °C was added BF3·Et2O (4.8 mL, 38.16 mmol). The mixture was stirred
at 50 °C for 48 h, diluted with water and stirred for 15 min. The mixture was diluted with
dichloromethane, washed with water, brine, and concentrated in vacuo, giving a residue
that was subjected to silica gel chromatography, giving compound 19 (2.07 g, 42%) and
compound 20 (1.29 g, 26%).
19: 1H NMR (300 MHz, CDCl3) 7.11 (d, J = 8.7 Hz, 2H), 7.03 (d, J = 8.7 Hz, 2H),
5.69 (dd, J1 = 10.5 Hz, J2 = 9.3 Hz, 1H), 5.58 (d, J = 3.6 Hz, 1H), 5.13 (dd, J1 = 10.2 Hz,
J2 = 9.3 Hz, 1H), 4.28 (dd, J1 = 12.3 Hz, J2 = 4.5 Hz, 1H), 4.20-4.14 (m, 1H), 4.05 (dd, J1
= 12.3 Hz, J2 = 2.1 Hz, 1H), 3.44 (dd, J1 = 10.5 Hz, J2 = 3.6 Hz, 1H), 2.55 (t, J = 7.7, 2H),
2.12 (s, 3H), 2.04 (s, 3H), 2.04 (s, 3H), 1.60-1.55 (m, 2H), 1.33-1.23 (m, 10H), 0.87 (t, J =
6.8, 3H). 13C NMR (75 MHz, CDCl3) 170.5, 170.1, 169.8, 154.1, 138.1, 129.6, 116.6, 97.0,
70.4, 68.5, 68.3, 61.7, 60.9, 35.2, 32.0, 31.7, 29.5, 29.3, 22.7, 20.8, 20.7, 20.7, 14.2.
20: 1H NMR (300 MHz, CDCl3) 7.11 (d, J = 8.7 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H),
5.08-4.91 (m, 2H), 4.90 (d, J = 8.1 Hz, 1H), 4.30 (dd, J1 = 12.3 Hz, J2 = 5.4 Hz, 1H), 4.14
(dd, J1 = 12.3 Hz, J2 = 2.4 Hz, 1H), 3.83-3.75 (m, 2H), 2.56 (t, J = 10.8, 2H), 2.10 (s, 3H),
2.08 (s, 3H), 2.03 (s, 3H), 1.60-1.55 (m, 2H), 1.30-1.26 (m, 10H), 0.87 (t, J = 6.8, 3H). 13C
NMR (75 MHz, CDCl3) 170.6, 170.0, 169.7, 154.8, 138.4, 129.5, 117.1, 100.9, 72.5, 72.0,
68.5, 63.6, 62.1, 35.2, 32.0, 31.7, 29.5, 29.3, 22.7, 20.8, 20.7, 14.2.
4-n-Octylphenyl-2-azido-2-deoxy α-D-glucopyranoside (21). To a solution of
compound 19 (2.0 g, 3.85 mmol) in anhydrous methanol (40 mL), was added freshly
prepared 0.1 M NaOMe solution in methanol (1.5 mL) dropwise. The resulting solution
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was stirred at room temperature for 25 min, then quenched with 8 drops of acetic acid and
concentrated in vacuo, giving a residue that was subjected to silica gel chromatograph to
give 1.36 g (90%) of 21. 1H NMR (300 MHz, CDCl3) 7.07 (d, J = 8.7 Hz, 2H), 6.98 (d, J
= 8.7 Hz, 2H), 5.50 (d, J = 3.3 Hz, 1H), 5.11 (br, 2H), 4.29-4.23 (m, 1H), 3.98-3.80 (m,
4H), 3.64 (br, 1H), 3.41 (dd, J1 = 10.5 Hz, J2 = 3.3 Hz, 1H), 2.53 (t, J = 7.8 Hz, 2H), 1.591.54 (m, 2H), 1.29-1.27 (m, 10H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3)
154.5, 137.9, 129.6, 116.9, 97.7, 72.2, 71.6, 70.0, 62.7, 61.2, 35.3, 32.0, 31.8, 29.6, 29.5,
29.4, 22.8, 14.2.
4-n-Octylphenyl -2-amino-2-deoxy α-D-glucopyranoside (22). Compound 21
(912 mg, 2.32 mmol) was dissolved in methanol (66 mL). Pd/C (10% w/w, 347 mg) was
added and the resulting suspension was stirred under an atmosphere of hydrogen (16 psi)
at room temperature for 2 h. The catalyst Pd/C was removed by filtration and the reaction
was concentrated in vacuo, giving a residue that was subjected to silica gel chromatograph
to give 851 mg (99%) of 22. 1H NMR (300 MHz, CDCl3) 7.11-7.09 (m, 4H), 5.46 (d, J =
3.6 Hz, 1H), 3.76-3.66 (m, 4H), 3.43 (t, J = 9.0 Hz, 1H), 2.78 (dd, J1 = 9.9 Hz, J2 = 3.6 Hz,
1H), 2.56 (t, J = 7.5 Hz, 2H), 1.61-1.57 (m, 2H), 1.33-1.30 (m, 10H), 0.91 (t, J = 6.8 Hz,
3H). 13C NMR (75 MHz, CDCl3) 156.6, 138.2, 130.3, 118.1, 99.9, 76.0, 74.7, 71.7, 62.4,
57.2, 36.1, 33.0, 32.9, 30.6, 30.4, 30.3, 23.7, 14.4.
4-n-Octylphenyl-3,4,6-tri-O-trimethylsilyl-2-azido-2-deoxy

α-D-glucopyra-

noside (23). To a solution of compound 22 (0.84 g, 2.29 mmol) in dry pyridine (8.4 mmol)
at 0 °C, was added a mixture of hexamethyldisilazane (1.48 g, 9.16 mmol) and
chlorotrimethylsilane (3.98 g, 36.64 mmol) dropwise. The resulting solution was warmed
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to room temperature and stirred overnight. The reaction was concentrated in vacuo, giving
a residue that was subjected to silica gel chromatograph to give 1.18 g (88%) of 23. 1H
NMR (300 MHz, CD3OD) 7.07 (d, J = 8.7 Hz, 2H), 6.99 (d, J = 8.7 Hz, 2H), 5.39 (d, J =
3.3 Hz, 1H), 3.76-3.66 (m, 4H), 3.58 (t, J = 8.7 Hz, 1H), 2.75 (dd, J1 = 9.6 Hz, J2 = 3.6 Hz,
1H), 2.54 (t, J = 7.8 Hz, 2H), 1.60-1.55 (m, 2H), 1.30 (br, 2H) 1.30-1.27 (m, 10H), 0.88 (t,
J = 6.8 Hz, 3H), 0.24 (s, 9H), 0.18 (s, 9H), 0.08 (s, 9H). 13C NMR (75 MHz, CD3OD) 155.2,
137.0, 129.3, 117.2, 99.6, 78.0, 73.7, 72.0, 62.0, 57.1, 35.3, 32.1, 31.8, 29.6, 29.4, 22.8,
14.3, 1.6, 1.0, -0.1.
4-n-Octylphenyl-3,4,6-tri-O-trimethylsilyl-2-azido-2-deoxy β -D-glucopyranoside (24). The target 24 was prepared starting with compound 20 using the same
procedure as that for 23. Yield 83% over three steps. 1H NMR (300 MHz, CDCl3) 7.06 (d,
J = 8.7 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 4.69 (d, J = 7.8 Hz, 1H), 3.82 (dd, J1 = 11.4 Hz,
J2 = 2.1 Hz, 1H), 3.73 (dd, J1 = 11.4 Hz, J2 = 4.8 Hz, 1H), 3.61 (t, J = 9.0 Hz, 1H), 3.45 (t,
J = 9.0 Hz, 1H), 3.32-3.27 (m, 1H), 2.93 (dd, J1 = 9.3 Hz, J2 = 8.1 Hz, 1H), 2.54 (t, J = 7.7
Hz, 2H), 1.61-1.51 (m, 4H), 1.32-1.24 (m, 10H), 0.88 (t, J = 6.8 Hz, 3H), 0.23 (s, 9H), 0.18
(s, 9H), 0.08 (s, 9H),. 13C NMR (75 MHz, CDCl3) 156.0, 137.3, 129.3, 117.4, 103.0, 79.2,
77.4, 71.7, 62.2, 58.0, 35.3, 32.1, 31.8, 29.7, 29.5, 29.4, 22.8, 14.3, 1.4, 1.0, -0.1.

168

169

4-n-Octylphenyl-2-(3-(flurosulfonyl)benzoylamino)-2-deoxy

α-D-Glucopy-

ranoside (25). To a solution of compound 23 (150 mg, 0.257 mmol), triethylamine (71.2
μL, 0.514 mmol) in anhydrous dichloromethane (15 mL), was added a solution of 14a (97
mg, 0.437 mmol) in anhydrous dichloromethane (2 mL) dropwise at room temperature.
The resulting mixture was stirred for 4 h and concentrated in vacuo, giving a residue that
was dissolved in a mixture of TFA/THF/H2O (0.4 mL/2.85 mL/0.15 mL) and stirred for 25
min at room temperature. The reaction mixture was concentrated in vacuo, giving a residue
that was subjected to silica gel chromatograph to give 103 mg (74%) of 25. 1H NMR (300
MHz, CD3OD/CDCl3 (1/1, v/v)) 9.3 (d, J = 7.8 Hz, 1H), 8.6 (s, 1H), 8.33 (d, J = 7.8 Hz,
1H), 8.22 (d, J = 7.8 Hz, 1H),7.83 (t, J = 7.8 Hz, 1H), 7.10-7.03 (m, 4H), 5.60 (d, J = 3.6
Hz, 1H), 4.33-4.26 (m, 1H), 4.11 (dd, J1 = 10.8 Hz, J2 = 8.7 Hz, 1H), 3.85-3.74 (m, 3H),
3.59 (t, J = 9.2 Hz, 1H), 2.53 (t, J = 7.5 Hz, 2H), 1.60-1.54 (m, 2H), 1.29-1.27 (m, 10H),
0.89 (t, J = 6.6 Hz, 3H). 13C NMR (75 MHz, CD3OD/CDCl3 (1/1, v/v)) 168.3, 156.8, 138.4,
137.8, 135.9, 134.6 (d, JC,F = 25.2 Hz), 132.0, 131.5, 130.4, 128.7, 118.1, 98.3, 74.6, 72.2,
72.2, 62.4, 56.6, 36.1, 33.0, 32.8, 30.5, 30.3, 30.2, 23.7, 14.4.
4-n-Octylphenyl-2-(3-(flurosulfonyl)benzoylamino)-2-deoxy α-D-Glucopyranoside-6-sulfate (26) This substance was prepared starting with compound 25 using the
same procedure employed for the preparation of 11. Yield 63%. 1H NMR (300 MHz,
CD3OD) 9.05 (d, J = 8.1 Hz, 1H), 8.57 (s, 1H), 8.34 (d, J = 7.8 Hz, 1H), 8.23 (d, J = 7.8
Hz, 1H), 7.85 (t, J = 7.8 Hz, 1H), 7.11-7.03 (m, 4H), 5.57 (d, J = 3.6 Hz, 1H), 4.33-4.27
(m, 3H), 4.10 (dd, J1 = 10.8 Hz, J2 = 8.7 Hz, 1H), 4.03-3.97 (m, 1H), 3.66 (t, J = 9.5 Hz,
1H), 2.54 (t, J = 7.5 Hz, 2H), 1.60-1.57 (m, 2H), 1.30-1.28 (m, 10H), 0.90 (t, J = 6.8 Hz,
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3H).

13

C NMR (75 MHz, DMSO-d6) 166.0, 155.8, 137.5, 136.4, 136.1, 132.5 (d, JC,F =

23.2 Hz), 131.7, 131.6, 130.1, 127.8, 118.0, 97.6, 72.2, 70.9, 70.5, 66.4, 55.7, 34.9, 31.8,
31.6, 29.4, 29.2, 29.1, 22.7, 14.6. HRMS (ESI-) calcd for C27H35FNO11S2 [M]- m/z
632.1636, found 632.1631.
4-n-Octylphenyl-2-(2-bromoacetylamino)-2-deoxy α-D-Glucopyranoside (27).
To a solution of compound 23 (160 mg, 0.27 mmol), trimethylamine (65.1 μL, 0.47 mmol)
in anhydrous dichloromethane (20 mL), was added a solution of 2-bromoacetic anhydride
(121.2 mg, 0.47 mmol) in anhydrous dichloromethane (2 mL) dropwise at room
temperature. The resulting mixture was stirred for 1.5 h and concentrated in vacuo, giving
a residue that was dissolved in a mixture of TFA/THF/H2O (0.4 mL/4.85 mL/0.15 mL) and
stirred for 30 min at room temperature. The reaction mixture was concentrated in vacuo,
giving a residue that was subjected to silica gel chromatograph to give 130 mg (98%) of
27. 1H NMR (300 MHz, CD3OD) 8.57 (d, J = 8.1 Hz, 1H), 7.12-7.04 (m, 4H), 5.45 (d, J =
3.3 Hz, 1H), 4.08-4.03 (m, 1H), 3.98-3.87 (m, 3H), 3.82-3.72 (m, 3H), 3.55-3.47 (m, 1H),
2.56 (t, J = 7.5 Hz, 2H), 1.59-1.56 (m, 2H), 1.32-1.30 (m, 10H), 0.93 (t, J = 6.8 Hz, 3H).
13

C NMR (75 MHz, CD3OD/CDCl3 (2/1, v/v)) 167.4, 154.6, 137.6, 129.3, 116.9, 96.8, 72.5,

71.7, 70.3, 61.2, 54.2, 35.0, 31.8, 31.6, 29.4, 29.2, 28.4, 22.6, 13.9.
4-n-Octylphenyl-2-(2-bromoacetylamino)-2-deoxy α-D-Glucopyranoside-6sulfate (28). This substance was prepared starting with compound 27 using the same
procedure employed for the preparation of 11. Yield 65%. 1H NMR (300 MHz, CD3OD)
7.13-7.04 (m, 4H), 5.42 (d, J = 3.6 Hz, 1H), 4.25-4.23 (m, 2H), 4.06 (dd, J1 = 10.8 Hz, J2
= 3.3 Hz, 1H) 3.98-3.86 (m, 4H), 3.58 (dd, J1 = 9.9 Hz, J2 = 9.0 Hz, 1H), 2.57 (t, J = 7.7
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Hz, 2H), 1.62-1.57 (m, 2H), 1.33-1.30 (m, 10H), 0.91 (t, J = 6.8 Hz, 3H). 13C NMR (75
MHz, CD3OD/D2O (5/1, v/v)) 170.2, 156.4, 138.6, 130.4, 118.5, 98.4, 72.4, 72.1, 71.3,
67.7, 55.7, 35.9, 32.8, 32.6, 30.3, 30.2, 30.0, 28.7, 23.5, 14.4. HRMS (ESI-) calcd for
C22H33BrNO9S [M]- m/z 566.1059, found 566.1069.
4-n-Octylphenyl-2-(vinylsulfonylamino)-2-deoxy α-D-Glucopyranoside (29). To
a solution of compound 23 (130 mg, 0.22 mmol), triethylamine (92 μL, 0.66 mmol), 4DMAP (2.7 mg, 0.022 mmol) in anhydrous dichloromethane (1.5 mL), was added 2chloroethanesulfonyl chloride (51 mg, 0.31 mmol) dropwise over 30 min at 0 ℃. The
resulting mixture was warmed to room temperature and stirred for 2 h. The reaction was
diluted dichloromethane, washed with water and dried over Na2SO4 and concentrated in
vacuo, giving a residue that was dissolved in a mixture of TFA/THF/H2O (0.4 mL/2.85
mL/0.15 mL) and stirred for 30 min at room temperature. The reaction mixture was
concentrated in vacuo, giving a residue that was subjected to silica gel chromatograph to
give 92 mg (92%) of 29. 1H NMR (300 MHz, CD3OD) 7.12-7.05 (m, 4H), 6.77 (dd, , J1 =
16.5 Hz, J2 = 10.2 Hz, 1H ), 6.17 (d, J = 16.5 Hz, 1H), 5.82 (d, J = 10.2 Hz, 1H), 5.45 (d,
J = 3.6 Hz, 1H), 3.85-3.70 (m, 4H), 3.47 (t, J = 8.3 Hz, 1H), 3.38-3.33 (m, 1H), 2.55 (t, J
= 7.5 Hz, 2H), 1.61-1.56 (m, 2H), 1.32-1.29 (m, 10H), 0.90 (t, J = 6.8 Hz, 3H). 13C NMR
(75 MHz, CD3OD) 156.5, 139.0, 138.3, 130.3, 125.2, 118.3, 99.7, 74.3, 72.7, 72.0, 62.3,
59.3, 36.1, 33.0, 32.9, 30.5, 30.4, 30.3, 23.7, 14.2.
4-n-Octylphenyl-2-(vinylsulfonylamino)-2-deoxy α-D-Glucopyranoside-6sulfate (30). This substance was prepared starting with compound 28 using the same
procedure employed for the preparation of 11. Yield 79%. 1H NMR (300 MHz, CD3OD)
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7.16-7.08 (m, 4H), 6.80 (dd, , J1 = 16.5 Hz, J2 = 10.2 Hz, 1H ), 6.21 (d, J = 16.5 Hz, 1H),
5.87 (d, J = 10.2 Hz, 1H), 5.44 (d, J = 3.3 Hz, 1H), 4.26-4.24(m, 2H), 3.95-3.90 (m, 1H),
3.86 (dd, J1 = 10.5 Hz, J2 = 9.0 Hz, 1H), 3.57 (dd, J1 = 9.9 Hz, J2 = 9.0 Hz, 1H), 3.39 (dd,
J1 = 10.5 Hz, J2 = 3.6 Hz, 1H), 2.59 (t, J = 7.7 Hz, 2H), 1.64-1.60 (m, 2H), 1.36-1.33 (m,
10H), 0.93 (t, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CD3OD) 156.6, 138.9, 138.4, 130.3,
125.3, 118.4, 99.8, 72.4, 71.7, 67.8, 59.2, 36.1, 33.0, 32.8, 30.5, 30.4, 30.3, 23.7, 14.4.
HRMS (ESI-) calcd for C22H34NO10S2 [M]- m/z 536.1624, found 536.1638.
4-n-Octylphenyl-2-(vinylsulfonylamino)-2-deoxy β-D-Glucopyranoside-6sulfate (31). This substance was prepared starting with compound 24 using the same
procedure employed for the preparation of 30. Yield 66% over 3 steps. 1H NMR (300 MHz,
CD3OD) 7.14 (d, J = 8.4 Hz, 2H), 7.04 (d, J = 8.4 Hz, 2H), 6.88 (dd, J1 = 16.5 Hz, J2 =
10.2 Hz, 1H ), 6.19 (d, J = 16.5 Hz, 1H), 5.87 (d, J = 10.2 Hz, 1H), 4.96 (d, J = 8.1 Hz,
1H), 4.42 (dd, J1 = 10.8 Hz, J2 = 1.5 Hz, 1H), 4.21(dd, J1 = 10.8 Hz, J2 = 5.7 Hz, 1H), 3.723.67 (m, 1H), 3.52-3.42 (m, 2H), 3.40-3.36 (m, 1H), 2.60 (t, J = 7.5 Hz, 2H), 1.64-1.61 (m,
2H), 1.36-1.27 (m, 10H), 0.94 (t, J = 6.6 Hz, 3H).

13

C NMR (75 MHz, CD3OD) 156.8,

140.0, 138.1, 130.3, 124.2, 117.7, 101.0, 76.2, 75.8, 71.7, 68.1, 61.1, 36.1, 33.0, 32.8, 30.5,
30.4, 30.3, 23.7, 14.4. HRMS (ESI-) calcd for C22H34NO10S2 [M]- m/z 536.1624, found
536.1634.

5.5.2 Reference for synthesis
1. Sarpe, V. A.; Kulkarni, S. S. Synthesis of Maradolipid. J. Org. Chem. 2011, 76,
6866–6870.

173
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3. Barry, C. S.; Backus, K. M.; Barry, III, C. E.; Davis, B. G. ESI-MS Assay of M.
tuberculosis Cell Wall Antigen 85 Enzymes Permits Substrate Profiling and Design
of a Mechanism-Based Inhibitor. J. Am. Chem. Soc., 2011, 133 (34), 13232–13235.
4. Grimster, N. P.; Connelly, S.; Baranczak, A.; Dong, J.; Krasnova, L. B.; Sharpless,
K. B.; Powers, E. T.; Wilson, I. A.; Kelly, J. W. Aromatic Sulfonyl Fluorides
Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while
Affording a Fluorescent Conjugate. J. Am. Chem. Soc., 2013, 135 (15), 5656–5668.
5. Masuya, T.; Murai, M.; Ifuku, K.; Morisaka, H.; Miyoshi, H. Site-Specific
Chemical Labeling of Mitochondrial Respiratory Complex I through LigandDirected Tosylate Chemistry. Biochemistry, 2014, 53 (14), 2307–2317.
6. Yan, R.-B.; Yang, F.; Wu, Y.; Zhang, L.-H. and Ye, X.-S. An efficient and
improved procedure for preparation of triflyl azide and application in catalytic
diazotransfer reaction. Tetrahedron Letters, 2005, 46, 8993–8995.

5.5.3 Expression and Purification of T6PPs.
All T6PPs mentioned were expressed in E.coli and purified as described in chapter 2.
5.5.4 Kinetic Characterization of T6PPs Inactivation by 26.
Time and Concentration Dependence of T6PP Inactivation by 26. T6PP
inactivation by 26 was studied at 25 ℃ and in the buffer containing: 50 mM Tris pH 7.5,
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50 mM NaCl, 5 mM MgCl2, 1 mM DTT. Incubating enzyme with various concentrations
of inactivator 26 in the buffer mentioned above and periodically measuring the activity of
the enzyme by removing an aliquot (5μL) of the inactivation stock solution and adding it
to EnzChek phosphate assay reaction mixture, which contains 1 mM MgCl2, 0.1 mM
sodium azide 1.0 unit/mL purine nucleoside phosphorylase, and 0.2 mM MESG in 50 mM
Tris-HCl (pH 7.5). The enzyme activity was measured by using EnzChek phosphate assay
kit which was described in chapter 4 in detail. The pseudo-first-order rate constant for
inactivation (kobs) (Appendix A5.10) was derived from the slope of the plot of ln (t/o) vs
t, where t is the velocity of the trehalose-6-phospahte hydrolysis reaction catalyzed by
T6PP incubated with 26 for time (t) and o is the velocity of the trehalose-6-phospahte
hydrolysis reaction catalyzed by T6PP in buffer. The resulting kobs values were plotted
against 26 concentration. The data were fitted by using Graphpad Prism 6 to the equation
kobs = (kinact[I]/(KI +[I]) to obtain KI and kinact values.
Trehalose-6-Sulfate (T6S) Partially Protect T6PP from Inhibitor 26 Mediated
Inactivation. The effect of T6S, a reversible and competitive T6PP inhibitor, on inhibitor
26-mediated T6PP inactivation was studied at 25 ℃ in a pH 7.0 buffer containing: 50 mM
Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1 mM DTT. T6PP was incubated with 26 in the
presence or absence of T6S respectively. At appropriate time intervals, aliquots 5μL were
removed from the reaction and added into EnzChek phosphate assay reaction mixture
containing: 1 mM MgCl2, 0.1 mM sodium azide 1.0 unit/mL purine nucleoside
phosphorylase, and 0.2 mM MESG in 50 mM Tris-HCl (pH 7.5) for phosphatase activity
measurements.
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5.5.5 ES-MS Analysis of T6PP Modification by Inhibitor 26.
T6PPs were treated with or without 26 (10-20 eq) in a buffer containing 50 mM Tris
pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1 mM DTT at room temperature for 30 minutes. Then
the reaction mixture were transferred to amicon ultra centrifugal filters and exchanged with
buffer 50 mM Tris 7.5 four times and concentrated for Mass spectrometry.
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APPENDIX
A.1 Published Collaborative Work
A.1.1 Covalent docking predicts substrates for haloalkanoate dehalogenase
superfamily phosphatases.
London N, Farelli JD, Brown SD, Liu C, Huang H, Korczynska M, Al-Obaidi NF,
Babbitt PC, Almo SC, Allen KN, Shoichet BK.
Abstract
Enzyme function prediction remains an important open problem. Though structurebased modeling, such as metabolite docking, can identify substrates of some enzymes, it is
ill-suited to reactions that progress through a covalent intermediate. Here we investigated
the ability of covalent docking to identify substrates that pass through such a covalent
intermediate, focusing particularly on the haloalkanoate dehalogenase superfamily. In
retrospective assessments, covalent docking recapitulated substrate binding modes of
known cocrystal structures and identified experimental substrates from a set of putative
phosphorylated metabolites. In comparison, noncovalent docking of high-energy
intermediates yielded nonproductive poses. In prospective predictions against seven
enzymes, a substrate was identified for five. For one of those cases, a covalent docking
prediction, confirmed by empirical screening, and combined with genomic context analysis,
suggested the identity of the enzyme that catalyzes the orphan phosphatase reaction in the
riboflavin biosynthetic pathway of Bacteroides.
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A.1.2 Structure of the trehalose-6-phosphate phosphatase from Brugia malayi
reveals key design principles for anthelmintic drugs.
Farelli JD, Galvin BD, Li Z, Liu C, Aono M, Garland M, Hallett OE, Causey TB, AliReynolds A, Saltzberg DJ, Carlow CK, Dunaway-Mariano D, Allen KN.

Abstract

Parasitic nematodes are responsible for devastating illnesses that plague many of
the world's poorest populations indigenous to the tropical areas of developing nations.
Among these diseases is lymphatic filariasis, a major cause of permanent and long-term
disability. Proteins essential to nematodes that do not have mammalian counterparts
represent targets for therapeutic inhibitor discovery. One promising target is trehalose-6phosphate phosphatase (T6PP) from Brugia malayi. In the model nematode Caenorhabditis
elegans, T6PP is essential for survival due to the toxic effect(s) of the accumulation of
trehalose 6-phosphate. T6PP has also been shown to be essential in Mycobacterium
tuberculosis. We determined the X-ray crystal structure of T6PP from B. malayi. The
protein structure revealed a stabilizing N-terminal MIT-like domain and a catalytic Cterminal C2B-type HAD phosphatase fold. Structure-guided mutagenesis, combined with
kinetic analyses using a designed competitive inhibitor, trehalose 6-sulfate, identified five
residues important for binding and catalysis. This structure-function analysis along with
computational mapping provided the basis for the proposed model of the T6PP-trehalose
6-phosphate complex. The model indicates a substrate-binding mode wherein shape
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complementarity and van der Waals interactions drive recognition. The mode of binding is
in sharp contrast to the homolog sucrose-6-phosphate phosphatase where extensive
hydrogen-bond interactions are made to the substrate. Together these results suggest that
high-affinity inhibitors will be bi-dentate, taking advantage of substrate-like binding to the
phosphoryl-binding pocket while simultaneously utilizing non-native binding to the
trehalose pocket. The conservation of the key residues that enforce the shape of the
substrate pocket in T6PP enzymes suggest that development of broad-range anthelmintic
and antibacterial therapeutics employing this platform may be possible.
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A.1.3 An improved method for the large scale preparation of α, α′-trehalose-6phosphate.
Liu C, Mariano PS.

Abstract
An improved method was developed for the efficient, large-scale synthesis of α,α′trehalose-6-phosphate starting with α,α′-trehalose. In the sequence, octa-trimethylsilylation
of α,α′-trehalose is followed by selective removal of the 6-O-trimethylsilyl protecting
group. Reaction of the mono-alcohol with (PhO)2POCl is then followed by simultaneous
hydrogenolysis and per-desilylation to generate α,α′-trehalose-6-phosphate, free of
contamination by inorganic phosphate.
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A.1.4 Panoramic view of a superfamily of phosphatases through substrate profiling.
Huang H, Pandya C, Liu C, Al-Obaidid N, Wang M, Zheng L, Keating ST, Aono M,
Loved JD, Evans B, Seidel R, Hillerich BS, Garforth S, Almo SC, Mariano PS, DunawayMariano D, Allen KN, and Farelli JD.
Abstract
Large-scale activity profiling of enzyme superfamilies provides information about
cellular functions as well as the intrinsic binding capabilities of conserved folds. Herein,
the functional space of the ubiquitous haloalkanoate dehalogenase superfamily (HADSF)
was revealed by screening a customized substrate library against >200 enzymes from
representative prokaryotic species, enabling inferred annotation of ~35% of the HADSF.
An extremely high level of substrate ambiguity was revealed, with the majority of HADSF
enzymes utilizing >5 substrates. Substrate profiling allowed assignment of function to
previously unannotated enzymes with known structure, uncovered potential new pathways,
and identified iso-functional orthologs from evolutionarily distant taxonomic groups.
Intriguingly, the HADSF subfamily having the least structural elaboration of the Rossmann
fold catalytic domain was the most specific, consistent with the concept that domain
insertions drive the evolution of new functions and that the broad specificity observed in
HADSF may be a relic of this process.
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A.2 Plots in Chapter Two
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Enzyme: Mt-T6PP(50 μM); Substrate: α-D-Glucose-1-phosphate;
kcat: 0.0022±0.0002 S-1 Km: 8 ±1 mM; kcat/Km: 0.28 M-1S-1.
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A.3 Plots in Chapter Three
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A. 4 Plots in Chapter Four
A.4.1 Bm-T6PP kinetic Plots in Table 4.1

Bm-F148A, kcat = 0.28±0.02 s-1, Km = 2200±400 μM, Ki = 360±70 μM.
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Bm-E157A, kcat = 25±0.6 s-1, Km = 230±20 μM, Ki = 71±6 μM.

Bm-R187A, kcat = 0.11±0.01s-1, Km = 3800±400 μM, Ki > 4 mM.
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Bm-E251A, kcat = 0.99±0.06 s-1, Km = 1500±200 μM, Ki > 4 Mm.

Bm-K253A, kcat = 0.098±0.002 s-1, Km = 6800±300 μM, Ki > 4 Mm.
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Bm-H260A, kcat = 0.28±0.03 s-1, Km = 1100±300 μM, Ki = 780±170 μM.

Bm-R262A, kcat = 0.13±0.01 s-1, Km = 2100±300 μM, Ki = 2400±500 μM.
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Bm-N263A, kcat = 23±0.7 s-1, Km = 890±70 μM, Ki = 320 ± 40 μM.

Bm-T288A, kcat = 11±0.6 s-1, Km = 1400 ± 200 μM, Ki = 1700 ± 200 μM.
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Bm-R291A, kcat = 0.39 ±0.07 s-1, Km = 2900 ± 900 μM, Ki > 4 mM.

Bm-E292A, kcat = 15 ±0.5 s-1, Km = 540 ± 60 μM, Ki = 380 ± 50 μM.
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Bm-E295A, kcat = 0.16 ±0.01 s-1, Km = 1500 ± 200 μM, Ki = 190 ± 20 μM.

Bm-R297A, kcat = 3 ±0.2 s-1, Km = 730 ± 90 μM, Ki = 460 ± 40 μM.
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A.4.2 Bm-T6PP kinetic Plots in Table 4.4

Enzyme: Bm-T6PP, Inhibitor: 5c, Ki = 320±30 μM.

Enzyme: Bm-T6PP, Inhibitor: 6a, Ki = 160±20 μM.
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Enzyme: Bm-T6PP, Inhibitor: 8a, Ki = 830±100 μM.

Enzyme: Bm-T6PP, Inhibitor: 8p, Ki = 61±10 μM.
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Enzyme: Bm-T6PP, Inhibitor: 9a, Ki = 5.3±0.6 μM.

Enzyme: Bm-T6PP, Inhibitor: 9b, Ki = 82±10 μM.
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Enzyme: Mt-T6PP, Inhibitor: 8b, Ki = 1600±270 μM.

Enzyme: Mt-T6PP, Inhibitor: 8i, Ki = 1700±350 μM.
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Enzyme: Sb-T6PP, Inhibitor: 8o, Ki = 140±20 μM.

Enzyme: Sb-T6PP, Inhibitor: 8p, Ki = 13±2 μM.
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Enzyme: Sb-T6PP, Inhibitor: 9a, Ki = 21±3 μM.

Enzyme: Sb-T6PP, Inhibitor: 9b, Ki = 78±9 μM.
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Enzyme: As-T6PP, Inhibitor: 8a, Ki = 1800±260 μM.

Enzyme: As-T6PP, Inhibitor: 8p, Ki = 180±20 μM.
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Enzyme: As-T6PP, Inhibitor: 9a, Ki = 84±10 μM.

Enzyme: As-T6PP, Inhibitor: 9b, Ki = 350±30 μM.
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Enzyme: St-T6PP, Inhibitor: 8p, Ki = 120±20 μM.

Enzyme: St-T6PP, Inhibitor: 9a, Ki = 56±6 μM.
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Enzyme: St-T6PP, Inhibitor: 9b, Ki = 280±30 μM.
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A.5 ESI mass spectra In Chapter Five
A.5.1 ESI mass spectra of Bm-T6PP treated with 26
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A.5.2 ESI mass spectra of Sb-T6PP treated with 26
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A.5.3 ESI mass spectra of Mt-T6PP treated with 26
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A.5.4 ESI mass spectra of St-T6PP treated with 26
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A.5.5 ESI mass spectra of Mt-T6PP-K253A
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A.5.6 ESI mass spectra of Mt-T6PP-K253A treated with 26
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A.5.7 ESI mass spectra of Bm-T6PP-K334A
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A.5.8 ESI mass spectra of Bm-T6PP-K334A treated with 26
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A.5.9 Sequence alignments of nematode and bactera T6PP enzymes
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A.5.10 Plots of pseudo-first order rate constant for inactivation (kobs)
A.5.10.1 Plots of kobs for 26 mediated As-T6PP inactivation.
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A.5.10.2 Plots of kobs for 26 mediated Bm-T6PP inactivation.
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A.5.10.3 Plots of kobs for 26 mediated Mt-T6PP inactivation.
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A.5.10.4 Plots of kobs for 26 mediated Sb-T6PP inactivation.
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A.5.10.5 Plots of kobs for 26 mediated St-T6PP inactivation.
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